

CITATION REPORT

List of articles citing

Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families

DOI: 10.1126/science.8346443
Science, 1993, 261, 921-3.

Source: <https://exaly.com/paper-pdf/23961153/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2267	Polyadenylation of nascent RNA during the embryogenesis of <i>Ilyanassa obsoleta</i> . 1975 , 95, 263-8		8
2266	Cloning of a cDNA encoding a putative human very low density lipoprotein/apolipoprotein E receptor and assignment of the gene to chromosome 9pter-p23. 1993 , 19, 557-69		75
2265	News & Views. 1993 , 16, 136-149		1
2264	An introduction to the molecular genetics of neurological disease. Recent advances. 1993 , 50, 1123-8		7
2263	Molecular genetics of Alzheimer's disease. 1993 , 5, 417-25		9
2262	Apolipoprotein E and Alzheimer's disease. 1993 , 342, 696		28
2261	Apolipoprotein E epsilon 4 allele distributions in late-onset Alzheimer's disease and in other amyloid-forming diseases. 1993 , 342, 710-1		478
2260	Apolipoprotein E-epsilon 4 allele and Alzheimer's disease. 1993 , 342, 1308-9		38
2259	APOE gene dose in Alzheimer's disease. 1993 , 342, 426		7
2258	National Policy Development for the Clinical Application of Genetic Diagnostic Technologies. 1993 , 270, 2948		57
2257	Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. 1993 , 90, 9649-53		1288
2256	apl-1, a <i>Caenorhabditis elegans</i> gene encoding a protein related to the human beta-amyloid protein precursor. 1993 , 90, 12045-9		177
2255	Alzheimer's disease: clinical Features. 1993 , 5, 327-349		14
2254	Genetics of Alzheimer's disease. Some molecular understanding of a diverse phenotype. 1994 , 164, 153-6		3
2253	The dementia syndromes. 1994 , 95, 91-101		
2252	Benefits and risks of emerging genetic technologies: the need for regulation. 1994 , 40, 1652-1657		10
2251	Alzheimer's Disease: Clinical Molecular Genetics. 1994 , 10, 239-247		14

2250	Apolipoprotein E (ApoE), a novel heparin-binding protein inhibits the development of Kaposi's sarcoma-like lesions in BALB/c nu/nu mice. 1994 , 180, 1949-54		23
2249	The National Academy of Sciences--National Research Council Veteran Twin Registry. 1994 , 43, 89-94		1
2248	Lower cognitive performance in normal older adult male twins carrying the apolipoprotein E epsilon 4 allele. 1994 , 51, 1189-92		144
2247	Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. <i>Science</i> , 1994 , 264, 850-2	33.3	735
2246	Peripheral markers and diagnostic criteria in Alzheimer's disease: critical evaluations. 1994 , 5, 213-25		9
2245	Apolipoprotein E Alleles, Dyslipidemia, and Coronary Heart Disease. 1994 , 272, 1666		232
2244	Effects of gender and menopausal status on the association of apolipoprotein E phenotype with plasma lipoprotein levels. Results from the Framingham Offspring Study. 1994 , 14, 1105-13		159
2243	Genetics, ethics, and Alzheimer disease. 1994 , 42, 782-6		19
2242	Vascular Amyloid in Alzheimer's disease angiopathy is produced by proliferating and degenerating smooth muscle cells. 1994 , 1, 8-16		50
2241	ApoE, amyloid, and Alzheimer's disease. <i>Science</i> , 1994 , 263, 454-5	33.3	15
2240	Alzheimer's disease and possible gene interaction. <i>Science</i> , 1994 , 263, 537	33.3	103
2239	An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. <i>Science</i> , 1994 , 264, 1336-40	33.3	1377
2238	Preclinical cognitive markers of dementia of the Alzheimer type.. 1994 , 8, 374-384		78
2237	The association between apolipoprotein E allele epsilon 4 and late-onset Alzheimer's disease: pathogenic relationship or differential survival bias. 1994 , 51, 750		17
2236	Effect of human apoE4 on the clearance of chylomicron-like lipid emulsions and atherogenesis in transgenic mice. 1994 , 14, 1542-52		16
2235	Alzheimer's disease, beta-amyloidosis, and aging. 1994 , 5, 275-92		23
2234	GRSF-1: a poly(A)+ mRNA binding protein which interacts with a conserved G-rich element. 1994 , 22, 2334-43		47
2233	Confirmation of association between the e4 allele of apolipoprotein E and Alzheimer's disease. 1994 , 31, 197-200		46

2232	Management of neurological disorders: dementia. 1994 , 57, 1451-6	10
2231	Molecular genetics: what's left for clinicians?. 1994 , 9, 349-51	0
2230	Inhibition of PC12 cell redox activity is a specific, early indicator of the mechanism of beta-amyloid-mediated cell death. 1994 , 91, 1470-4	376
2229	Extravascular proteolysis and the nervous system: serine protease/serpin balance. 1994 , 20, 426-32	19
2228	Apolipoprotein E5 and E7 in apparently healthy Japanese males: frequencies and relation to plasma lipid levels. 1994 , 39, 315-24	12
2227	Apolipoprotein E-4 gene dose in clinically diagnosed Alzheimer's disease: prevalence, plasma cholesterol levels and cerebrovascular change. 1994 , 243, 291-2	43
2226	Presence of apolipoprotein E on extracellular neurofibrillary tangles and on meningeal blood vessels precedes the Alzheimer beta-amyloid deposition. 1994 , 88, 413-9	66
2225	Pathological alterations of the cerebral microvasculature in Alzheimer's disease and related dementing disorders. 1994 , 87, 469-80	248
2224	DNA markers associated with high versus low IQ: the IQ Quantitative Trait Loci (QTL) Project. 1994 , 24, 107-18	87
2223	A microtiter plate assay for determining apolipoprotein E genotype and discovery of a rare allele. 1994 , 3, 379-85	18
2222	Genetic heterogeneity of apolipoprotein E and its influence on plasma lipid and lipoprotein levels. 1994 , 4, 178-94	111
2221	Familial risks for Alzheimer disease from a population-based series. 1994 , 11, 365-74	16
2220	Genetic influences on age-related change in total cholesterol, low density lipoprotein-cholesterol, and triglyceride levels: longitudinal apolipoprotein E genotype effects. 1994 , 11, 375-84	48
2219	Interaction between genetic and environmental risk factors for Alzheimer's disease: a reanalysis of case-control studies. 1994 , 11, 539-51	82
2218	Alzheimer's disease: Recent advances in molecular pathology and genetics. 1994 , 9, 431-444	7
2217	High-resolution separation of PCR product and gene diagnosis by capillary gel electrophoresis. 1994 , 8, 291-3	18
2216	Turning point in the design of linkage studies of schizophrenia. 1994 , 54, 83-92	94
2215	Association of the apolipoprotein E epsilon 4 allele with clinical subtypes of autopsy-confirmed Alzheimer's disease. 1994 , 54, 199-205	76

2214	Genetic linkage mapping for a susceptibility locus to bipolar illness: chromosomes 2, 3, 4, 7, 9, 10p, 11p, 22, and Xpter. 1994 , 54, 206-18	43
2213	Repeat length variation in the dopamine D4 receptor gene shows no evidence of association with schizophrenia. 1994 , 54, 256-8	31
2212	Association of apolipoprotein E allele epsilon 4 with late-onset sporadic Alzheimer's disease. 1994 , 54, 286-8	34
2211	Novel amyloid precursor protein gene mutation (codon 665Asp) in a patient with late-onset Alzheimer's disease. 1994 , 35, 432-8	25
2210	Are the associations between Alzheimer's disease and polymorphisms in the apolipoprotein E and the apolipoprotein CII genes due to linkage disequilibrium?. 1994 , 36, 97-100	79
2209	Familial Alzheimer's disease. 1994 , 36, 335-6	9
2208	The apolipoprotein E epsilon 4 allele does not influence the clinical expression of the amyloid precursor protein gene codon 693 or 692 mutations. 1994 , 36, 434-7	52
2207	Dose-dependent association of apolipoprotein E allele epsilon 4 with late-onset, sporadic Alzheimer's disease. 1994 , 36, 656-9	68
2206	Apolipoprotein E-epsilon 4 allele doses in late-onset Alzheimer's disease. 1994 , 36, 681-2	22
2205	Predictive value of apolipoprotein E genotyping in Alzheimer's disease: results of an autopsy series and an analysis of several combined studies. 1994 , 36, 889-95	119
2204	Diagnosis and the new genetics. 1994 , 5, 654-62	
2203	APOE is a major susceptibility gene for Alzheimer's disease. 1994 , 5, 663-7	82
2202	Mammalian gene studies. 1994 , 5, 671-705	
2201	Pharmaceutical biotechnology. 1994 , 5, 706-35	
2200	Single-day apolipoprotein E genotyping. 1994 , 53, 125-7	132
2199	Apolipoprotein E, epsilon 4 allele as a major risk factor for sporadic early and late-onset forms of Alzheimer's disease: analysis of the 19q13.2 chromosomal region. 1994 , 3, 569-74	344
2198	Unifying features of systemic and cerebral amyloidosis. 1994 , 8, 49-64	59
2197	Possible factors in the etiology of Alzheimer's disease. 1994 , 9, 1-13	30

2196	The role of beta-amyloid peptide in Alzheimer's disease. 1994 , 9, 3-31	6
2195	Aging: Prospects for further increases in the functional life span. 1994 , 17, 119-146	80
2194	Genetic associations with human longevity at the APOE and ACE loci. 1994 , 6, 29-32	921
2193	ApoE and ACE genes: impact on human longevity. 1994 , 6, 4-5	42
2192	ApoE-epsilon 4 and early-onset Alzheimer's. 1994 , 7, 10-1	133
2191	Apolipoprotein E4 allele in a population-based study of early-onset Alzheimer's disease. 1994 , 7, 74-8	413
2190	Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. 1994 , 7, 180-4	1497
2189	Alzheimer's disease. Risky apolipoprotein in brain. 1994 , 372, 45-6	51
2188	Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. 1994 , 372, 92-4	835
2187	Alzheimer's disease. The apolipoprotein E connection. 1994 , 4, 362-5	34
2186	Molecular Biology of 'Szheimer's Disease and Neuron's Death. 1994 , 14, 115-117	0
2185	Dorothy Russell Memorial Lecture. The molecular pathology of Alzheimer's disease: are we any closer to understanding the neurodegenerative process?. 1994 , 20, 322-38	21
2184	Analysing brain function and dysfunction in transgenic animals. 1994 , 20, 350-8	11
2183	No evidence of linkage or allelic association of schizophrenia with DNA markers at pericentric region of chromosome 9. 1994 , 36, 589-94	9
2182	Molecular basis and diagnosis of neurogenetic disorders. 1994 , 124, 119-40	17
2181	Apolipoprotein E-immunoreactivity in aged rhesus monkey cortex: colocalization with amyloid plaques. 1994 , 15, 621-7	49
2180	Development of small molecule probes for the beta-amyloid protein of Alzheimer's disease. 1994 , 15, 691-8	154
2179	Alzheimer's disease and soluble A beta. 1994 , 15, 143-52	112

2178	APP processing, A beta-amyloidogenesis, and the pathogenesis of Alzheimer's disease. 1994 , 15, 253-6	37
2177	Neuronal degenerative mechanisms as clues to pathogenesis and treatment of Alzheimer's disease. 1994 , 15 Suppl 2, S61-5	2
2176	Chaperoning Alzheimer's amyloids. 1994 , 15 Suppl 2, S97-9	6
2175	Alzheimer's disease: implications of genetic studies. 1994 , 15 Suppl 2, S141-4	6
2174	Genes in early onset Alzheimer's disease: implications for AD research. 1994 , 15 Suppl 2, S149-53	4
2173	Targets for Alzheimer's disease research: from basic mechanisms to rational therapies. 1994 , 15 Suppl 2, S157-60	
2172	The future of Alzheimer's disease research: a molecular genetic perspective. 1994 , 15 Suppl 2, S161-4	22
2171	Apolipoprotein E is a relevant susceptibility gene that affects the rate of expression of Alzheimer's disease. 1994 , 15 Suppl 2, S165-7	22
2170	New epidemiologic strategies in Alzheimer's disease may provide clues to prevention and cause. 1994 , 15 Suppl 2, S175-7	35
2169	Complex genetic disease: can genetic strategies in Alzheimer's disease and new genetic mechanisms be applied to epilepsy?. 1994 , 35 Suppl 1, S20-8	4
2168	Apolipoprotein E epsilon 4 allele frequency in patients with Lewy body dementia, Alzheimer's disease and age-matched controls. 1994 , 176, 45-6	69
2167	Clinical Diversity in Late Onset Alzheimer's Disease. 1994 , 2, 177	
2166	Apolipoprotein E uptake and degradation via chloroquine-sensitive pathway in cultivated monkey cells overexpressing low density lipoprotein receptor. 1994 , 180, 193-6	12
2165	Lipoproteins, neurobiology, and Alzheimer's disease: structure and function of apolipoprotein E. 1994 , 4, 507-515	53
2164	The genetic basis of complex human behaviors. <i>Science</i> , 1994 , 264, 1733-9	333 846
2163	The apolipoprotein E alleles as major susceptibility factors for Creutzfeldt-Jakob disease. The French Research Group on Epidemiology of Human Spongiform Encephalopathies. 1994 , 344, 1315-8	115
2162	Apolipoprotein E immunoreactive deposits in inclusion-body muscle diseases. 1994 , 343, 364-5	40
2161	Protective effect of apoE epsilon 2 in Alzheimer's disease. 1994 , 344, 473	66

2160	Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer's disease. 1994 , 344, 769-72	983
2159	Parkinson's disease, but not Alzheimer's disease, Lewy body variant associated with mutant alleles at cytochrome P450 gene. 1994 , 344, 815	7
2158	Protection against Alzheimer's disease with apoE epsilon 2. 1994 , 343, 1432-3	195
2157	Prolonged hypogonadism after pulsed gonadotropin-releasing hormone agonist for prostate cancer. 1994 , 344, 274-5	6
2156	Diagnosis of Alzheimer's disease by apolipoprotein E genotyping. 1994 , 344, 275	9
2155	Low levels of serum apolipoprotein A I and A II in senile dementia. 1994 , 48, 589-93	18
2154	ApoE allele frequencies in Italian sporadic and familial Alzheimer's disease. 1994 , 177, 100-2	122
2153	Towards a pharmacological approach of Alzheimer's disease based on the molecular biology of the amyloid precursor protein (APP). 1994 , 55, 2179-87	5
2152	Synuclein proteins and Alzheimer's disease. 1994 , 17, 404-5	44
2151	Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease. 1994 , 17, 525-30	576
2150	A chemical approach to elucidate the mechanism of transthyretin and E-protein amyloid fibril formation. 1994 , 1, 186-205	97
2149	Confirmation that familial clustering and age of onset in late onset Alzheimer's disease are determined at the apolipoprotein E locus. 1994 , 174, 222-4	36
2148	A hypothesis on the aetiology of Alzheimer's disease: description of a model involving a misfolded chaperone. 1994 , 43, 372-80	7
2147	Psychopharmacological Treatment Complications in the Elderly. 1994 , 2, 87-89	
2146	Senile dementia of the Lewy body type has an apolipoprotein E epsilon 4 allele frequency intermediate between controls and Alzheimer's disease. 1994 , 182, 1-2	55
2145	Apolipoprotein E and Alzheimer's disease. 1994 , 4, 703-7	33
2144	Isoform-specific interactions of apolipoprotein E with the microtubule-associated protein MAP2c: implications for Alzheimer's disease. 1994 , 182, 55-8	76
2143	Hannah's Heirs: The Quest for the Genetic Origins of Alzheimer's Disease. 1994 , 2, 86-87	

2142	Regional differences in apolipoprotein E immunoreactivity in diffuse plaques in Alzheimer's disease brain. 1994 , 167, 73-6	43
2141	Alzheimer's disease: a review of recent findings. 1994 , 48, 312-8	7
2140	APOE genotype does not modulate age of onset in families with chromosome 14 encoded Alzheimer's disease. 1994 , 169, 179-80	119
2139	Cell biology of the amyloid beta-protein precursor and the mechanism of Alzheimer's disease. 1994 , 10, 373-403	649
2138	Association of apolipoprotein E4 with sporadic Alzheimer's disease is more pronounced in early onset type. 1994 , 175, 74-6	46
2137	Amyloid beta-protein precursor: new clues to the genesis of Alzheimer's disease. 1994 , 4, 708-16	89
2136	Frequency of the apolipoprotein E epsilon 2 allele is diminished in sporadic Alzheimer disease. 1994 , 175, 46-8	106
2135	Lack of association between apolipoprotein E allele epsilon 4 and sporadic Alzheimer's disease. 1994 , 169, 175-8	53
2134	Attentional disengagement deficit in nondemented elderly over 75 years of age. 1994 , 1, 188-202	33
2133	Book Reviews. 1994 , 1, 213-217	
2132	Genetic dissection of complex traits. <i>Science</i> , 1994 , 265, 2037-48	33.3 2789
2131	Aging and genetic variation of plasma apolipoproteins. Relative loss of the apolipoprotein E4 phenotype in centenarians. 1994 , 14, 1084-9	145
2130	Racemization: its biological significance on neuropathogenesis of Alzheimer's disease. 1994 , 174, 251-62	41
2129	Amyloidosis in Alzheimer's disease. 1994 , 22, 171-5	3
2128	Transthyretin sequesters amyloid beta protein and prevents amyloid formation. 1994 , 91, 8368-72	339
2127	Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. 1994 , 94, 860-9	302
2126	Patterns of risk in first-degree relatives of patients with Alzheimer's disease. 1994 , 51, 577-86	71
2125	Clinical approaches to dementia. 1994 , 101, 375-82	2

2124	Neuropathology and apolipoprotein E profile of aged chimpanzees: implications for Alzheimer disease. 1994 , 91, 9382-6	143
2123	Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease. 1994 , 91, 11183-6	421
2122	Advanced Maillard reaction end products are associated with Alzheimer disease pathology. 1994 , 91, 5710-4	677
2121	Apolipoprotein E and Alzheimer disease. 1995 , 92, 4725-7	414
2120	A mitochondrial DNA clone is associated with increased risk for Alzheimer disease. 1995 , 92, 6892-5	173
2119	Low density lipoprotein receptor-related protein mediates apolipoprotein E-dependent neurite outgrowth in a central nervous system-derived neuronal cell line. 1995 , 92, 9480-4	312
2118	Discovery of a brain promoter from the human transferrin gene and its utilization for development of transgenic mice that express human apolipoprotein E alleles. 1995 , 92, 12115-9	23
2117	Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer disease. 1995 , 92, 763-7	322
2116	Genetic dissection of Alzheimer disease, a heterogeneous disorder. 1995 , 92, 8552-9	157
2115	Understanding the biology of aging: the key to prevention and therapy. 1995 , 43, 426-34	42
2114	Canadian guidelines for the development of antidementia therapies: a conceptual summary. 1995 , 22, 62-71	36
2113	Genes and psychosis: old wine in new bottles?. 1995 , 92, 81-6	11
2112	A new apolipoprotein AI variant, Trp50Arg, causes hereditary amyloidosis. 1995 ,	
2111	Fibrillogenesis in Alzheimer's disease of amyloid beta peptides and apolipoprotein E. 1995 , 306 (Pt 2), 599-604	225
2110	The cortical neuritic dystrophy of Alzheimer's disease: nature, significance, and possible pathogenesis. 1995 , 6, 218-24	4
2109	Apolipoprotein E genotype and Lewy body disease. 1995 , 45, 97-103	82
2108	Apolipoprotein E and Alzheimer's disease: the implications of progress in molecular medicine. 1995 , 85, 1280-4	30
2107	Gene Defects & Therapies: An Update on the Expanding Nature of Science. 1995 , 57, 70-75	

2106	Identification and expression analysis of a potential familial Alzheimer disease gene on chromosome 1 related to AD3. 1995 , 92, 12180-4	53
2105	Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. 1995 , 92, 12260-4	517
2104	Fairhill guidelines on ethics of the care of people with Alzheimer's disease: a clinical summary. Center for Biomedical Ethics, Case Western Reserve University and the Alzheimer's Association. 1995 , 43, 1423-9	83
2103	Genetic susceptibility to Alzheimer disease. 1995 , 11, 504-8	109
2102	Molecular biology and genetics of Alzheimer's disease. 1995 , 2, 465-76	2
2101	Evidence that the APOE locus influences rate of disease progression in late onset familial Alzheimer's Disease but is not causative. 1995 , 60, 1-6	63
2100	Characteristics of familial aggregation in early-onset Alzheimer's disease: evidence of subgroups. 1995 , 60, 221-7	6
2099	Schizophrenia: a genome scan targets chromosomes 3p and 8p as potential sites of susceptibility genes. 1995 , 60, 252-60	225
2098	Apolipoprotein E in the genetics and epidemiology of Alzheimer's disease. 1995 , 60, 456-60	31
2097	Evidence for apolipoprotein E epsilon 4 association in early-onset Alzheimer's patients with late-onset relatives. 1995 , 60, 550-3	23
2096	Allele doses of apolipoprotein E type epsilon 4 in sporadic late-onset Alzheimer's disease. 1995 , 60, 566-9	9
2095	APOE genotype influences functional status among elderly without dementia. 1995 , 60, 583-7	40
2094	The CYP2D6B mutant allele is overrepresented in the Lewy body variant of Alzheimer's disease. 1995 , 37, 110-2	84
2093	Apolipoprotein E genotypes and Alzheimer's disease in a community study of elderly African Americans. 1995 , 37, 118-20	118
2092	Apolipoprotein E genotypes in Parkinson's disease with and without dementia. 1995 , 37, 242-5	59
2091	Apolipoprotein E and Alzheimer's disease: ethnic variation in genotypic risks. 1995 , 37, 254-9	216
2090	Evidence that A beta 42 is the real culprit in Alzheimer's disease. 1995 , 37, 287-8	305
2089	Cerebrospinal fluid levels of amyloid beta-protein in Alzheimer's disease: inverse correlation with severity of dementia and effect of apolipoprotein E genotype. 1995 , 37, 512-8	109

2088	Gene dose of the epsilon 4 allele of apolipoprotein E and disease progression in sporadic late-onset Alzheimer's disease. 1995 , 37, 596-604	130
2087	The apolipoprotein E epsilon 2 allele is associated with an increased risk of early-onset Alzheimer's disease and a reduced survival. 1995 , 37, 605-10	115
2086	Apolipoprotein E genotyping in the diagnosis of Alzheimer's disease: a cautionary view. 1995 , 38, 2-4	69
2085	Apolipoprotein E genotyping in the differential diagnosis, not prediction, of Alzheimer's disease. 1995 , 38, 6-14	207
2084	A case-control study of apolipoprotein E genotypes in Alzheimer's disease associated with Down's syndrome. Dutch Study Group on Down's Syndrome and Ageing. 1995 , 38, 225-30	49
2083	An Italian kindred with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). 1995 , 38, 231-6	34
2082	Apolipoprotein E epsilon 4 allele is not associated with earlier age at onset in amyotrophic lateral sclerosis. 1995 , 38, 460-3	67
2081	Lack of an association between apolipoprotein E epsilon 4 and Alzheimer's disease in elderly Nigerians. 1995 , 38, 463-5	141
2080	Apolipoprotein E genotypes and age of onset in early-onset familial Alzheimer's disease. 1995 , 38, 678-80	59
2079	Apolipoprotein E genotype in patients with Alzheimer's disease: implications for the risk of dementia among relatives. 1995 , 38, 797-808	65
2078	Apolipoprotein E genotyping in the diagnosis of Alzheimer's disease. 1995 , 38, 967-70	3
2077	Brain-specific expression of human microtubule-associated protein 1A (MAP1A) gene and its assignment to human chromosome 15. 1995 , 40, 820-5	6
2076	Apolipoprotein III is dramatically up-regulated during the programmed death of insect skeletal muscle and neurons. 1995 , 26, 119-29	59
2075	Phenotyping of apolipoprotein E using immobilized pH gradient gels for one-dimensional and two-dimensional separations. 1995 , 16, 1184-6	7
2074	The neurobiology and genetics of Alzheimer's disease. 1995 , 10, S243-S246	3
2073	Aluminium and the risk for Alzheimer's disease. 1995 , 6, 233-275	164
2072	Apolipoprotein E4 allele and Alzheimer disease: examination of allelic association and effect on age at onset in both early- and late-onset cases. 1995 , 12, 83-92	56
2071	Dementia among elderly apolipoprotein E type 4/4 homozygotes: a prospective study. 1995 , 12, 309-11	4

2070	Underexpression of the apolipoprotein E2 and E4 alleles in the Greek Cypriot population of Cyprus. 1995 , 12, 489-97	24
2069	Autopsy diagnoses of Alzheimer disease: Independent reviews and clinical implications. 1995 , 10, 505-510	2
2068	Apolipoprotein E genotyping methods for the clinical laboratory. 1995 , 9, 63-9	18
2067	Scopolamine-induced impairment as a potential predictor of Alzheimer's disease in individuals with Apolipoprotein E type 4 alleles. 1995 , 20, 1519-20	6
2066	The genetic contribution to the phenotype. 1995 , 95, 127-48	59
2065	Astroglial localization of cholesteryl ester transfer protein in normal and Alzheimer's disease brain tissues. 1995 , 90, 633-6	26
2064	Apolipoprotein E (apoE) polymorphism and its influence on ApoE concentrations in the cerebrospinal fluid in Finnish patients with Alzheimer's disease. 1995 , 95, 39-42	95
2063	High frequency of the apo epsilon 4 allele in Khoi San from South Africa. 1995 , 95, 46-8	41
2062	Cerebral beta amyloid deposition in patients with malignant neoplasms: its prevalence with aging and effects of radiation therapy on vascular amyloid. 1995 , 90, 135-41	30
2061	Apolipoprotein E genotype and neuropathological phenotype in two members of a German family with chromosome 14-linked early onset Alzheimer's disease. 1995 , 90, 257-65	20
2060	Systemic vascular smooth muscle cell impairment in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. 1995 , 89, 500-12	265
2059	Glial expression of the beta-amyloid precursor protein (APP) in global ischemia. 1995 , 15, 647-54	84
2058	Genetic association of the very low density lipoprotein (VLDL) receptor gene with sporadic Alzheimer's disease. 1995 , 11, 207-9	153
2057	Sand in the sheets. 1995 , 1, 120-2	7
2056	Apolipoprotein E epsilon 4 allele is associated with deposition of amyloid beta-protein following head injury. 1995 , 1, 135-7	443
2055	Alzheimer's disease. Mouse model made. 1995 , 373, 476-7	11
2054	Alzheimer's disease. Missense on the membrane. 1995 , 375, 734-5	25
2053	Lipoprotein glomerulopathy: A new aspect of lipid induced glomerular injury. 1995 , 1, 17-24	20

2052	The effect of diagnosing Alzheimer's disease on frequency of physician visits: a case-control study. 1995 , 10, 187-93	29
2051	A potential role for apoptosis in neurodegeneration and Alzheimer's disease. 1995 , 10, 19-45	340
2050	Free radical theory of aging: Alzheimer's disease pathogenesis. 1995 , 18, 97-119	77
2049	Neurodegenerative diseases and risk factors: a literature review. 1995 , 40, 847-58	27
2048	Characterization of an upstream regulatory sequence and its binding protein in the mouse apolipoprotein E gene. 1995 , 1262, 124-32	1
2047	Subcellular localization of the low density lipoprotein receptor-related protein (alpha 2-macroglobulin receptor) in human brain. 1995 , 691, 235-8	49
2046	Apolipoproteins E3 and E4 induce, and transthyretin prevents accumulation of the Alzheimer's beta-amyloid peptide in cultured vascular smooth muscle cells. 1995 , 698, 217-22	64
2045	Improved PCR amplification/HhaI restriction for unambiguous determination of apolipoprotein E alleles. 1995 , 41, 187-190	15
2044	Apolipoprotein E genotyping on agarose gels. 1995 , 41, 1046-1047	50
2043	Leukocyte hexokinase activity in aging and Alzheimer disease. 1995 , 6, 200-4	1
2042	Familial Alzheimer's disease and cortical Lewy bodies: is there a genetic susceptibility factor?. 1995 , 6, 191-4	2
2041	Amyloid, aluminium and the aetiology of Alzheimer's disease. 1995 , 163, 256-9	26
2040	Molecular Genetic Advances in Neurodegenerative Disorders. 1995 , 15, 915-926	2
2039	Physiological significance of apolipoprotein mutants. 1995 , 9, 768-76	16
2038	The genetics of Alzheimer's disease and mutations in the amyloid E protein precursor gene. 1995 , 59-78	5
2037	Apolipoprotein E and Alzheimer's disease. 1995 , 225-245	2
2036	A novel cytochrome P450 expressed primarily in brain. 1995 , 270, 29739-45	127
2035	There is a pathologic relationship between ApoE-epsilon 4 and Alzheimer's disease. 1995 , 52, 650-1	21

2034	The new genetics in psychiatry. 1995 , 1, 109-115	
2033	Genes and recent developments in the epidemiology of Alzheimer's disease and related dementia. 1995 , 17, 39-47	16
2032	Accumulation of aluminium and silicon in lipofuscin granules. 1995 , 41 Suppl 2, 131-44	12
2031	Complete Penetrance of Creutzfeldt-Jakob Disease in Libyan Jews Carrying the E200K Mutation in the Prion Protein Gene. 1995 , 1, 607-613	71
2030	Alzheimer's disease—New approaches to old problems. 1995 , 7, 419-435	1
2029	Health effects of aluminum: a critical review with emphasis on aluminum in drinking water. 1995 , 3, 29-81	76
2028	The inhibitory effect of apolipoprotein E4 on neurite outgrowth is associated with microtubule depolymerization. 1995 , 270, 19791-9	200
2027	Apolipoprotein E: a review of its roles in lipoprotein metabolism, neuronal growth and repair and as a risk factor for Alzheimer's disease. 1995 , 25, 223-9	48
2026	The impact of genetic and environmental factors on the pathobiology of Alzheimer's disease: a multifactorial disorder?. 1995 , 7, 361-383	2
2025	Stable expression and secretion of apolipoproteins E3 and E4 in mouse neuroblastoma cells produces differential effects on neurite outgrowth. 1995 , 270, 27063-71	253
2024	Genetic variation and aging. 1995 , 29, 553-75	93
2023	Rate of progression of Alzheimer's disease is associated with genetic risk. 1995 , 52, 918-23	24
2022	Risk factors in clinically diagnosed presenile dementia of the Alzheimer type: a case-control study in northern England. 1995 , 49, 253-8	85
2021	Molecular Genetics and Psychology. 1995 , 4, 114-117	14
2020	Effects of apoprotein E on intracellular metabolism of model triglyceride-rich particles are distinct from effects on cell particle uptake. 1995 , 270, 1761-9	53
2019	The Amyloid Peptide and Its Precursor in Alzheimer's Disease. 1995 , 6,	23
2018	Apolipoprotein E, survival in Alzheimer's disease patients, and the competing risks of death and Alzheimer's disease. 1995 , 45, 1323-8	146
2017	Neuropathological changes in Down's syndrome hippocampal formation. Effect of age and apolipoprotein E genotype. 1995 , 52, 373-8	123

2016	The Apolipoprotein E E4 Allele and Sex-Specific Risk of Alzheimer's Disease. 1995 , 273, 373	23
2015	Apolipoprotein E epsilon 4 allele and the lifetime risk of Alzheimer's disease. What physicians know, and what they should know. 1995 , 52, 1074-9	136
2014	Statement on Use of Apolipoprotein E Testing for Alzheimer Disease. 1995 , 274, 1627	128
2013	Suicidal behaviors and the tryptophan hydroxylase gene. 1995 , 52, 846-9	63
2012	Apolipoprotein E deficiency leads to cutaneous foam cell formation in mice. 1995 , 104, 246-50	26
2011	Altered expression of transforming growth factor-beta in Alzheimer's disease. 1995 , 45, 1561-9	138
2010	Transgenic mice and modeling Alzheimer's disease. 1995 , 6, 87-96	6
2009	Episodic memory changes are associated with the APOE-epsilon 4 allele in nondemented older adults. 1995 , 45, 2203-6	220
2008	Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: a case-control study. 1995 , 45, 1092-6	342
2007	Apolipoprotein E Type 4 Allele and Cerebral Glucose Metabolism in Relatives at Risk for Familial Alzheimer Disease. 1995 , 273, 942	314
2006	Effectiveness and Safety of Velnacrine for the Treatment of Alzheimer's Disease. 1995 , 155, 1766	31
2005	Lack of association of apolipoprotein E allele epsilon 4 with late-onset Alzheimer's disease among Finnish centenarians. 1995 , 45, 903-7	113
2004	Apolipoprotein E E4 Allele and Risk of Dementia. 1995 , 273, 374	23
2003	The prevention of neurogenetic disease. 1995 , 52, 356-62	8
2002	Alzheimer's disease in the National Academy of Sciences-National Research Council Registry of Aging Twin Veterans. III. Detection of cases, longitudinal results, and observations on twin concordance. 1995 , 52, 763-71	149
2001	Apolipoprotein E epsilon 4 allele is a risk factor for familial and sporadic presenile Alzheimer's disease in both homozygote and heterozygote carriers. 1995 , 32, 642-4	33
2000	Apolipoprotein E: Emerging Story in the Pathogenesis of Alzheimer's Disease. 1995 , 1, 298-306	7
1999	Alzheimer's disease with and without coexisting Parkinson's disease changes: apolipoprotein E genotype and neuropathologic correlates. 1995 , 45, 1985-90	60

1998	The regions of the Fe65 protein homologous to the phosphotyrosine interaction/phosphotyrosine binding domain of Shc bind the intracellular domain of the Alzheimer's amyloid precursor protein. 1995 , 270, 30853-6	243
1997	Apolipoprotein E carboxyl-terminal fragments are complexed to amyloids A and L. Implications for amyloidogenesis and Alzheimer's disease. 1995 , 270, 17610-5	47
1996	Apolipoprotein E Status as a Predictor of the Development of Alzheimer's Disease in Memory-Impaired Individuals. 1995 , 273, 1274	391
1995	Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. 1995 , 15, 361-72	732
1994	Characterization of stable complexes involving apolipoprotein E and the amyloid beta peptide in Alzheimer's disease brain. 1995 , 15, 219-28	181
1993	Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins. 1995 , 15, 1203-18	482
1992	Gene expression and cellular content of cathepsin D in Alzheimer's disease brain: evidence for early up-regulation of the endosomal-lysosomal system. 1995 , 14, 671-80	309
1991	Is there a genetic susceptibility to idiopathic parkinsonism?. 1995 , 1, 73-84	6
1990	Lipids and atherosclerosis. 1995 , 16, 509-710	10
1989	Allelic associations between 100 DNA markers and high versus low IQ. 1995 , 21, 31-48	69
1988	Two new genes for Alzheimer's disease. 1995 , 18, 436	4
1987	The endosomal-lysosomal system of neurons: new roles. 1995 , 18, 489-96	124
1986	Association of apolipoprotein E genotype with brain levels of apolipoprotein E and apolipoprotein J (clusterin) in Alzheimer disease. 1995 , 33, 174-8	169
1985	Expression and distribution of low density lipoprotein receptor-related protein mRNA in the rat central nervous system. 1995 , 33, 37-46	36
1984	The association of apolipoprotein E polymorphism with memory: a population based study. 1995 , 191, 141-4	79
1983	ApoE3 binding to tau tandem repeat I is abolished by tau serine262 phosphorylation. 1995 , 192, 209-12	50
1982	ApoE immunoreactivity and microglial cells in Alzheimer's disease brain. 1995 , 195, 5-8	102
1981	The extent of amyloid deposition in brain in patients with Down's syndrome does not depend upon the apolipoprotein E genotype. 1995 , 196, 105-8	21

1980	Fibrillogenesis of synthetic amyloid-beta peptides is dependent on their initial secondary structure. 1995 , 200, 105-8	132
1979	No association found between Alzheimer's disease and a mitochondrial tRNA glutamine gene variant. 1995 , 201, 107-10	45
1978	Apolipoprotein E (APOE) allele frequencies in late-onset sporadic Alzheimer's disease (AD), mixed dementia and vascular dementia: lack of association of epsilon 4 allele with AD in Italian octogenarian patients. 1995 , 201, 231-4	39
1977	Apolipoprotein E type epsilon 4 allele frequency is increased in patients with schizophrenia. 1995 , 202, 101-4	60
1976	Localization of a domain in apolipoprotein E with both cytostatic and cytotoxic activity. 1995 , 34, 11142-51	56
1975	Characterization of subpopulations of lipoprotein particles isolated from human cerebrospinal fluid. 1995 , 1255, 192-200	124
1974	Identification of a unique apolipoprotein E allele in <i>Microcebus murinus</i> ; ApoE brain distribution and co-localization with beta-amyloid and tau proteins. 1995 , 2, 169-76	16
1973	Co-expression of beta-amyloid precursor protein (betaAPP) and apolipoprotein E in cell culture: analysis of betaAPP processing. 1995 , 2, 177-87	48
1972	A population-based study of tau protein and ubiquitin in cerebrospinal fluid in 85-year-olds: relation to severity of dementia and cerebral atrophy, but not to the apolipoprotein E4 allele. 1995 , 4, 433-42	54
1971	Effects of apolipoprotein E genotype on cortical neuropathology in senile dementia of the Lewy body and Alzheimer's disease. 1995 , 4, 443-8	26
1970	Marked decrease of plasma apolipoprotein AI and AII in Japanese patients with late-onset non-familial Alzheimer's disease. 1995 , 239, 209-11	55
1969	On the metabolism of apolipoprotein E and the Alzheimer diseases. 1995 , 132, 149-56	46
1968	Apolipoprotein E immunoreactivity within neurofibrillary tangles: relationship to Tau and PHF in Alzheimer's disease. 1995 , 132, 162-71	45
1967	Apolipoprotein E increases the fibrillogenic potential of synthetic peptides derived from Alzheimer's, gelsolin and AA amyloids. 1995 , 371, 110-4	41
1966	Apolipoprotein E mRNA in the brains of patients with Alzheimer's disease. 1995 , 129, 56-61	42
1965	Comparison of cathepsin protease activities in brain tissue from normal cases and cases with Alzheimer's disease, Lewy body dementia, Parkinson's disease and Huntington's disease. 1995 , 131, 65-70	49
1964	Apolipoprotein E genotype in Spanish patients of Alzheimer's or Parkinson's disease. 1995 , 134, 146-9	21
1963	Beta APP mRNA transcription is increased in cultured fibroblasts from the familial Alzheimer's disease-1 family. 1995 , 28, 319-37	58

1962	Apolipoprotein E genotype, Alzheimer's pathologies and related gene expression in the aged population. 1995 , 29, 92-8	39
1961	Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. 1995 , 16, 523-30	389
1960	Chrysamine-G binding to Alzheimer and control brain: autopsy study of a new amyloid probe. 1995 , 16, 541-8	113
1959	Alzheimer pathology of patients carrying apolipoprotein E epsilon 4 allele. 1995 , 16, 505-13	55
1958	Influence of the apolipoprotein E genotype on amyloid deposition and neurofibrillary tangle formation in Alzheimer's disease. 1995 , 69, 757-61	198
1957	Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein. 1995 , 333, 1242-7	412
1956	The case for heterogeneity in the etiology of schizophrenia. 1995 , 17, 161-75	131
1955	Familial non-specific dementia maps to chromosome 3. 1995 , 4, 1625-8	153
1954	Two conformational states of amyloid beta-peptide: implications for the pathogenesis of Alzheimer's disease. 1995 , 186, 115-8	64
1953	Apolipoprotein epsilon 4 allele and disease progression in patients with late-onset Alzheimer's disease. 1995 , 183, 32-4	76
1952	A severe loss of choline acetyltransferase in the frontal cortex of Alzheimer patients carrying apolipoprotein epsilon 4 allele. 1995 , 187, 79-82	148
1951	Apolipoprotein E4 genotype is not a risk factor for systemic AA amyloidosis or familial amyloid polyneuropathy. 1995 , 2, 163-166	7
1950	Apolipoprotein E, synaptic plasticity and Alzheimer's disease. 1995 , 27, 663-70	76
1949	The neuroscience perspective and the changing role of the psychiatrist : the challenge for psychiatric educators. 1995 , 19, 202-12	5
1948	Cognitive impairment in elderly people. Predisposing factors and implications for experimental drug studies. 1995 , 7, 459-79	37
1947	Arginine residues at codons 112 and 158 in the apolipoprotein E gene correspond to the ancestral state in humans. 1995 , 112, 85-90	94
1946	Falls, a community care perspective. 1995 , 345, 1549-51	72
1945	CORRECTION. 1995 , 345, 1551	

1944	Apolipoprotein E-epsilon 4 gene dose. 1995 , 346, 967-8		14
1943	Apolipoprotein E allele epsilon 4, dementia, and cognitive decline in a population sample. 1995 , 346, 1387-90		238
1942	A mitochondrial bottleneck hypothesis of Alzheimer's disease. 1995 , 1, 240-7		15
1941	Association of apolipoprotein epsilon 4 allele and neuropathologic findings in patients with dementia. 1995 , 90, 239-43		38
1940	Candidate gene for the chromosome 1 familial Alzheimer's disease locus. <i>Science</i> , 1995 , 269, 973-7	33.3	2156
1939	A familial Alzheimer's disease locus on chromosome 1. <i>Science</i> , 1995 , 269, 970-3	33.3	663
1938	Apolipoprotein E4 allele frequency in Spanish Alzheimer and control cases. 1995 , 189, 182-6		33
1937	Volumes of hippocampus, amygdala and frontal lobe in Alzheimer patients with different apolipoprotein E genotypes. 1995 , 67, 65-72		147
1936	Apolipoprotein E polymorphism and Alzheimer's disease in eastern Finland. 1995 , 185, 13-5		34
1935	ApoE genotype and familial Alzheimer's disease: a possible influence on age of onset in APP717 Val->Ile mutated families. 1995 , 183, 1-3		62
1934	Apolipoprotein E polymorphism influences not only cerebral senile plaque load but also Alzheimer-type neurofibrillary tangle formation. 1995 , 66, 583-7		145
1933	Apolipoprotein E allelic frequencies in patients with lobar atrophy. 1995 , 188, 205-7		32
1932	Allelic variation of apolipoprotein E in Japanese sporadic Creutzfeldt-Jakob disease patients. 1995 , 187, 209-11		19
1931	Genes and human behavior. 1995 , 46, 625-54		82
1930	Apolipoprotein E alleles but neither apolipoprotein B nor apolipoprotein AI/CIII alleles are associated with late onset, familial Alzheimer's disease. 1995 , 188, 202-4		11
1929	Aging in rats is associated with an increase in adrenal apolipoprotein E. 1995 , 107, 93-7		5
1928	Apolipoprotein E type epsilon 4 allele frequency is not increased in patients with sporadic inclusion-body myositis. 1995 , 183, 35-8		29
1927	Diagnostic testing and dementia. 1996 , 14, 45-59		7

1926	Genetic and aging epidemiology. The merging of two disciplines. 1996 , 14, 467-75	4
1925	The clinical epidemiology of Alzheimer's disease. 1996 , 14, 337-51	32
1924	Héfhoghlt'ghéhtique de la maladie d'Alzheimer. 1996 , 7, 27-30	
1923	Apolipoprotein E alleles as risk factors in Alzheimer's disease. 1996 , 47, 387-400	527
1922	Rational design of an animal model for Alzheimer's disease: introduction of multiple human genomic transgenes to reproduce AD pathology in a rodent. 1996 , 17, 173-82	25
1921	APP transgenesis: approaches toward the development of animal models for Alzheimer disease neuropathology. 1996 , 17, 153-71	44
1920	APOE alleles in Alzheimer's disease and vascular dementia in a population aged 85+. 1996 , 17, 373-6	26
1919	Relationship between multifunctional protein éusteriné and Alzheimer disease. 1996 , 17, 717-722	0
1918	Inflammatory processes and antiinflammatory drugs in Alzheimer's disease: a current appraisal. 1996 , 17, 789-94	155
1917	Alzheimer A beta neurotoxicity: promotion by antichymotrypsin, ApoE4; inhibition by A beta-related peptides. 1996 , 17, 773-80	98
1916	Expression of CAP37, a novel inflammatory mediator, in Alzheimer's disease. 1996 , 17, 753-759	4
1915	Increased density of senile plaques (SP), but not neurofibrillary tangles (NFT), in non-demented individuals with the apolipoprotein E4 allele: comparison to confirmed Alzheimer's disease patients. 1996 , 138, 97-104	40
1914	Effect of cerebrospinal fluid from normal and Alzheimer's patients with different apolipoprotein E phenotypes on in vitro aggregation of amyloid beta-protein. 1996 , 141, 54-8	14
1913	Effect of age, ethnicity, and head injury on the association between APOE genotypes and Alzheimer's disease. 1996 , 802, 6-15	77
1912	Familial and population-based studies of apolipoprotein E and Alzheimer's disease. 1996 , 802, 16-26	25
1911	No association between alpha 1-antichymotrypsin and familial Alzheimer's disease. 1996 , 802, 35-41	8
1910	Apolipoprotein E, A beta-amyloid, and the molecular pathology of Alzheimer's disease. Therapeutic implications. 1996 , 802, 42-9	8
1909	Apolipoprotein E and Alzheimer's disease. A rapidly expanding field with medical and epidemiological consequences. 1996 , 802, 50-7	59

1908	Predictive value of APOE genotyping in incipient Alzheimer's disease. 1996 , 802, 58-69	48
1907	Early detection of Alzheimer's disease by combining apolipoprotein E and neuroimaging. 1996 , 802, 70-8	46
1906	The use of apolipoprotein E genotyping as a diagnostic test in suspected Alzheimer's disease. 1996 , 802, 79-91	11
1905	The effect of apolipoprotein E genotype on biochemical markers of Alzheimer's disease. 1996 , 802, 92-100	1
1904	Apolipoprotein E genotype and gender influence response to tacrine therapy. 1996 , 802, 101-10	80
1903	A pilot experience in genetic counseling for Alzheimer's disease. Findings relevant to the potential use of APOE genotyping in cognitively impaired individuals. 1996 , 802, 120-7	4
1902	The National Institute on Aging/Alzheimer's Association recommendations on the application of apolipoprotein E genotyping to Alzheimer's disease. 1996 , 802, 149-76	57
1901	NIA/AlzA Conference on apolipoprotein E genotyping in Alzheimer's disease. Bibliography. 1996 , 802, 177-224	
1900	Apolipoprotein E. Structure, function, and possible roles in Alzheimer's disease. 1996 , 777, 139-45	59
1899	Morphological, biochemical, and genetic support for an apolipoprotein E effect on microtubular metabolism. 1996 , 777, 146-57	38
1898	Clinical and neuropathological correlates of apolipoprotein E genotype in Alzheimer's disease. Window on molecular epidemiology. 1996 , 777, 158-65	23
1897	Apolipoprotein E, plaques, tangles and cholinergic dysfunction in Alzheimer's disease. 1996 , 777, 166-74	55
1896	Alzheimer's disease and apolipoprotein E in Italy. 1996 , 777, 260-5	15
1895	Apolipoprotein E polymorphism is associated with both senile plaque load and Alzheimer-type neurofibrillary tangle formation. 1996 , 777, 276-80	17
1894	Differential regulation of APP secretion by apolipoprotein E3 and E4. 1996 , 777, 322-6	8
1893	A hypothesis on the pathogenesis of Alzheimer's disease. 1996 , 786, 152-68	40
1892	Receptor-effector coupling dysfunctions in Alzheimer's disease. 1996 , 786, 294-304	25
1891	Free intracellular calcium in aging and Alzheimer's disease. 1996 , 786, 305-20	15

1890	Seeding of A beta fibril formation is inhibited by all three isotypes of apolipoprotein E. 1996 , 35, 12623-8	109
1889	Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. 1996 , 334, 752-8	1163
1888	A Reductionist View of Alzheimer's Disease. 1996 , 29, 317-321	94
1887	Native complex formation between apolipoprotein E isoforms and the Alzheimer's disease peptide A beta. 1996 , 35, 7123-30	57
1886	Transthyretin gene in Alzheimer's disease patients. 1996 , 204, 212-4	26
1885	No association between apolipoprotein E epsilon4 allele and the age of onset in type I familial amyloid polyneuropathy. 1996 , 204, 209-11	8
1884	Memory functions in human subjects with different apolipoprotein E phenotypes during a 3-year population-based follow-up study. 1996 , 204, 177-80	81
1883	Apolipoprotein E polymorphism and susceptibility to early- and late-onset sporadic Alzheimer's disease in Hokkaido, the northern part of Japan. 1996 , 206, 17-20	20
1882	Significantly increased frequency of the apolipoprotein E epsilon 4 allele in elderly non-demented leprosy patients. 1996 , 207, 206-8	8
1881	No association between very low density lipoprotein receptor (VLDL-R) and Alzheimer disease in American Caucasians. 1996 , 209, 105-8	27
1880	Expression of apolipoprotein E inhibits aggregation of the C-terminal fragments of beta-amyloid precursor protein. 1996 , 210, 65-8	7
1879	Assignment of Alzheimer's presenilin-1 (PS-1) gene to 14q24.3 by fluorescence in situ hybridization. 1996 , 214, 69-71	2
1878	Comparable amyloid beta-protein (A beta) 42(43) and A beta 40 deposition in the aged monkey brain. 1996 , 214, 196-8	19
1877	Apolipoprotein E in Alzheimer's disease risk and case detection: a case-control study. 1996 , 49, 1143-8	43
1876	No association between chromosome-18 markers and lithium-responsive affective disorders. 1996 , 63, 17-23	49
1875	Lithium-responsive affective disorders: no association with the tyrosine hydroxylase gene. 1996 , 64, 91-6	48
1874	Apolipoprotein E, memory and Alzheimer's disease. 1996 , 19, 224-8	80
1873	Induction of apolipoprotein E mRNA in the hippocampus of the gerbil after transient global ischemia. 1996 , 38, 37-44	32

1872	Identification and characterization of presenilin I-467, I-463 and I-374. 1996 , 381, 7-11	36
1871	Interaction between human amphipathic apolipoproteins and amyloid beta-peptide: surface plasmon resonance studies. 1996 , 383, 9-12	32
1870	Immunohistochemical analysis of presenilin-1 expression in the mouse brain. 1996 , 383, 219-22	49
1869	Quantification of presenilin-1 mRNA in Alzheimer's disease brains. 1996 , 394, 279-84	20
1868	Human apolipoprotein E2, E3, and E4 isoform-specific transgenic mice: human-like pattern of glial and neuronal immunoreactivity in central nervous system not observed in wild-type mice. 1996 , 3, 229-45	152
1867	Apolipoprotein E genotype and Alzheimer's disease in an elderly Norwegian cohort. 1996 , 5, 43-7	6
1866	Microtubule formation and neurite extension are blocked by apolipoprotein E4. 1996 , 7, 725-731	5
1865	Focal cortical atrophy syndromes. 1996 , 31, 188-229	57
1864	Structural correlates of cognition in dementia: quantification and assessment of synapse change. 1996 , 5, 417-21	281
1863	Neurogenetic diseases: molecular diagnosis and therapeutic approaches. 1996 , 74, 71-84	13
1862	APOE epsilon 4 allele in Alzheimer's and non-Alzheimer's dementias. 1996 , 348, 960-1	9
1861	Specificity, sensitivity, and predictive value of apolipoprotein-E genotyping for sporadic Alzheimer's disease. 1996 , 348, 90-3	220
1860	Apolipoprotein E genotyping in Alzheimer's disease. 1996 , 347, 1091-1095	225
1859	Genetic association between intronic polymorphism in presenilin-1 gene and late-onset Alzheimer's disease. Alzheimer's Disease Collaborative Group. 1996 , 347, 509-12	234
1858	Attenuation of apolipoprotein E Epsilon4 allele gene dose in late age. 1996 , 347, 542	16
1857	Apolipoprotein E allele distribution in parents of Down's syndrome children. 1996 , 347, 862-5	51
1856	Association of the APOE epsilon 4 allele with clinical subtypes of late life depression. 1996 , 40, 1008-16	76
1855	Quantification of APP and APLP2 mRNA in APOE genotyped Alzheimer's disease brains. 1996 , 43, 85-95	24

1854	Sequence analysis of presenilin-1 gene mutation in Japanese Alzheimer's disease patients. 1996 , 218, 139-41	42
1853	Human APOE protein localized in brains of transgenic mice. 1996 , 219, 57-9	17
1852	Analysis of the APOE alleles impact in Down's syndrome. 1996 , 220, 57-60	19
1851	The significance of the activity of CSF cholinesterases in dementias. 1996 , 47, 363-76	14
1850	Molecular genetics of Alzheimer's disease. 1996 , 165, 13-7	20
1849	Clinical subgroups of the Alzheimer syndrome. 1996 , 165, 51-7	19
1848	Diagnosis of Alzheimer's disease: defining genetic profiles (genotype vs phenotype). 1996 , 165, 72-84	14
1847	Treatment of Alzheimer's disease: future directions. 1996 , 165, 128-36	7
1846	Transgenic models of neurodegenerative diseases. 1996 , 6, 651-60	26
1845	The amyloid precursor protein of Alzheimer's disease in the reduction of copper(II) to copper(I). <i>Science</i> , 1996 , 271, 1406-9	33-3 618
1844	Inhibitors of the Maillard Reaction. 1996 , 6, 167-177	8
1843	Alzheimer Amyloid- β Peptide Forms Denaturant-Resistant Complex with Type β but Not Type β Isoform of Native Apolipoprotein E. 1996 , 2, 175-180	69
1842	Identifying genes for cognitive abilities and disabilities. 1996 , 89-104	5
1841	Genetic correlations in Lewy body disease. 1996 , 336-349	3
1840	Alzheimer's disease and apolipoprotein E genotype in Western Australia: an autopsy-verified series. 1996 , 165, 77-80	9
1839	Psychiatric genetics. 1996 , 169, 386-92	1
1838	The Underlying Molecular Mechanism of Apolipoprotein E Polymorphism: Relationships to Lipid Disorders, Cardiovascular Disease, and Alzheimer's Disease. 1996 , 16, 105-123	37
1837	Scrapie in mice deficient in apolipoprotein E or glial fibrillary acidic protein. 1996 , 47, 449-53	45

1836	Low apolipoprotein E4 allelic frequency in Alzheimer's disease and functional psychiatric disorders. 1996 , 7, 118-9	1
1835	Apolipoprotein E genotype does not promote the clinical progression of manifest Alzheimer's disease. 1996 , 7, 120	0
1834	Human apolipoprotein E: the Alzheimer's disease connection. 1996 , 10, 1485-94	277
1833	Apolipoprotein E and Alzheimer's disease: strength of association is related to age at onset. 1996 , 7, 251-5	10
1832	Transcription factor AP-2 regulates human apolipoprotein E gene expression in astrocytoma cells. 1996 , 16, 7550-6	57
1831	The gain of apolipoprotein E genotyping to separate patients with Alzheimer's disease from normal individuals: relevance to community studies. 1996 , 7, 336-42	1
1830	Properties of the endosomal-lysosomal system in the human central nervous system: disturbances mark most neurons in populations at risk to degenerate in Alzheimer's disease. 1996 , 16, 186-99	311
1829	Impact of sample selection on APOE epsilon 4 allele frequency: a comparison of two Alzheimer's disease samples. 1996 , 44, 704-7	50
1828	Genetic epidemiology. 1996 , 52, 408-33	23
1827	Progress in Molecular Genetics of Alzheimer's Disease. 1996 , 2, 3-6	5
1826	Molecular genetic research on IQ: can it be done? Should it be done?. 1996 , 28, 491-507	2
1825	What genetic research on intelligence tells us about the environment. 1996 , 28, 587-606	5
1824	Recent advances in the genetics of Alzheimer's disease and vascular dementia with an emphasis on gene-environment interactions. 1996 , 44, 1242-50	29
1823	Apolipoprotein E genotype: utility in clinical practice in Alzheimer's disease. 1996 , 44, 1469-71	7
1822	The molecular genetics of affective disorders: An overview. 1996 , 13, 155-161	
1821	Prevalence of dementia and distribution of ApoE alleles in Japanese centenarians: an almost-complete survey in Yamanashi Prefecture, Japan. 1996 , 44, 151-5	52
1820	Alzheimer's syndrome, not Alzheimer's disease. 1996 , 44, 96-7	3
1819	Temporal progression of hippocampal atrophy and apolipoprotein E gene in Alzheimer's disease. 1996 , 44, 216-7	7

1818	From genes to public health: the applications of genetic technology in disease prevention. Genetics Working Group. 1996 , 86, 1717-22	81
1817	Use of genetically engineered mice as models for understanding human neurodegenerative disease. 1996 , 44, 717-22	4
1816	Cholinomimetic treatment of Alzheimer's disease. 1996 , 109, 299-309	6
1815	Immunohistochemical study on the deposition of apolipoprotein E in cerebral and islet amyloidoses in cynomolgus monkeys (<i>Macaca fascicularis</i>). 1996 , 45, 199-203	4
1814	Biological markers for the clinical diagnosis of Alzheimer's disease. 1996 , 179, 65-79	19
1813	Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein. 1996 , 271, 4436-40	348
1812	Normal distribution of apolipoprotein E alleles in progressive supranuclear palsy. 1996 , 46, 1156-7	21
1811	Strategies and applications of DNA level diagnosis in genetic diseases: past experiences and future directions. 1996 , 2, 409-46	
1810	Apolipoprotein E in cerebrospinal fluid from patients with Alzheimer's disease and other forms of dementia is reduced but without any correlation to the apoE4 isoform. 1996 , 7, 273-8	15
1809	Clinical and neuropsychological characteristics in familial and sporadic Alzheimer's disease: relation to apolipoprotein E polymorphism. 1996 , 46, 413-9	133
1808	Genetic modulation of the senescent phenotype of Homo sapiens. 1996 , 31, 49-59	14
1807	Alzheimer's disease: preliminary study of spatial distribution at birth place. 1996 , 42, 871-8	17
1806	Inconstant apolipoprotein E (ApoE)-like immunoreactivity in amyloid beta protein deposits: relationship with APOE genotype in aging brain and Alzheimer's disease. 1996 , 92, 180-5	23
1805	Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL): a morphological study of a German family. 1996 , 92, 341-50	55
1804	Polymorphisms of apolipoproteins A-IV and E in a Turkish population living in Germany. 1996 , 98, 285-90	14
1803	Alpha 1-antichymotrypsin gene polymorphism and risk for Alzheimer's disease. 1996 , 103, 1205-10	33
1802	Synaptic pathology in Alzheimer's disease: relation to severity of dementia, but not to senile plaques, neurofibrillary tangles, or the ApoE4 allele. 1996 , 103, 603-18	154
1801	Lack of association between schizophrenia and the apolipoprotein E epsilon 4 allele. 1996 , 246, 182-4	22

1800	Propionibacterium acnes in the cortex of patients with Alzheimer's disease. 1996 , 246, 108-9	19
1799	A beta A4 amyloid precursor protein gene and Alzheimer's disease. 1996 , 237, 6-15	30
1798	Dementia of the Alzheimer type and related dementias in the aged: DAT subgroups and senile dementia of the neurofibrillary tangle type. 1996 , 16, 89-98	42
1797	No association between c-fos gene polymorphisms and sporadic Alzheimer's disease. 1996 , 50, 331-3	1
1796	Pathological diagnosis of Alzheimer-type dementia for old-old and oldest-old patients. 1996 , 46, 842-54	18
1795	Cerebral amyloid angiopathies. 1996 , 22, 216-227	34
1794	Apolipoprotein E distribution among different plaque types in Alzheimer's disease: implications for its role in plaque progression. 1996 , 22, 334-41	36
1793	Cell surface APP751 forms complexes with protease nexin 2 ligands and is internalized via the low density lipoprotein receptor-related protein (LRP). 1996 , 740, 6-14	98
1792	Brain beta-spectrin is a component of senile plaques in Alzheimer's disease. 1996 , 743, 249-57	19
1791	Lipid disorders contributing to coronary heart disease: an update. 1996 , 21, 736-80	4
1790	Brain parenchymal and microvascular amyloid in Alzheimer's disease. 1996 , 6, 179-95	143
1789	The neurochemistry of Alzheimer's disease. 1996 , 168, 77-86	10
1788	Pupil response to tropicamide in Alzheimer's disease and other neurodegenerative disorders. 1996 , 94, 104-9	29
1787	Presenilin-1 polymorphism in patients with Alzheimer's disease, vascular dementia and alcohol-associated dementia in Japanese population. 1996 , 94, 326-8	26
1786	Issues in genetic testing for susceptibility to alcoholism: lessons from Alzheimer's disease and Huntington's disease. 1996 , 20, 1430-7	14
1785	An ApoE-Abeta inhibition complex in Abeta fibril extension. 1996 , 3, 949-56	38
1784	Clinical and pathological correlates of apolipoprotein E epsilon 4 in Alzheimer's disease. 1996 , 39, 62-70	336
1783	Abeta-peptide length and apolipoprotein E genotype in Alzheimer's disease. 1996 , 39, 395-9	116

1782	Alzheimer's disease and apolipoprotein E-4 allele in an Amish population. 1996 , 39, 700-4	39
1781	Apolipoprotein E and cognitive change in an elderly population. 1996 , 40, 55-66	178
1780	Genetic studies in Alzheimer's disease with an NACP/alpha-synuclein polymorphism. 1996 , 40, 207-15	110
1779	Apolipoprotein E genotype in elderly nondemented subjects without senile changes in the brain. 1996 , 40, 243-5	16
1778	Lack of association of very low density lipoprotein receptor gene polymorphism with Caucasian Alzheimer's disease. 1996 , 40, 251-4	33
1777	Apolipoprotein E and alpha1-antichymotrypsin polymorphism in Alzheimer's disease. 1996 , 40, 678-80	33
1776	Genetic factors in Alzheimer's disease: a review of recent advances. 1996 , 40, 829-40	68
1775	Allelic association but only weak evidence for linkage to the apolipoprotein E locus in late-onset Swedish Alzheimer families. 1996 , 67, 306-11	19
1774	Editorial Review. The genetics of Alzheimer's disease—new opportunities and new challenges. 1996 , 11, 491-497	6
1773	Apolipoprotein E-epsilon 4 allele and familial risk in Alzheimer's disease. 1996 , 13, 285-98	16
1772	High prevalence of serum apolipoprotein E4 isoprotein in rheumatoid arthritis patients with amyloidosis. 1996 , 39, 1728-32	22
1771	Human senescence. 1996 , 18, 1009-16	85
1770	Apolipoprotein E type 4 allele and Alzheimer's disease: effect on age at onset and relative risk in different age groups. 1996 , 243, 452-6	38
1769	Treatment Development Strategies for Alzheimer's Disease. 1996 , 2, 238-255	1
1768	A complete genomic screen for multiple sclerosis underscores a role for the major histocompatibility complex. The Multiple Sclerosis Genetics Group. 1996 , 13, 469-71	559
1767	Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. 1996 , 14, 55-61	780
1766	Injury-induced synthesis and release of apolipoprotein E and clusterin from rat neural cells. 1996 , 8, 2652-61	35
1765	SPECT and MRI analysis in Alzheimer's disease: relation to apolipoprotein E epsilon 4 allele. 1996 , 60, 644-9	92

1764	Diffuse Lewy body disease without amyloid plaques in a patient homozygous for apolipoprotein E allele epsilon 4: a case report. 1996 , 9, 181-4	
1763	Apolipoprotein E genotype and Alzheimer's disease in Hong Kong elderly Chinese. 1996 , 46, 146-9	54
1762	Apolipoprotein E epsilon 4 allele, cognitive decline, and deterioration of everyday performance in Alzheimer's disease. 1996 , 47, 440-3	78
1761	No founder effect in three novel Alzheimer's disease families with APP 717 Val-->Ile mutation. Clerget-darpoux. French Alzheimer's Disease Study Group. 1996 , 33, 661-4	14
1760	Apolipoprotein E: non-cognitive symptoms and cognitive decline in late onset Alzheimer's disease. 1996 , 61, 580-3	48
1759	The interaction between apolipoprotein E and Alzheimer's amyloid beta-peptide is dependent on beta-peptide conformation. 1996 , 271, 10602-6	98
1758	Human apolipoprotein E4 domain interaction. Arginine 61 and glutamic acid 255 interact to direct the preference for very low density lipoproteins. 1996 , 271, 19053-7	238
1757	Molecular Diagnosis of Genetic Diseases. 1996 ,	2
1756	Cerebrospinal fluid concentrations of soluble amyloid beta-protein and apolipoprotein E in patients with Alzheimer's disease: correlations with amyloid load in the brain. 1996 , 53, 189-93	50
1755	Association of serum cholesterol and triglyceride levels with agitation and cognitive function in a geropsychiatry unit. 1996 , 9, 53-6	10
1754	Regulation of amyloid protein precursor (APP) binding to collagen and mapping of the binding sites on APP and collagen type I. 1996 , 271, 1613-20	120
1753	Apolipoprotein E genotype determines survival in the oldest old (85 years or older) who have good cognition. 1996 , 53, 418-22	105
1752	The significance of glucose turnover in the brain in the pathogenetic mechanisms of Alzheimer's disease. 1996 , 7, 1-19	44
1751	Apolipoprotein E genotype and rate of decline in probable Alzheimer's disease. 1996 , 53, 345-50	98
1750	Lewy Body Disease and Dementia. 1996 , 156, 487	35
1749	The geneticist's approach to complex disease. 1996 , 47, 333-53	55
1748	Apolipoprotein E-containing high density lipoprotein promotes neurite outgrowth and is a ligand for the low density lipoprotein receptor-related protein. 1996 , 271, 30121-5	174
1747	Amyloid beta-protein and the genetics of Alzheimer's disease. 1996 , 271, 18295-8	654

1746	The apolipoprotein E allele epsilon 4 does not correlate with the number of senile plaques or neurofibrillary tangles in patients with Alzheimer's disease. 1996 , 61, 352-6	32
1745	Degradation of amyloid beta-protein by a serine protease-alpha2-macroglobulin complex. 1996 , 271, 8443-51	63
1744	The "nonamyloidogenic" p3 fragment (amyloid beta17-42) is a major constituent of Down's syndrome cerebellar preamyloid. 1996 , 271, 33623-31	110
1743	The length of amyloid-beta in hereditary cerebral hemorrhage with amyloidosis, Dutch type. Implications for the role of amyloid-beta 1-42 in Alzheimer's disease. 1996 , 271, 32185-91	74
1742	The serpin-enzyme complex receptor recognizes soluble, nontoxic amyloid-beta peptide but not aggregated, cytotoxic amyloid-beta peptide. 1996 , 271, 18032-44	68
1741	Familial and sporadic Alzheimer's disease: neuropathology cannot exclude a final common pathway. 1996 , 46, 406-12	98
1740	A prospective study of the clinical utility of ApoE genotype in the prediction of outcome in patients with memory impairment. 1996 , 46, 149-54	136
1739	Electromagnetic field exposure may cause increased production of amyloid beta and eventually lead to Alzheimer's disease. 1996 , 47, 1594-600	50
1738	Apolipoprotein E phenotype frequency and cerebrospinal fluid concentration are not associated with Creutzfeldt-Jakob disease. 1996 , 53, 1233-8	21
1737	Lack of association between alpha 1-antichymotrypsin polymorphism, Alzheimer's disease, and allele epsilon 4 of apolipoprotein E. 1996 , 47, 1575-7	43
1736	Apolipoprotein E genotype does not influence rates of cognitive decline in Alzheimer's disease. 1996 , 47, 444-8	130
1735	Pathogenesis of Alzheimer's disease: current status on apolipoprotein E4 gene research. 1996 , 7, 277-83	1
1734	The Genes Involved in Alzheimer's Disease. 1996 , 49-59	
1733	The A4 amyloid precursor protein gene and Alzheimer's disease. 1996 , 89-98	
1732	Medical education. 1996 , 53, 215	
1731	Genetic factors for the development of Alzheimer disease in the Cherokee Indian. 1996 , 53, 997-1000	31
1730	Alzheimer's disease: interaction of apolipoprotein E genotype, family history of dementia, gender, education, ethnicity, and age of onset. 1996 , 46, 1575-9	112
1729	The role of the Maillard reaction in other pathologies: Alzheimer's disease. 1996 , 11 Suppl 5, 7-12	33

1728 High-altitude pulmonary edema. **1996**, 335, 207

1727 Microtiter Array Diagonal Gel Electrophoresis (MADGE) for Population Scale Genotype Analyses. **1996**, 5, 269-81 3

1726 Who should provide genetic education prior to gene testing? Computers and other methods for improving patient understanding. **1997**, 1, 131-6 23

1725 Estrogen, apolipoprotein E, and dementia. **1997**, 6, 677

1724 Corticobasal degeneration: neuropathologic and clinical heterogeneity. **1997**, 48, 959-69 209

1723 Interfamilial and intrafamilial phenotypic heterogeneity in familial Alzheimer's disease. **1997**, 10, 1-6 5

1722 ApoE-4 and age at onset of Alzheimer's disease: the NIMH genetics initiative. **1997**, 48, 139-47 400

1721 Alzheimer's disease: diagnosis and treatment. **1997**, 4, 306-16 9

1720 Neurotropic viruses and Alzheimer's disease: a search for varicella zoster virus DNA by the polymerase chain reaction. **1997**, 62, 586-9 28

1719 Genetic modification of the phenotypes produced by amyloid precursor protein overexpression in transgenic mice. **1997**, 6, 1951-9 140

1718 The role of amyloid in the pathogenesis of Alzheimer's disease. **1997**, 378, 937-50 33

1717 Apolipoprotein E ϵ 4 Associated With Chronic Traumatic Brain Injury in Boxing. **1997**, 278, 136 359

1716 Apoptosis, neurotrophic factors and neurodegeneration. **1997**, 8, 223-65 38

1715 Apolipoprotein E in cerebrospinal fluid in 85-year-old subjects. Relation to dementia, apolipoprotein E polymorphism, cerebral atrophy, and white matter lesions. **1997**, 54, 267-72 28

1714 Alzheimer's disease: clinical implications of the apolipoprotein E genotype. **1997**, 48, S30-4 29

1713 Apolipoprotein E epsilon4 allele decreases functional connectivity in Alzheimer's disease as measured by EEG coherence. **1997**, 63, 59-65 81

1712 Genetics of Parkinson's disease. **1997**, 6, 1687-91 102

1711 Cognitive impairment in the Amish: a four county survey. **1997**, 26, 387-94 19

1710	Apolipoprotein E phenotype and cognitive decline in a prospective study of elderly community women. 1997 , 54, 1110-4	134
1709	No difference in cerebral glucose metabolism in patients with Alzheimer disease and differing apolipoprotein E genotypes. 1997 , 54, 273-7	63
1708	Complete Genomic Screen in Late-Onset Familial Alzheimer Disease. 1997 , 278, 1237	177
1707	Exploring the Etiology of Alzheimer Disease Using Molecular Genetics. 1997 , 277, 825	132
1706	D2 dopamine receptor A1 allele in Alzheimer disease and aging. 1997 , 54, 281-5	10
1705	The Clinical Introduction of Genetic Testing for Alzheimer DiseaseAn Ethical Perspective. 1997 , 277, 832	93
1704	Characterization of three human apolipoprotein E isoforms (E2, E3 and E4) expressed in Escherichia coli. 1997 , 35, 581-9	1
1703	Diagnosis and Treatment of Alzheimer Disease and Related Disorders. 1997 , 278, 1363	461
1702	Apolipoprotein E ϵ 4 and Incidence of Alzheimer Disease in a Community Population of Older Persons. 1997 , 277, 822	75
1701	Head injury and risk of Alzheimer's disease by apolipoprotein E genotype. 1997 , 146, 373-84	135
1700	Transcriptional regulation of the mouse presenilin-1 gene. 1997 , 272, 23489-97	25
1699	Adult-onset genetic disease: mechanisms, analysis and prediction. 1997 , 90, 83-103	5
1698	Clinical rationale of genetic testing in dementia. 1997 , 62, 217-21	8
1697	The impact of apolipoprotein E4 on cause of death in Alzheimer's disease. 1997 , 49, 76-81	20
1696	Genetic association of the low-density lipoprotein receptor-related protein gene (LRP), an apolipoprotein E receptor, with late-onset Alzheimer's disease. 1997 , 49, 56-61	298
1695	Evidence for association of HLA-A2 allele with onset age of Alzheimer's disease. 1997 , 49, 512-8	82
1694	Effects of Age, Sex, and Ethnicity on the Association Between Apolipoprotein E Genotype and Alzheimer Disease. 1997 , 278, 1349	2208
1693	The role of heredity in late-onset Alzheimer disease and vascular dementia. A twin study. 1997 , 54, 264-70	140

- 1692 Apolipoprotein E epsilon 4 allele and hippocampal volume in twins with normal cognition. **1997**, 48, 985-9 138
- 1691 SHORT COMMUNICATION. **1997**, 35,
- 1690 The presenilins and Alzheimer's disease. **1997**, 6, 1639-46 145
- 1689 Alzheimer's disease and history of blood transfusion by apolipoprotein-E genotype. **1997**, 16, 86-93 13
- 1688 Identification of the prooxidant site of human ceruloplasmin: a model for oxidative damage by copper bound to protein surfaces. **1997**, 94, 11546-51 99
- 1687 Cognitive markers preceding Alzheimer's dementia in the healthy oldest old. **1997**, 45, 584-9 122
- 1686 Effect of genetic risk factors and disease progression on the cerebrospinal fluid tau levels in Alzheimer's disease. **1997**, 45, 1228-31 15
- 1685 HLA-DR antigens associated with major genetic risk for late-onset Alzheimer's disease. **1997**, 8, 1467-9 49
- 1684 Apolipoprotein E genotype in schizophrenia: frequency, age of onset, and neuropathologic features. **1997**, 8, 1523-6 32
- 1683 The 'research magnificent' in late life: psychiatric epidemiology and the primary health care of older adults. **1997**, 27, 185-204 27
- 1682 Genetic epidemiology of Alzheimer disease. **1997**, 19, 107-19 35
- 1681 Apolipoprotein E gene and sporadic frontal lobe dementia. **1997**, 48, 1526-9 62
- 1680 Mnemonics usage and cognitive decline in age-associated memory impairment. **1997**, 9, 47-56 14
- 1679 Neuropsychological changes in subjects at risk of inheriting Alzheimer's disease. **1997**, 8, 2449-53 11
- 1678 Altered synaptic plasticity in hippocampal CA1 area of apolipoprotein E deficient mice. **1997**, 8, 2505-10 59
- 1677 Cognitive predictors of incident Alzheimer's disease: A prospective longitudinal study.. **1997**, 11, 413-420 142
- 1676 Apolipoprotein E forms stable complexes with recombinant Alzheimer's disease beta-amyloid precursor protein. **1997**, 325 (Pt 1), 169-75 25
- 1675 Apolipoprotein E-epsilon 2 and Alzheimer's disease: genotype influences pathologic phenotype. **1997**, 48, 515-9 66

1674	Genetic testing for Alzheimer disease. Practical and ethical issues. 1997 , 54, 1226-9	53
1673	Diabetics do not have increased Alzheimer-type pathology compared with age-matched control subjects. A retrospective postmortem immunocytochemical and histofluorescent study. 1997 , 49, 1306-11	151
1672	Apolipoprotein E polymorphism and plasma cholesterol response to dietary change. 1997 , 80, 15-21	8
1671	Hypothesis: Amyloid precursor protein is a key sorting and targeting receptor for neuropeptidases. 1997 , 4, 233-239	
1670	Hormone replacement: therapeutic strategies in the treatment of Alzheimer's disease and ageing-related cognitive disorders. 1997 , 7, 611-629	5
1669	Alzheimer's disease and related dementias: prospects for treatment. 1997 , 6, 735-57	5
1668	Increased apoptosis arising from increased expression of the Alzheimer's disease-associated presenilin-2 mutation (N141I). 1997 , 139, 485-95	120
1667	Increased prevalence and earlier onset of mood disorders among relatives of prepubertal versus adult probands. 1997 , 36, 466-73	89
1666	Interaction of nascent ApoE2, ApoE3, and ApoE4 isoforms expressed in mammalian cells with amyloid peptide beta (1-40). Relevance to Alzheimer's disease. 1997 , 36, 10571-80	121
1665	The genetics of dementia in late life. 1997 , 20, 59-76	7
1664	Optimization of apolipoprotein E genotyping. 1997 , 2, 271-276	16
1663	The association between Apo E genotype and depressive symptoms in elderly African-American subjects. 1997 , 5, 339-43	12
1662	A risk-benefit assessment of tacrine in the treatment of Alzheimer's disease. 1997 , 16, 66-77	16
1661	Increased J774 macrophage cytotoxicity of late postprandial triglyceride-rich lipoproteins from normolipidemic young men expressing an apolipoprotein epsilon 4 allele. 1997 , 132, 157-63	4
1660	The apolipoprotein E epsilon4 allele causes a faster decline of cognitive performances in Down's syndrome subjects. 1997 , 145, 87-91	66
1659	Alpha1-antichymotrypsin polymorphism in Japanese cases of Alzheimer's disease. 1997 , 152, 136-9	12
1658	Genetics and the pathobiology of ageing. 1997 , 352, 1773-80	47
1657	Clinical Features of Early-Onset Alzheimer Disease in a Large Kindred With an E280A Presenilin-1 Mutation. 1997 , 277, 793	169

1656	Concentration-dependent inhibitory effects of apolipoprotein E on Alzheimer's beta-amyloid fibril formation in vitro. 1997 , 36, 6243-50	103
1655	beta-Amyloid-associated free radical oxidative stress and neurotoxicity: implications for Alzheimer's disease. 1997 , 10, 495-506	305
1654	Alzheimer's disease: genotypes, phenotypes, and treatments. <i>Science</i> , 1997 , 275, 630-1	33-3 826
1653	Detection of apolipoprotein E/dimeric soluble amyloid beta complexes in Alzheimer's disease brain supernatants. 1997 , 240, 715-20	60
1652	Mitochondrial DNA mutations in Alzheimer's disease. 1997 , 241, 221-5	44
1651	Aging, metabolism, and Alzheimer disease: review and hypotheses. 1997 , 143, 82-102	107
1650	Astrocytes and microglia respond to estrogen with increased apoE mRNA in vivo and in vitro. 1997 , 143, 313-8	200
1649	Regional and cellular localization of presenilin-2 RNA in rat and human brain. 1997 , 145, 555-64	10
1648	The distribution of beta-amyloid precursor protein in rat cortex after systemic kainate-induced seizures. 1997 , 147, 361-76	15
1647	Apolipoprotein E uptake and low-density lipoprotein receptor-related protein expression by the NTERA2/D1 cell line: a cell culture model of relevance for late-onset Alzheimer's disease. 1997 , 4, 58-67	11
1646	Biology of A beta amyloid in Alzheimer's disease. 1997 , 4, 313-28	187
1645	ApoE synthesis in human neuroblastoma cells. 1997 , 4, 356-64	32
1644	Apolipoprotein E, a gene with complex biological interactions in the aging brain. 1997 , 4, 170-85	85
1643	Biomarkers of Inherited and Acquired Susceptibility to Toxic Substances. 1997 , 184-189	
1642	Current concepts in the pathogenesis of Alzheimer's disease. 1997 , 103, 3S-10S	150
1641	Genetic predictors of common disease: apolipoprotein E genotype as a paradigm. 1997 , 7, 357-62	28
1640	The relationship between blood pressure and dementia: a review. 1997 , 51, 367-75	103
1639	Proteolytic processing of presenilin-1 (PS-1) is not associated with Alzheimer's disease with or without PS-1 mutations. 1997 , 418, 162-6	29

1638	Preliminary report of a genetic basis for cognitive decline after cardiac operations. The Neurologic Outcome Research Group of the Duke Heart Center. 1997 , 64, 715-20	266
1637	Effects of triamcinolone on brain and cerebrospinal fluid apolipoprotein E levels in rats. 1997 , 60, 1757-61	5
1636	Genetics of aging. <i>Science</i> , 1997 , 278, 407-11	33-3 353
1635	Alzheimer's disease and DLST genotype. 1997 , 350, 1367-8	30
1634	Lymphocyte content of amyloid precursor protein is increased in Down's syndrome and aging. 1997 , 18, 97-103	29
1633	The role of the phosphoinositide signalling system in the pathogenesis of sporadic Alzheimer's disease: a hypothesis. 1997 , 25, 373-80	18
1632	Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. 1997 , 66, 385-407	1439
1631	The use of animal models to study the effects of aging on cognition. 1997 , 48, 339-70	348
1630	Evidence that the apolipoprotein E-genotype effects on lipid levels can change with age in males: a longitudinal analysis. 1997 , 61, 171-81	49
1629	The effect of apolipoprotein E genotype on expression of an autosomal dominant schizophreniform disorder with progressive dementia and neurofibrillary tangles. 1997 , 41, 191-5	5
1628	A twin study of late-onset depression and apolipoprotein E epsilon 4 as risk factors for Alzheimer's disease. 1997 , 41, 851-6	148
1627	Depression and dementia in relation to apolipoprotein E polymorphism in a population sample age 75+. 1997 , 42, 898-903	45
1626	Apolipoprotein E genotype and psychosis. 1997 , 41, 906-8	27
1625	Apolipoprotein E4 in schizophrenia: a study of one hundred sixteen cases with concomitant neuropathological examination. 1997 , 42, 296-8	16
1624	Murine models of brain aging and age-related neurodegenerative diseases. 1997 , 85, 1-26	86
1623	The genetics of Alzheimer's disease. 1997 , 52, 447-54	47
1622	Apolipoprotein E genotype and amyloid load in Alzheimer disease and control brains. 1997 , 18, 121-7	30
1621	Assignment of Alzheimer's presenilin-2 (PS-2) gene to 1q42.1 by fluorescence in situ hybridization. 1997 , 221, 205-7	4

1620	Apolipoprotein E e4 allele frequency in patients with multiple system atrophy. 1997 , 221, 161-4	27
1619	Dependence of cerebrospinal fluid Tau protein levels on apolipoprotein E4 allele frequency in patients with Alzheimer's disease. 1997 , 225, 213-5	35
1618	T/G polymorphism at intron 9 of presenilin 1 gene is associated with, but not responsible for sporadic late-onset Alzheimer's disease in Japanese population. 1997 , 227, 123-6	18
1617	beta-Amyloid (A beta) deposition in the medial temporal lobe of patients with dementia with Lewy bodies. 1997 , 227, 193-6	24
1616	A polymorphism in the presenilin 1 gene does not modify risk for Alzheimer's disease in a cohort with sporadic early onset. 1997 , 228, 212-4	16
1615	Analysis of apolipoprotein E, alpha1-antichymotrypsin and presenilin-1 genes polymorphisms in dementia caused by normal pressure hydrocephalus in man. 1997 , 229, 177-80	18
1614	Mutation analysis of chromosome 19 calmodulin (CALM3) gene in Alzheimer's disease patients. 1997 , 229, 157-60	3
1613	Association of the apolipoprotein A-IV codon 360 mutation in patients with Alzheimer's disease. 1997 , 230, 151-4	28
1612	No association between alpha1-antichymotrypsin polymorphism, apolipoprotein E and patients with late-onset Alzheimer's disease. 1997 , 231, 56-8	14
1611	Apolipoprotein E epsilon2 allele and early onset schizophrenia. 1997 , 231, 53-5	20
1610	Cerebrospinal fluid apo E and apo A-I concentrations in early- and late-onset Alzheimer's disease. 1997 , 231, 175-8	55
1609	Nicotinic receptors, muscarinic receptors and choline acetyltransferase activity in the temporal cortex of Alzheimer patients with differing apolipoprotein E genotypes. 1997 , 232, 37-40	36
1608	In an epidemiological sample the apolipoprotein E4 allele is associated to dementia and loss of memory function only in the very old. 1997 , 222, 29-32	26
1607	Genetic association studies between dementia of the Alzheimer's type and three receptors for apolipoprotein E in a Caucasian population. 1997 , 222, 187-90	135
1606	Increased plasma apolipoprotein E (apoE) levels in Alzheimer's disease. 1997 , 223, 29-32	91
1605	Levels of cerebrospinal fluid apolipoprotein E in patients with Alzheimer's disease and healthy controls. 1997 , 224, 99-102	24
1604	A cellular mechanism for the neuronal changes underlying Alzheimer's disease. 1997 , 78, 629-39	31
1603	Age-related congophilic inclusions in the brains of apolipoprotein E-deficient mice. 1998 , 82, 171-80	19

1602	Evaluation of risk factors for Alzheimer's disease in elderly east Africans. 1997 , 44, 573-7	31
1601	Genetics and intelligence: What's new?. 1997 , 24, 53-77	160
1600	Alzheimer's disease: risk and protection. 1997 , 167, 443-6	15
1599	Plastic neuronal remodeling is impaired in patients with Alzheimer's disease carrying apolipoprotein epsilon 4 allele. 1997 , 17, 516-29	288
1598	Standardization (External and Internal) of HPLC Assay for Plasma Homocysteine. 1997 , 43, 1653-1669	52
1597	Automated On-Line Hydrolysis of Benzodiazepines Improves Sensitivity of Urine Screening by a Homogeneous Enzyme Immunoassay. 1997 , 43, 1659-1660	5
1596	The genetics of Alzheimer's disease: progress, possibilities, and pitfalls. 1997 , 5, 234-7	6
1595	Prospective Genetic Epidemiology of Dementia in the Very Old. 1997 , 167, 128-135	
1594	Lewy bodies and progressive dementia: A critical review and meta-analysis. 1997 , 3, 179-194	30
1593	Alzheimer's disease. 1997 , 40, 230-45	18
1592	Cerebrovascular pathology in Alzheimer's disease compared to normal aging. 1997 , 43, 26-43	69
1591	Genes implicated in the pathogenesis of Alzheimer's disease. 1997 , 2, d253-9	1
1590	Distribution of apolipoprotein E gene polymorphisms in Japanese patients with Alzheimer's disease and in Japanese centenarians. 1997 , 47, 22-6	15
1589	Alzheimer's disease research: a game of connect the dots. 1997 , 43, 8-19	10
1588	Effects of apolipoprotein E on dementia and aging in the Shanghai Survey of Dementia. 1997 , 49, 779-85	69
1587	Apolipoprotein E4 and Alzheimer's disease in São Paulo-Brazil. 1997 , 55, 1-7	17
1586	Neurotoxicity of the 22 kDa thrombin-cleavage fragment of apolipoprotein E and related synthetic peptides is receptor-mediated. 1997 , 17, 5678-86	103
1585	Genetics of the Alzheimer Diseases. 1997 , 167, 115-118	

1584	Improved Method for Genotyping Apolipoprotein E Polymorphisms by a PCR-Based Assay Simultaneously Utilizing Two Distinct Restriction Enzymes. 1997 , 43, 1657-1659	137
1583	Apolipoprotein E genotyping by capillary electrophoretic analysis of restriction fragments. 1997 , 43, 1321-1324	13
1582	Presence of the apolipoprotein E type epsilon 4 allele is not associated with neurofibrillary pathology or biochemical changes to tau protein. 1997 , 8, 288-95	11
1581	Molecular pathology of Alzheimer's disease. 1997 , 17, 263-269	0
1580	Association of the mitochondrial tRNA ^A 4336G mutation with Alzheimer's and Parkinson's diseases. 1997 , 23, 315-321	54
1579	Relationship between apolipoprotein E and the amyloid deposits and dystrophic neurites of Alzheimer's disease. 1997 , 23, 483-91	22
1578	Coronary artery disease, hypertension, ApoE, and cholesterol: a link to Alzheimer's disease?. 1997 , 826, 128-46	219
1577	ApoE, Alzheimer's disease, and recovery from brain stress. 1997 , 826, 200-12	59
1576	Magnetic resonance spectroscopic changes in Alzheimer's disease. 1997 , 826, 282-306	48
1575	Apolipoprotein E allele frequencies in patients with late-onset sporadic Alzheimer's dementia in Hungary. 1997 , 95, 56-9	26
1574	Is celiac disease associated with Alzheimer's disease?. 1997 , 95, 147-51	8
1573	HIV dementia and apolipoprotein E. 1997 , 95, 315-8	41
1572	Neuronal thread protein gene modulation with cerebral infarction. 1997 , 17, 623-35	18
1571	Examination of the role of endopeptidase 3.4.24.15 in A beta secretion by human transfected cells. 1997 , 121, 556-62	34
1570	A systems perspective begins to emerge in Alzheimer's. 1997 , 15, 1347-8	1
1569	Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E. 1997 , 388, 878-81	524
1568	Observation of metastable Abeta amyloid protofibrils by atomic force microscopy. 1997 , 4, 119-25	585
1567	Oxidative stress hypothesis in Alzheimer's disease. 1997 , 23, 134-47	1731

1566	Abeta1-40 but not Abeta1-42 levels in cortex correlate with apolipoprotein E epsilon4 allele dosage in sporadic Alzheimer's disease. 1997 , 748, 250-2	82
1565	Amino-terminus truncated apolipoprotein E is the major species in amyloid deposits in Alzheimer's disease-affected brains: a possible role for apolipoprotein E in Alzheimer's disease. 1997 , 768, 208-14	24
1564	Identification of a neuronal endocytic pathway activated by an apolipoprotein E (apoE) receptor binding peptide. 1997 , 778, 6-15	20
1563	Reduced levels of antioxidants in brains of apolipoprotein E-deficient mice following closed head injury. 1997 , 56, 669-73	59
1562	Apolipoprotein E and Alzheimer's disease: a review of recent studies. 1997 , 56, 675-85	51
1561	The amyloid precursor protein gene: a neuropeptide gene with diverse functions in the central nervous system. 1997 , 31, 523-35	24
1560	Successful coping, adaptation and resilience in the elderly: an interpretation of epidemiologic data. 1997 , 68, 189-219	42
1559	Apolipoprotein E phenotypes and cardiovascular responses to experimentally induced mental stress in adolescent boys. 1997 , 20, 571-87	16
1558	Apolipoprotein E and apolipoprotein A-1 knock-out mice readily develop amyloid A protein amyloidosis. 1997 , 85, 104-8	19
1557	Association of bone mineral density with apolipoprotein E phenotype. 1997 , 12, 1438-45	141
1556	Human genetics: past, present, and future, with special reference to major trends in Japan. 1997 , 42, 265-316	13
1555	Na,K-ATPase mRNA levels and plaque load in Alzheimer's disease. 1997 , 9, 151-66	54
1554	Association of transferrin C2 allele with late-onset Alzheimer's disease. 1997 , 101, 126-9	107
1553	Low prevalence of apolipoprotein E epsilon 4 allele in the neurofibrillary tangle predominant form of senile dementia. 1997 , 94, 403-9	61
1552	Activation of microglia in the brains of humans with heart disease and hypercholesterolemic rabbits. 1997 , 75, 130-8	126
1551	[Dementia in the very elderly. Results of the Berlin Aging Study]. 1997 , 68, 719-29	30
1550	Morbus Alzheimer und Östrogene. 1997 , 30, 660-662	
1549	Apolipoprotein E phenotype is not related to late-life depression in a population-based sample. 1998 , 33, 21-6	32

1548	The ability of THA treatment to increase cortical alpha waves is related to apolipoprotein E genotype of Alzheimer disease patients. 1997 , 129, 285-8	24
1547	Absence of central cholinergic deficits in ApoE knockout mice. 1997 , 132, 135-44	41
1546	Apolipoprotein E epsilon 4 allele distribution in Wernicke-Korsakoff syndrome with or without global intellectual deficits. 1997 , 104, 913-20	20
1545	Early diagnosis of Alzheimer's disease. 1997 , 1997, 39-51	3
1544	Apolipoprotein Epsilon4 allele, a risk factor for late onset nonfamilial Alzheimer's disease among Israeli Jews. 1997 , 24, 175-81	3
1543	Apolipoprotein E genotype in senile dementia and Down's syndrome. 1998 , 26, 15-21	2
1542	Human behavioural genetics of cognitive abilities and disabilities. 1997 , 19, 1117-24	26
1541	alpha 1-Antichymotrypsin as a risk modifier for late-onset Alzheimer's disease in Japanese apolipoprotein E epsilon 4 allele carriers. 1997 , 42, 115-7	44
1540	Apolipoprotein E epsilon2 does not increase risk of early-onset sporadic Alzheimer's disease. 1997 , 42, 376-8	14
1539	Copper/zinc superoxide dismutase 1 and sporadic amyotrophic lateral sclerosis: analysis of 155 cases and identification of a novel insertion mutation. 1997 , 42, 803-7	105
1538	Some contributions to the epidemiology of dementia and depression. 1997 , 12, 145-54	11
1537	ApoE genotype does not affect plasma tPA and PAI-1 antigen levels. 1997 , 74, 172-175	4
1536	The use of apolipoprotein E genotype for preclinical detection of risk's group for Alzheimer's disease. 1997 , 74, 216-7	11
1535	Lack of association between bipolar disorder and tyrosine hydroxylase: a meta-analysis. 1997 , 74, 348-52	27
1534	Rapid elevation of neuronal cytoplasmic calcium by apolipoprotein E peptide. 1997 , 173, 73-83	46
1533	E280A PS-1 mutation causes Alzheimer's disease but age of onset is not modified by ApoE alleles. 1997 , 10, 186-95	59
1532	Gender-specific nonrandom association between the alpha 1-antichymotrypsin and apolipoprotein E polymorphisms in the general population and its implication for the risk of Alzheimer's disease. 1997 , 14, 169-80	10
1531	No association or linkage between an intronic polymorphism of presenilin-1 and sporadic or late-onset familial Alzheimer disease. 1997 , 14, 307-15	29

1530	Positional cloning: A review and perspective. 1997 , 41, 129-141	2
1529	Association of human, rat, and rabbit apolipoprotein E with β amyloid. 1997 , 49, 9-18	60
1528	Apolipoprotein E genotyping in patients with neurodegenerative diseases. 1997 , 30, 405-11	5
1527	Advances and challenges in the prevention and treatment of Alzheimer's disease. 1998 , 15, 386-98	84
1526	Apolipoprotein E polymorphism in sheep. 1998 , 36, 395-405	0
1525	Do aluminium and/or glutamate induce Alz-50 reactivity? A light microscopic immunohistochemical study. 1998 , 27, 45-57	8
1524	Interaction of apolipoprotein E epsilon 4 with other genetic and non-genetic risk factors in late onset Alzheimer disease: problems facing the investigator. 1998 , 23, 369-76	11
1523	Expression of differential immune factors in temporal cortex and cerebellum: The role of β 1-antichymotrypsin, apolipoprotein E, and reactive glia in the progression of Alzheimer's disease. 1998 , 396, 511-520	54
1522	Genetic dissection of Alzheimer's disease and related dementias: amyloid and its relationship to tau. 1998 , 1, 355-8	274
1521	Apolipoprotein E isoforms increase intracellular Ca^{2+} differentially through a omega-agatoxin IVa-sensitive Ca^{2+} -channel. 1998 , 8, 641-53	53
1520	Transgenic mouse models of Alzheimer's disease and amyotrophic lateral sclerosis. 1998 , 8, 735-57	20
1519	Child Development, Molecular Genetics, and What to Do with Genes Once They Are Found. 1998 , 69, 1223-1242	3
1518	The implications of genetic studies on the pathogenesis of Alzheimer's disease. 1998 , 18, 103-110	
1517	Alzheimer's disease as a polygenic disease. 1998 , 18, 111-115	1
1516	Aging of the human limbic system: Observations of centenarian brains and analyses of genetic risk factors for senile changes. 1998 , 18, 228-234	3
1515	Modelling motor neuron degenerative disease. 1998 , 24, 90-6	2
1514	Apolipoprotein E isoform-specific differences in outcome from focal ischemia in transgenic mice. 1998 , 18, 361-6	131
1513	Neuroprotective efficacy and mechanisms of novel pyrrolopyrimidine lipid peroxidation inhibitors in the gerbil forebrain ischemia model. 1998 , 18, 539-47	21

1512	A polymorphism in the regulatory region of APOE associated with risk for Alzheimer's dementia. 1998 , 18, 69-71	266
1511	Very early changes in olfactory functioning due to Alzheimer's disease and the role of apolipoprotein E in olfaction. 1998 , 855, 723-31	137
1510	Apolipoprotein E and Alzheimer's disease. The tip of the susceptibility iceberg. 1998 , 855, 738-43	67
1509	Histopathological studies of senile plaques and cerebral amyloidosis in cynomolgus monkeys. 1998 , 27, 244-52	56
1508	Increased apolipoprotein E4 allele frequency is associated with vascular dementia in the Hungarian population. 1998 , 98, 166-8	30
1507	Evaluation of lipoproteins/apolipoproteins as therapeutic agents for the treatment of vascular and nonvascular disease. 1998 , 81, 36F-39F	1
1506	Apolipoprotein-E deficiency results in an altered stress responsiveness in addition to an impaired spatial memory in young mice. 1998 , 788, 151-9	40
1505	Initiation and propagation stages of beta-amyloid are associated with distinctive apolipoprotein E, age, and gender profiles. 1998 , 798, 18-24	28
1504	Cloning of the cDNA encoding rat presenilin-2. 1998 , 1396, 259-62	4
1503	Hippocampal atrophy and apolipoprotein E genotype are independently associated with Alzheimer's disease. 1998 , 43, 303-10	158
1502	Alzheimer's disease genetics: home runs and strikeouts. 1998 , 44, 716-9	9
1501	Apolipoprotein E (ApoE) peptide regulates tau phosphorylation via two different signaling pathways. 1998 , 51, 658-65	22
1500	Apolipoprotein E4 induces neuronal cell death under conditions of suppressed de novo cholesterol synthesis. 1998 , 54, 58-67	55
1499	Effect of apolipoprotein E status on clinical features of dementia. 1998 , 13, 177-85	3
1498	Renin, ANP, ACE polymorphisms, blood pressure and age in American Samoans: Preliminary data. 1998 , 10, 439-449	7
1497	Zinc in human health: An update. 1998 , 11, 63-87	87
1496	ApoE genotype is a risk factor in nonpresenilin early-onset Alzheimer's disease families. 1998 , 81, 117-21	49
1495	Alzheimer diseases: a model of gene mutations and susceptibility polymorphisms for complex psychiatric diseases. 1998 , 81, 49-57	61

1494	Multiple threshold model for the onset of Alzheimer's disease in the NAS-NRC twin panel. 1998 , 81, 92-7	44
1493	Initial results of a genome survey for novel Alzheimer's disease risk genes: association with a locus on the X chromosome. 1998 , 81, 98-107	11
1492	Apolipoprotein E allelic frequency in elderly smokers. 1998 , 76, 32-36	3
1491	Initial results of a genome survey for novel Alzheimer's disease risk genes: Association with a locus on the X chromosome. 1998 , 81, 196-205	19
1490	Founder effect in GLC1A-linked familial open-angle glaucoma in Northern France. 1998 , 76, 438-445	37
1489	The case described by Alois Alzheimer in 1911. Historical and conceptual perspectives based on the clinical record and neurohistological sections. 1998 , 248, 111-22	115
1488	Identification and localization of Chlamydia pneumoniae in the Alzheimer's brain. 1998 , 187, 23-42	334
1487	The human FE65 gene: genomic structure and an intronic biallelic polymorphism associated with sporadic dementia of the Alzheimer type. 1998 , 103, 295-303	65
1486	No genetic association between the LRP receptor and sporadic or late-onset familial Alzheimer disease. 1998 , 1, 179-83	38
1485	The relationship between apolipoprotein E and serum oxidation-related variables is apolipoprotein E phenotype dependent. 1998 , 28, 116-21	41
1484	Cellular and molecular basis of estrogen's neuroprotection. Potential relevance for Alzheimer's disease. 1998 , 17, 73-86	99
1483	Recent advances in molecular genetics of cardiovascular disorders. 1998 , 4, 152-160	6
1482	Oxidative stress and neurodegenerative disorders. 1998 , 5, 401-14	151
1481	Monogenic determinants of familial Alzheimer's disease: presenilin-2 mutations. 1998 , 54, 910-9	14
1480	The role of APOE polymorphisms in late-onset dementias. 1998 , 54, 928-34	74
1479	Recent work on Alzheimer's disease transgenics. 1998 , 9, 561-4	19
1478	Evidence that glypican is a receptor mediating beta-amyloid neurotoxicity in PC12 cells. 1998 , 10, 2085-93	13
1477	Phenotype analysis in neurological models of human disease. 1998 , 24, 83-87	2

1476	Myelin disorders. 1998 , 24, 87-90	3
1475	Genetic modelling of muscular dystrophies. 1998 , 24, 96-100	2
1474	Transgenic models for Alzheimer's disease. 1998 , 24, 101-3	12
1473	Phenotype analysis in neurological models of human disease. 1998 , 24, 83-7	4
1472	Myelin disorders. 1998 , 24, 87-90	2
1471	Introduction. 1998 , 24, 82-82	1
1470	Test of candidate gene--quantitative trait locus association applied to fatness in mice. 1998 , 81 (Pt 6), 630-7	40
1469	PCR-based apolipoprotein E genotype analysis from archival fixed brain. 1998 , 80, 209-14	13
1468	Apo E genotyping in Alzheimer disease (AD): multidimensional counseling by the geriatric assessment unit (GAU) to properly address scientific and bioethical issues emerging from molecular gerontology to geriatric practice. 1998 , 27, 49-56	2
1467	Risk factors for cognitive disorders in the elderly: A review. 1998 , 26, 7-15	5
1466	The genetics and complexity of allergy and asthma. 1998 , 19, 325-32	96
1465	Characterization of the sheep apolipoprotein E (ApoE) gene and allelic variations of the ApoE gene in scrapie Suffolk sheep. 1998 , 208, 131-8	7
1464	The regulation of amyloid precursor protein metabolism by cholinergic mechanisms and neurotrophin receptor signaling. 1998 , 56, 541-69	179
1463	Increased levels of alpha-1-antichymotrypsin in brains of patients with Alzheimer's disease correlate with activated astrocytes and are affected by APOE 4 genotype. 1998 , 88, 105-10	64
1462	The biology of intelligence: From association to mechanism. 1998 , 26, 63-73	11
1461	mtDNA polymorphisms in Japanese sporadic Alzheimer's disease. 1998 , 19, S47-51	25
1460	Cis-acting human ApoE tissue expression element is associated with human pattern of intraneuronal ApoE in transgenic mice. 1998 , 19, S53-8	18
1459	Genetic risk factors in Japanese Alzheimer's disease patients: alpha1-ACT, VLDLR, and ApoE. 1998 , 19, S43-6	24

1458	Complete genomic screen in late-onset familial Alzheimer's disease. 1998 , 19, S39-42	43
1457	Accumulation of amyloid beta protein in transgenic mice. 1998 , 19, S59-63	7
1456	Evolution in the conceptualization of dementia and Alzheimer's disease: Greco-Roman period to the 1960s. 1998 , 19, 173-89	242
1455	Human apolipoprotein E allele-specific brain expressing transgenic mice. 1998 , 19, 407-13	30
1454	Metabolic alterations in postmortem Alzheimer's disease brain are exaggerated by Apo-E4. 1998 , 19, 511-5	44
1453	Alpha-antichymotrypsin gene polymorphism and risk for Alzheimer's disease in the Spanish population. 1998 , 240, 107-9	23
1452	Implication of alpha1-antichymotrypsin polymorphism in familial Alzheimer's disease. 1998 , 244, 85-8	16
1451	Butyrylcholinesterase K variant and apolipoprotein E4 genes do not act in synergy in Finnish late-onset Alzheimer's disease patients. 1998 , 250, 69-71	39
1450	Loss of somatostatin-like immunoreactivity in the frontal cortex of Alzheimer patients carrying the apolipoprotein epsilon 4 allele. 1998 , 255, 21-4	68
1449	Behavioural, physiological and morphological analysis of a line of apolipoprotein E knockout mouse. 1998 , 85, 93-110	106
1448	Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. 1998 , 88, 1337-42	1182
1447	Surfactant proteins: molecular genetics of neonatal pulmonary diseases. 1998 , 60, 365-84	63
1446	Amyloid angiopathy in a Volga German family with Alzheimer's disease and a presenilin-2 mutation (N141I). 1998 , 43, 131-5	61
1445	Hippocampal volumes in cognitively normal persons at genetic risk for Alzheimer's disease. 1998 , 44, 288-91	228
1444	What are the facts and artifacts of the pathogenesis and etiology of Alzheimer disease?. 1998 , 16, 35-41	34
1443	Genetic testing: implications for professional nursing. 1998 , 14, 184-8	9
1442	Cholesterol-dependent generation of a unique amyloid beta-protein from apically missorted amyloid precursor protein in MDCK cells. 1998 , 1373, 119-30	37
1441	Allelic polymorphisms in the transcriptional regulatory region of apolipoprotein E gene. 1998 , 421, 105-8	180

1440	Apolipoprotein E, transthyretin and actin in the CSF of Alzheimer's patients: relation with the senile plaques and cytoskeleton biochemistry. 1998 , 425, 225-8	79
1439	Quantitation of apolipoprotein epsilon gene expression by competitive polymerase chain reaction in a patient with familial apolipoprotein E deficiency. 1998 , 274, 119-37	2
1438	Twelve-nucleotide repeat polymorphism of D4 dopamine receptor gene in Chinese familial schizophrenic patients. 1998 , 43, 432-5	17
1437	Magnetic resonance imaging correlates of depression in early- and late-onset Alzheimer's disease. 1998 , 44, 592-9	19
1436	Selegiline in the treatment of mild and moderate stages of Alzheimer disease. 1998 , 8, S271-S272	
1435	Apolipoprotein E4 allele frequency in vascular dementia in the Hungarian population. 1998 , 8, S272	
1434	Genetic association mapping based on discordant sib pairs: the discordant-alleles test. 1998 , 62, 950-61	183
1433	Detecting marker-disease association by testing for Hardy-Weinberg disequilibrium at a marker locus. 1998 , 63, 1531-40	310
1432	Genetic classification of primary neurodegenerative disease. <i>Science</i> , 1998 , 282, 1075-9	333 244
1431	Psychiatric genetics: search for phenotypes. 1998 , 21, 102-5	265
1430	Alzheimer's disease: genetic studies and transgenic models. 1998 , 32, 461-93	349
1429	Alzheimer's disease. Cholinergic therapy and beyond. 1998 , 6, S56-63	8
1428	[Wine and heart]. 1998 , 51, 435-49	6
1427	Alzheimer's disease: identification of genes and genetic risk factors. 1998 , 117, 315-25	7
1426	Potential therapeutic targets for Alzheimer's disease. 1998 , 2, 157-179	5
1425	Ceruloplasmin copper induces oxidant damage by a redox process utilizing cell-derived superoxide as reductant. 1998 , 37, 14222-9	52
1424	Elevated low-density lipoprotein in Alzheimer's disease correlates with brain abeta 1-42 levels. 1998 , 252, 711-5	271
1423	Increased apolipoprotein E mRNA in the hippocampus in Alzheimer disease and in rats after entorhinal cortex lesioning. 1998 , 149, 79-86	44

1422	Absence of association of alpha1-antichymotrypsin polymorphisms with Alzheimer's disease: a report on autopsy-confirmed cases. 1998 , 151, 237-40	9
1421	Evidence for normal aging of the septo-hippocampal cholinergic system in apoE (-/-) mice but impaired clearance of axonal degeneration products following injury. 1998 , 151, 314-25	102
1420	Phosphoinositide hydrolysis activated by muscarinic or glutamatergic, but not adrenergic, receptors is impaired in ApoE-deficient mice and by hydrogen peroxide and peroxytrite. 1998 , 152, 123-8	13
1419	High frequency of apolipoprotein E epsilon4 allele in young individuals with very mild Alzheimer's disease-related neurofibrillary changes. 1998 , 153, 152-5	87
1418	Mechanisms of uptake of gallium by human neuroblastoma cells and effects of gallium and aluminum on cell growth, lysosomal protease, and choline acetyl transferase activity. 1998 , 153, 342-50	5
1417	Clusterin (apolipoprotein J) protein levels are increased in hippocampus and in frontal cortex in Alzheimer's disease. 1998 , 154, 511-21	110
1416	A genome survey for novel Alzheimer disease risk loci: results at 10-cM resolution. 1998 , 50, 121-8	91
1415	Population studies of polymorphisms at loci of neuropsychiatric interest (tryptophan hydroxylase (TPH), dopamine transporter protein (SLC6A3), D3 dopamine receptor (DRD3), apolipoprotein E (APOE), mu opioid receptor (OPRM1), and ciliary neurotrophic factor (CNTF)). 1998 , 52, 289-97	65
1414	Uptake and internalization of exogenous apolipoprotein E3 by cultured human central nervous system neurons. 1998 , 5, 271-9	17
1413	Amyloid-beta deposition in skeletal muscle of transgenic mice: possible model of inclusion body myopathy. 1998 , 153, 1687-93	75
1412	The relationship between apolipoprotein E, dementia, and vascular illness. 1998 , 140, 173-80	47
1411	Aggregation of amyloid beta-protein as function of age and apolipoprotein E in normal and Alzheimer's serum. 1998 , 154, 159-63	8
1410	Association of apolipoprotein E genotype and intronic polymorphism of the presenilin-1 gene with Alzheimer's disease in elderly Taiwan Chinese. 1998 , 157, 158-61	19
1409	No association between apolipoprotein E alleles and olivopontocerebellar atrophy. 1998 , 158, 110-2	5
1408	Familial Alzheimer's disease genes in Japanese. 1998 , 160, 76-81	43
1407	Age-Related Na,K-ATPase mRNA Expression and Alzheimer's Disease. 1998 , 113-119	2
1406	Epidemiology of dementia and Alzheimer's disease. 1998 , 6, S3-18	215
1405	Cholinergic deficiency in Alzheimer's disease. Pathogenic model. 1998 , 6, S49-55	7

1404	Differential diagnosis and early detection of dementia. 1998 , 6, S26-33	15
1403	Dementia Screening and Surveillance. 1998 , 3, 173-181	1
1402	Genetic variation as a guide to drug development. <i>Science</i> , 1998 , 281, 1820-1	33-3 90
1401	Risk for Alzheimer's disease correlates with transcriptional activity of the APOE gene. 1998 , 7, 1887-92	126
1400	Apolipoprotein E and alpha-1 antichymotrypsin polymorphism genotyping in Alzheimer's disease and in dementia with Lewy bodies. Distinctions between diseases. 1998 , 50, 388-91	27
1399	Accelerated decline in apolipoprotein E-epsilon4 homozygotes with Alzheimer's disease. 1998 , 51, 149-53	130
1398	High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. 1998 , 55, 937-45	399
1397	Modulation of secreted beta-amyloid precursor protein and amyloid beta-peptide in brain by cholesterol. 1998 , 273, 16576-82	195
1396	A population study of apoE genotype at the age of 85: relation to dementia, cerebrovascular disease, and mortality. 1998 , 64, 37-43	99
1395	Recent advances in the genetics of Alzheimer's disease. 1998 , 11, 42-54	35
1394	Cerebral amyloid angiopathy: prospects for clinical diagnosis and treatment. 1998 , 51, 690-4	198
1393	Pronounced impact of Th1/E47cs mutation compared with -491 AT mutation on neural APOE gene expression and risk of developing Alzheimer's disease. 1998 , 7, 1511-6	101
1392	Opposite roles of apolipoprotein E in normal brains and in Alzheimer's disease. 1998 , 95, 15598-602	80
1391	Longitudinal SPECT study in Alzheimer's disease: relation to apolipoprotein E polymorphism. 1998 , 64, 742-6	48
1390	Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study. 1998 , 64, 298-305	149
1389	No association between the K variant of the butyrylcholinesterase gene and pathologically confirmed Alzheimer's disease. 1998 , 7, 937-9	46
1388	APOE polymorphisms and late-onset Alzheimer disease: the importance of ethnicity. 1998 , 279, 788-9	3
1387	Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: the Rotterdam Study. 1998 , 55, 964-8	324

1386	Is exposure to aluminum a risk factor for the development of Alzheimer disease?--No. 1998 , 55, 737-9	35
1385	Association of CYP2D microsatellite polymorphism with Lewy body variant of Alzheimer's disease. 1998 , 50, 1556-62	28
1384	Genetic susceptibility to brain injury in sports: a role for genetic testing in athletes?. 1998 , 26, 25-6	21
1383	The prionoses and other conformational disorders. 1998 , 5, 212-24	37
1382	The potential application of cyclo-oxygenase type 2 inhibitors to Alzheimer's disease. 1998 , 7, 519-26	1
1381	The complexity of the genotype-phenotype relationship and the limitations of using genetic "markers" at the individual level. 1998 , 11, 373-89	6
1380	Occupational exposures to solvents and aluminium and estimated risk of Alzheimer's disease. 1998 , 55, 627-33	46
1379	Estimation of the genetic contribution of presenilin-1 and -2 mutations in a population-based study of presenile Alzheimer disease. 1998 , 7, 43-51	356
1378	Apolipoprotein E phenotype associations with plasma lipoproteins and bone mass in postmenopausal women. 1998 , 1, 188-95	5
1377	Prevalence of dementia of Alzheimer type and apolipoprotein E phenotypes in aged patients with Down's syndrome. 1998 , 39, 234-7	38
1376	Francis Galton: and eugenics today. 1998 , 24, 99-105	53
1375	Differential cellular accumulation/retention of apolipoprotein E mediated by cell surface heparan sulfate proteoglycans. Apolipoproteins E3 and E2 greater than e4. 1998 , 273, 13452-60	99
1374	The APOE-epsilon4 allele and the risk of Alzheimer disease among African Americans, whites, and Hispanics. 1998 , 279, 751-5	480
1373	Cerebrospinal fluid levels of amyloid precursor protein and amyloid beta-peptide in Alzheimer's disease and major depression - inverse correlation with dementia severity. 1998 , 39, 111-8	71
1372	Aggravated decrease in the activity of nucleus basalis neurons in Alzheimer's disease is apolipoprotein E-type dependent. 1998 , 95, 11445-9	39
1371	Nerve growth factor induces rapid increases in functional cell surface low density lipoprotein receptor-related protein. 1998 , 273, 13359-65	52
1370	Interaction of cytosolic adaptor proteins with neuronal apolipoprotein E receptors and the amyloid precursor protein. 1998 , 273, 33556-60	446
1369	A new polymorphism in the APOE promoter associated with risk of developing Alzheimer's disease. 1998 , 7, 533-40	135

1368	Alzheimer's Syndrome and not Alzheimer's disease: The historical struggle to define the disease. 1998 , 13, 92-95	1
1367	Genetic studies on chromosome 12 in late-onset Alzheimer disease. 1998 , 280, 619-22	68
1366	Apolipoprotein E epsilon4 allele and familial aggregation of Alzheimer disease. 1998 , 55, 810-6	55
1365	Wide range of disease onset in a family with Alzheimer disease and a His163Tyr mutation in the presenilin-1 gene. 1998 , 55, 698-702	37
1364	Laboratory investigations by DNA amplification: from research to practice. 1998 , 35 (Pt 1), 5-11	3
1363	New methods in psychiatric epidemiology. 1998 , 52 Suppl, S261-4	4
1362	Status of risk factors for vascular dementia. 1998 , 17, 2-9	154
1361	EN-Acetyl-D-Hexosaminidase to Aspartate Aminotransferase. NA-NA	
1360	Apo A-I and apo E concentrations in cerebrospinal fluids of patients with acute meningitis. 1998 , 35 (Pt 3), 408-14	15
1359	A review on blood pressure and ischaemic white matter lesions. 1998 , 9 Suppl 1, 13-9	67
1358	Molecular Genetics of Familial Alzheimer Disease. 1998 , 315, 266-272	
1357	Reactive Oxygen Species Mediate Cellular Damage in Alzheimer Disease. 1998 , 1, 45-55	157
1356	Genetic risk factors in Alzheimer's disease. 1998 , 51, 293-304	35
1355	The impact of Alzheimer disease genetics on expert and advanced gerontological nursing practice. 1998 , 9, 513-23	2
1354	Clinical characteristics of attention deficit hyperactivity disorder in African American children. 1998 , 155, 696-8	28
1353	Minimisation: the platinum standard for trials?. Randomisation doesn't guarantee similarity of groups; minimisation does. 1998 , 317, 362-3	228
1352	Alzheimer disease. 1998 , 42, 1-54	166
1351	DNA polymorphisms of apolipoprotein B and angiotensin I-converting enzyme genes and relationships with lipid levels in Italian patients with vascular dementia or Alzheimer's disease. 1998 , 9, 186-90	53

1350	Gene-environment interaction in Alzheimer's disease: a potential role for cholesterol. 1998 , 17, 225-32	54
1349	The genetics of Alzheimer disease: current status and future prospects. 1998 , 55, 294-6	133
1348	The APOE epsilon4 allele is associated with decline on delayed recall performance in community-dwelling older adults. 1998 , 46, 1493-8	91
1347	Endogenous apolipoprotein E suppresses LPS-stimulated microglial nitric oxide production. 1998 , 9, 615-8	62
1346	Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease. 1998 , 50, 669-77	180
1345	Role of apolipoprotein E in modulating neurite outgrowth: potential effect of intracellular apolipoprotein E. 1998 , 26, 257-62	37
1344	Apolipoprotein E and neuronal plasticity following experimental de-afferentation and in Alzheimer's disease. 1998 , 26, 262-6	8
1343	Three-year changes in cognitive performance as a function of apolipoprotein E genotype: Evidence from very old adults without dementia.. 1998 , 13, 80-87	84
1342	Role of APOE in dementia: A critical reappraisal. 1998 , 28, 195-201	7
1341	Apolipoprotein E polymorphism is not associated with longevity or disability in a sample of Italian octo- and nonagenarians. 1998 , 44, 293-9	40
1340	Contributions of Behavioral Genetics Research to Clinical Psychology. 1998 , 87-114	2
1339	The changing classification and diagnosis of diabetes. New classification is based on pathogenesis, not insulin dependence. 1998 , 317, 359-60	18
1338	Association between apolipoprotein E epsilon4 and the rate of cognitive decline in community-dwelling elderly individuals with and without dementia. 1998 , 55, 1065-9	128
1337	Increased synaptic sprouting in response to estrogen via an apolipoprotein E-dependent mechanism: implications for Alzheimer's disease. 1998 , 18, 3180-5	209
1336	Cerebrovascular Pathology Contributes to the Heterogeneity of Alzheimer's Disease. 1998 , 1, 119-134	54
1335	Experimental approaches to cognitive disturbance in Alzheimer's disease. 1998 , 6, 11-22	12
1334	Etiology and pathogenesis of Alzheimer's disease. 1998 , 55 Suppl 2, S5-10	21
1333	Interaction of presenilins with the filamin family of actin-binding proteins. 1998 , 18, 914-22	117

1332	Clinical Studies of Oestrogen Therapy for Dementia. 1998 , 4, 12-17	5
1331	Biological and psychosocial risk factors for dementia and memory loss. 1998 , 243-254	1
1330	The essential role of inflammation and induced gene expression in the pathogenic pathway of Alzheimer's disease. 1998 , 3, d436-46	18
1329	Alzheimer's amyloid beta and lipid metabolism: a missing link?. 1998 , 12, 1097-9	40
1328	Inferior temporal lobe atrophy and APOE genotypes in Alzheimer's disease. X-ray computed tomography, magnetic resonance imaging and Xe-133 SPECT studies. 1998 , 9, 90-8	27
1327	The expression of presenilin-1 mRNA in skin fibroblasts from Alzheimer's disease. 1998 , 9, 145-8	6
1326	Lack of association between an intronic polymorphism in the presenilin-1 gene and sporadic late-onset Alzheimer disease in Polish patients. 1998 , 9, 137-9	8
1325	Alzheimer's disease and heparan sulfate proteoglycan. 1998 , 3, d327-37	24
1324	Truncated apolipoprotein E (ApoE) causes increased intracellular calcium and may mediate ApoE neurotoxicity. 1999 , 19, 7100-10	130
1323	Expression of human apolipoprotein E3 or E4 in the brains of Apoe ^{-/-} mice: isoform-specific effects on neurodegeneration. 1999 , 19, 4867-80	311
1322	A quantitative and immunohistochemical study on apolipoprotein E in brain tissue in Alzheimer's disease. 1999 , 10, 452-9	23
1321	Brain Accumulation of Amyloid-beta in Non-Alzheimer Neurodegeneration. 1999 , 1, 183-193	11
1320	Apolipoprotein E and alpha1-antichymotrypsin genotypes and age of onset of familial Alzheimer's disease. 1999 , 10, 1-5	5
1319	Diet and oxidative stress: a novel synthesis of epidemiological data on Alzheimer's disease. 1999 , 1, 203-6	43
1318	DNA Microarrays for Polymorphism Detection and Genotyping: Utility in the Understanding of Complex Neuropsychiatric Diseases. 1999 , 4, 59-74	1
1317	Characterization of Apolipoprotein E-containing Lipoproteins in Cerebrospinal Fluid: Effect of Phenotype on the Distribution of Apolipoprotein E. 1999 , 45, 1431-1438	29
1316	Apolipoprotein E in Cerebrospinal Fluid: Relation to Phenotype and Plasma Apolipoprotein E Concentrations. 1999 , 45, 497-504	40
1315	Epidemiology of Dementia in Geneva. 1999 , 30, 94-100	3

1314	Ethical Issues Resulting from Genetic Technology. 1999 , 3, 67-78	0
1313	Apolipoprotein E polymorphism in elderly Chilean people with Alzheimer's disease. 1999 , 18, 48-52	22
1312	A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. 1999 , 53, 197-201	347
1311	Decreased melatonin levels in postmortem cerebrospinal fluid in relation to aging, Alzheimer's disease, and apolipoprotein E-epsilon4/4 genotype. 1999 , 84, 323-7	243
1310	Demenz bei neurodegenerativen Erkrankungen. 1999 , 26, 243-249	
1309	Women and Alzheimer's disease. 1999 , 84, 1830-4	14
1308	The genetics of Alzheimer's disease. 2000 , 32, 23-43	5
1307	Molecular genetics of Alzheimer disease. 1999 , 19, 371-83	42
1306	Event-related potential changes in groups at increased risk for Alzheimer disease. 1999 , 56, 1398-403	44
1305	The neurobiology and pharmacotherapy of Alzheimer's disease. 1999 , 11, 19-31	43
1304	The tangled biology of tau. 1999 , 96, 7120-1	23
1303	APOE-epsilon4 count predicts age when prevalence of AD increases, then declines: the Cache County Study. 1999 , 53, 321-31	324
1302	In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease. 1999 , 52, 691-9	299
1301	Genetic Predictors of Perioperative Neurologic and Neuropsychological Injury and Recovery. 1999 , 3, 34-46	5
1300	Case-control study of presenilin-1 intronic polymorphism in sporadic early and late onset Alzheimer's disease. 1999 , 66, 722-6	15
1299	Effects of a frequent apolipoprotein E isoform, ApoE4Freiburg (Leu28-->Pro), on lipoproteins and the prevalence of coronary artery disease in whites. 1999 , 19, 1306-15	26
1298	Diagnosis and management of Alzheimer disease. 1999 , 12, 375-85	10
1297	A full genome scan for late onset Alzheimer's disease. 1999 , 8, 237-45	279

1296	Apolipoprotein E epsilon4 allele is a risk factor for Alzheimer's disease: the central region of portugal (Coimbra) as a case study. 1999 , 42, 183-4	6
1295	Apolipoprotein E genotype and schizophrenia. 1999 , 39, 141-3	18
1294	A myristoylated calcium-binding protein that preferentially interacts with the Alzheimer's disease presenilin 2 protein. 1999 , 145, 1277-92	119
1293	Amyloid and lipids in the pathology of Alzheimer disease. 1999 , 6, 136-45	57
1292	The genetics of Alzheimer disease and the application of molecular tests. 1999 , 3, 37-45	15
1291	Mounting evidence for the involvement of zinc and copper in Alzheimer's disease. 1999 , 29, 569-70	18
1290	Novel intronic polymorphisms in the presenilin-2 gene and a case-control association study of Alzheimer's disease. 1999 , 53, 579-85	3
1289	Apolipoprotein E phenotypes in healthy normal controls and demented subjects with Alzheimer's disease and vascular dementia in Mie Prefecture of Japan. 1999 , 53, 643-8	22
1288	Apolipoprotein E phenotypes in demented and cognitively impaired patients with and without cerebrovascular disease. 1999 , 6, 415-21	27
1287	Beta-amyloid peptide interacts specifically with the carboxy-terminal domain of human apolipoprotein E: relevance to Alzheimer's disease. 1999 , 72, 230-7	69
1286	Regulation of amyloid precursor protein cleavage. 1999 , 72, 443-60	170
1285	Genetics and Child Psychiatry: II Empirical Research Findings. 1999 , 40, 19-55	225
1284	Increased apolipoprotein B serum concentration in Alzheimer's disease. 1999 , 100, 61-3	58
1283	Linkage disequilibrium in the 13q12 region in Finnish late onset Alzheimer's disease patients. 1999 , 7, 652-8	8
1282	Complex Genetic Disorders: Evaluating When Genetic Research Findings Are Applicable for Genetic Counseling Practice. 1999 , 8, 73-84	3
1281	Is there a genetic basis for the deposition of beta-amyloid after fatal head injury?. 1999 , 19, 19-30	17
1280	Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. 1999 , 52, 1397-403	1139
1279	Molecular pathogenesis of apolipoprotein E-mediated amyloidosis in late-onset Alzheimer's disease. 1999 , 56, 268-79	17

1278	Alzheimer's and prion disease as disorders of protein conformation: implications for the design of novel therapeutic approaches. 1999 , 77, 412-8	60
1277	[Inheritable causes and risk factors of Alzheimer's disease]. 1999 , 70, 195-205	12
1276	The relevance of apolipoprotein E polymorphism to Alzheimer's disease. 1999 , 14, 40-8	1
1275	Development in the research of molecular mechanism of Alzheimer's disease. 1999 , 44, 1257-1264	1
1274	Diminished neuronal metabolic activity in Alzheimer's disease. Review article. 1999 , 106, 955-86	29
1273	Promoter polymorphism (-491A/T) in the APOE gene of Finnish Alzheimer's disease patients and control individuals. 1999 , 246, 821-4	34
1272	Is the LDL receptor-related protein involved in Alzheimer's disease?. 1999 , 2, 109-13	24
1271	No association between the HLA-A2 allele and Alzheimer disease. 1999 , 2, 177-82	15
1270	Apolipoprotein E and beta-amyloid levels in the hippocampus and frontal cortex of Alzheimer's disease subjects are disease-related and apolipoprotein E genotype dependent. 1999 , 843, 87-94	112
1269	Apolipoprotein E4 isoform-specific actions on neuronal cells in culture. 1999 , 107, 233-43	12
1268	Oxidative damage and protection by antioxidants in the frontal cortex of Alzheimer's disease is related to the apolipoprotein E genotype. 1999 , 27, 544-53	205
1267	Stroke-like episodes in autosomal recessive cytochrome oxidase deficiency. 1999 , 45, 389-392	35
1266	Radiation-induced cerebral vasculopathy in children with neurofibromatosis and optic pathway glioma. 1999 , 45, 393-6	201
1265	HLA A2 allele is associated with age at onset of Alzheimer's disease. 1999 , 45, 397-400	27
1264	Monospecific anti-GD1b IgG is required to induce rabbit ataxic neuropathy. 1999 , 45, 400-403	54
1263	Cerebral tumor-like American trypanosomiasis in acquired immunodeficiency syndrome. 1999 , 45, 403-6	38
1262	Mitochondrial abnormalities: A primary basis for oxidative damage in Alzheimer's disease. 1999 , 46, 26-33	10
1261	Electrophoretic analysis of oxidative modification of apolipoprotein E in very low density lipoprotein from fresh human plasma. 1999 , 20, 1418-24	5

1260	Lipoprotein effects on β -amyloid accumulation and degradation by microglia in vitro. 1999 , 57, 504-520	33
1259	Higher avidity binding of apolipoprotein (E β II) complex than of apolipoprotein E monomer to β -amyloid. 1999 , 58, 301-307	20
1258	Risk of Alzheimer's disease is associated with a very low-density lipoprotein receptor genotype in Northern Ireland. 1999 , 88, 140-4	17
1257	Apolipoprotein E alleles in childhood-onset schizophrenia. 1999 , 88, 211-213	17
1256	The glutamatergic system and neurodegeneration in dementia: preventive strategies in Alzheimer's disease. 1999 , 14, 3-47	110
1255	Factors associated with depressive symptoms in non-demented community-dwelling elderly. 1999 , 14, 331-337	32
1254	The current status of apo E4 as a risk factor for Alzheimer's disease: an epidemiological perspective. 1999 , 14, 695-700	16
1253	Risk factors and differential diagnosis of Alzheimer's disease. 1999 , 249 Suppl 3, 37-42	11
1252	The mammalian low-density lipoprotein receptor family. 1999 , 19, 141-72	314
1251	Goals and objectives for molecular pathology education in residency programs. The Association for Molecular Pathology Training and Education Committee. 1999 , 1, 5-15	16
1250	Apolipoprotein E genetic variation and Alzheimer's disease. a meta-analysis. 1999 , 10, 199-209	112
1249	Apolipoprotein E and Alzheimer's Disease. 1999 , 11, 411-420	4
1248	Neuropsychology of sports-related head injury: Dementia Pugilistica to Post Concussion Syndrome. 1999 , 13, 193-209	95
1247	Apolipoprotein E deficiency worsens outcome from global cerebral ischemia in the mouse. 1999 , 30, 1118-24	102
1246	Multipoint oligogenic analysis of age-at-onset data with applications to Alzheimer disease pedigrees. 1999 , 64, 839-51	82
1245	Identifying families with likely genetic protective factors against Alzheimer disease. 1999 , 64, 832-8	22
1244	A middle-aged woman, being treated for hypercholesterolaemia, presents with abnormal liver function. 1999 , 3, 43-47	
1243	Ionizing radiation and genetic risks. VI. Chronic multifactorial diseases: a review of epidemiological and genetical aspects of coronary heart disease, essential hypertension and diabetes mellitus. 1999 , 436, 21-57	30

1242	Fetal brain infection with human parvovirus B19. 1999 , 21, 661-3	66
1241	Apolipoprotein E promoter polymorphism and sporadic Alzheimer's disease in a Japanese population. 1999 , 259, 56-8	41
1240	The polymorphism in exon 3 of the low density lipoprotein receptor-related protein gene is weakly associated with Alzheimer's disease. 1999 , 259, 29-32	48
1239	Apolipoprotein E genotype does not affect the age of onset of dementia in families with defined tau mutations. 1999 , 260, 193-5	25
1238	No association between the alpha-2 macroglobulin I1000V polymorphism and Alzheimer's disease. 1999 , 262, 137-9	45
1237	Frequency of HLA-A and B alleles in early and late-onset Alzheimer's disease. 1999 , 262, 140-2	17
1236	The -491A/T polymorphism of the Apolipoprotein E gene is associated with the ApoEepsilon4 allele and Alzheimer's disease. 1999 , 263, 217-9	22
1235	A novel mutation in the apolipoprotein E gene (APOE*4 Pittsburgh) is associated with the risk of late-onset Alzheimer's disease. 1999 , 263, 129-32	30
1234	Apolipoprotein E4 accelerates dementia and increases cerebrospinal fluid tau levels in Alzheimer's disease. 1999 , 267, 65-8	54
1233	Genetic variability at the amyloid-beta precursor protein locus may contribute to the risk of late-onset Alzheimer's disease. 1999 , 269, 67-70	39
1232	Analysis of association between Alzheimer disease and the K variant of butyrylcholinesterase (BCHE-K). 1999 , 269, 115-9	34
1231	Risk for Alzheimer's disease in older late-onset cases is associated with HLA-DRB1*03. 1999 , 275, 137-40	23
1230	Apolipoprotein E promotes the binding and uptake of beta-amyloid into Chinese hamster ovary cells in an isoform-specific manner. 1999 , 90, 1217-26	99
1229	Lipoprotein receptor-related protein in brain and in cultured neurons of mice deficient in receptor-associated protein and transgenic for apolipoprotein E4 or amyloid precursor protein. 1999 , 94, 315-21	9
1228	Autoradiographic comparison of [3H](-)-nicotine, [3H]cytisine and [3H]epibatidine binding in relation to vesicular acetylcholine transport sites in the temporal cortex in Alzheimer's disease. 1999 , 94, 685-96	41
1227	Alzheimer's disease. 1999 , 31, 185-200	20
1226	Alzheimer's disease and oxidative stress: implications for novel therapeutic approaches. 1999 , 57, 301-23	368
1225	Progress toward valid transgenic mouse models for Alzheimer's disease. 1999 , 20, 201-11	61

1224	Herpes simplex virus type 1 and Alzheimer's disease. 1999 , 20, 457-65	63
1223	Apolipoprotein E is found in astrocytes but not in microglia in the normal mouse brain. 1999 , 35, 123-33	28
1222	HLA-A and CTGB33 polymorphisms and variation in IQ scores. 1999 , 26, 795-799	1
1221	Psychiatric genetics: progress, problems, and potential. 1999 , 354 Suppl 1, S111-4	18
1220	Cell surface heparan sulfate proteoglycans and lipoprotein metabolism. 1999 , 56, 857-70	58
1219	Decreased Melatonin Levels in Postmortem Cerebrospinal Fluid in Relation to Aging, Alzheimer's Disease, and Apolipoprotein E-4/4 Genotype. 1999 , 84, 323-327	175
1218	Loss of olfactory function in dementing disease. 1999 , 66, 177-82	123
1217	Transcription factor AP-2 activity is modulated by protein kinase A-mediated phosphorylation. 1999 , 444, 27-31	52
1216	Identification of caspases that cleave presenilin-1 and presenilin-2. Five presenilin-1 (PS1) mutations do not alter the sensitivity of PS1 to caspases. 1999 , 445, 149-54	44
1215	Kinetics of apolipoprotein E isoforms-binding to the major glycosaminoglycans of the extracellular matrix. 1999 , 459, 353-7	20
1214	Apolipoprotein E and the neuropathology of Alzheimer's disease. 1999 , 30, 1125-7	2
1213	Apolipoprotein E epsilon 4 allele and Japanese late-onset depressive disorders. 1999 , 45, 308-12	14
1212	Apolipoprotein E-epsilon 4 frequency in affective disorder. 1999 , 45, 430-4	22
1211	Apolipoprotein E genotype and noncognitive symptoms in Alzheimer's disease. 1999 , 45, 422-5	62
1210	Apolipoprotein E epsilon 4, other risk factors, and course of Alzheimer's disease. 1999 , 45, 633-8	53
1209	Clinical and neurobiological correlates of D10S1423 genotype in Alzheimer's disease. 1999 , 46, 740-9	11
1208	Clinical and neurobiological correlates of DXS1047 genotype in Alzheimer's disease. 1999 , 46, 173-81	12
1207	Apolipoprotein E: a pharmacogenetic target for the treatment of Alzheimer's disease. 1999 , 4, 335-41	34

1206	Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. 1999 , 274, 25945-52	871
1205	Apolipoprotein E-varepsilon4 frequency in deficit schizophrenia. 1999 , 14, 148-51	8
1204	Uses of Evolutionary Theory in the Human Genome Project. 1999 , 30, 23-49	21
1203	Contribution of cysteine 158, the glycosylation site threonine 194, the amino- and carboxy-terminal domains of apolipoprotein E in the binding to amyloid peptide beta (1-40). 1999 , 38, 8918-25	30
1202	A role for apoE in regulating the levels of alpha-1-antichymotrypsin in the aging mouse brain and in Alzheimer's disease. 1999 , 155, 869-75	27
1201	Specific regional transcription of apolipoprotein E in human brain neurons. 1999 , 154, 601-11	135
1200	Tau pathology generated by overexpression of tau. 1999 , 155, 1781-5	12
1199	Ligand-dependent tau filament formation: implications for Alzheimer's disease progression. 1999 , 38, 14851-9	136
1198	Assembly of A beta amyloid protofibrils: an in vitro model for a possible early event in Alzheimer's disease. 1999 , 38, 8972-80	458
1197	Increased cerebral cortical lipid peroxidation and abnormal phospholipids in aged homozygous apoE-deficient C57BL/6J mice. 1999 , 158, 234-41	29
1196	Entorhinal cortex beta-amyloid load in individuals with mild cognitive impairment. 1999 , 158, 469-90	184
1195	Sialylated human apolipoprotein E (apoEs) is preferentially associated with neuron-enriched cultures from APOE transgenic mice. 1999 , 6, 63-75	39
1194	Chromosome missegregation and trisomy 21 mosaicism in Alzheimer's disease. 1999 , 6, 167-79	114
1193	Functional characterization of apolipoprotein E isoforms overexpressed in Escherichia coli. 1999 , 16, 224-30	84
1192	Carboxyl-terminal domain of human apolipoprotein E: expression, purification, and crystallization. 1999 , 17, 267-72	23
1191	Neuropsychological function and apolipoprotein E genotype in the preclinical detection of Alzheimer's disease.. 1999 , 14, 295-303	184
1190	An analysis of diversity in the cognitive performance of elderly community dwellers: Individual differences in change scores as a function of age.. 1999 , 14, 365-379	151
1189	Neuroimaging findings in twins discordant for Alzheimer's disease. 1999 , 10, 51-8	95

1188	White matter lesions in Alzheimer patients are influenced by apolipoprotein E genotype. 1999 , 10, 89-96	44
1187	The utility of apolipoprotein E genotyping in the diagnosis of Alzheimer disease in a community-based case series. 1999 , 56, 1489-95	38
1186	CHAPTER 5.6 Identification and functional analysis of genes and genetic risk factors in Alzheimer's disease. 1999 , 841-862	
1185	Differential effects of apolipoprotein E isoforms on metal-induced aggregation of A beta using physiological concentrations. 1999 , 38, 4595-603	117
1184	Apolipoprotein E: from atherosclerosis to Alzheimer's disease and beyond. 1999 , 10, 207-17	281
1183	Tau and apo E in CSF: potential aid for discriminating Alzheimer's disease from other dementias. 1999 , 10, 3491-5	43
1182	Research in biomedical gerontology in the Millennium. 1999 , 9, 291-296	
1181	The molecular basis and genetic determinants of Alzheimer's disease. 1999 , 9, 297-304	
1180	Enhanced cognitive performance with estrogen use in nondemented community-dwelling older women. 1999 , 47, 1171-5	72
1179	Lipoprotein glomerulopathy: renal lipidosis induced by novel apolipoprotein E variants. 1999 , 83, 193-201	33
1178	Traumatic brain injury and time to onset of Alzheimer's disease: a population-based study. 1999 , 149, 32-40	231
1177	Metallothionein in olfactory mucosa of Alzheimer's disease patients and apoE-deficient mice. 1999 , 10, 1919-24	14
1176	A presenilin-1 Thr116Asn substitution in a family with early-onset Alzheimer's disease. 1999 , 10, 2255-60	25
1175	Lack of effect of apolipoprotein E E4 allele on neuropsychiatric manifestations in Alzheimer's disease. 1999 , 11, 66-70	41
1174	Venous thrombosis in older people: prevalence of the factor V gene mutation Q506. 1999 , 47, 1160-1	
1173	Tau protein in normal and Alzheimer's disease brain: an update. 1999 , 1, 329-51	86
1172	Chapter 5.8 Transgenic mouse models of Alzheimer's disease. 1999 , 880-894	1
1171	Apolipoprotein E genotype and lipid and lipoprotein levels in dementia. 2000 , 11, 70-3	29

1170	Associations Between Retrospectively Recalled Napping Behavior and Later Development of Alzheimer's Disease: Association with APOE Genotypes. 2000,	
1169	A longitudinal quantitative EEG study of Alzheimer's disease: relation to apolipoprotein E polymorphism. 2000, 11, 29-35	32
1168	Apolipoprotein E, methylenetetrahydrofolate reductase (MTHFR) mutation and the risk of senile dementia--an epidemiological study using the polymerase chain reaction (PCR) method. 2000, 10, 163-72	41
1167	Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer's amyloid β peptides. 2000, 348, 359	75
1166	Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer's amyloid β peptides. 2000, 348, 359-365	189
1165	DNA. 2000, 126, 806-828	124
1164	Advances in pharmacogenetics and pharmacogenomics. 2000, 40, 930-8	61
1163	The apolipoprotein E epsilon4 allele is unlikely to be a major risk factor of age-related macular degeneration in Chinese. 2000, 214, 289-91	69
1162	Relationships between cerebrovascular events, APOE polymorphism and Alzheimer's disease in a community sample. 2000, 19, 320-6	10
1161	Introduction. 2000, 61, 118-23	14
1160	Apolipoprotein E and intronic polymorphism of presenilin 1 and alpha-1-antichymotrypsin in Alzheimer's disease and vascular dementia. 2000, 11, 239-44	22
1159	The very high prevalence of AD in an Arab population is not explained by APOE epsilon4 allele frequency. 2000, 55, 731	32
1158	Effect of the apolipoprotein E epsilon4 allele on white matter hyperintensities in dementia. 2000, 31, 1263-8	64
1157	Psychopharmacological Agents. 2000,	
1156	Hippocampal sulcal cavities on MRI: relationship to age and apolipoprotein E genotype. 2000, 54, 2150-3	33
1155	Genetic association of a cystatin C gene polymorphism with late-onset Alzheimer disease. 2000, 57, 1579-83	118
1154	Involvement of apolipoprotein E in multiple sclerosis: absence of remyelination associated with possession of the APOE epsilon2 allele. 2000, 59, 361-7	30
1153	Apolipoprotein E and Alzheimer disease: an update on genetic and functional analyses. 2000, 59, 751-8	112

1152	Preliminary report on the association of apolipoprotein E polymorphisms, with postoperative peak serum creatinine concentrations in cardiac surgical patients. 2000 , 93, 325-31	69
1151	Incidence of dementia in relation to stroke and the apolipoprotein E epsilon4 allele in the very old. Findings from a population-based longitudinal study. 2000 , 31, 53-60	64
1150	Genetics and brain injury: apolipoprotein E. 2000 , 15, 869-74	38
1149	Alpha2-macroglobulin gene polymorphisms show racial diversity and are not associated with Alzheimer's disease. 2000 , 11, 1167-71	17
1148	Early diagnosis of Alzheimer disease with positron emission tomography. 2000 , 14 Suppl 1, S109-13	25
1147	Genetic Risk Factors for Schizophrenia. 2000 , 29, 13-38	0
1146	Cholesterol homeostasis in rat astrocytoma cells GA-1. 2000 , 128, 837-45	8
1145	Genetic association study between alpha 1-antichymotrypsin polymorphism and Alzheimer disease in Chinese Han population. 2000 , 96, 133-5	6
1144	Analysis of blood plasma proteins in patients with Alzheimer's disease by two-dimensional electrophoresis, sequence homology and immunodetection. 2000 , 21, 1832-45	31
1143	Association between presenilin-1 polymorphism and maternal meiosis II errors in Down syndrome. 2000 , 93, 366-72	21
1142	Memory performance and the apolipoprotein E polymorphism in a community sample of middle-aged adults. 2000 , 96, 707-11	102
1141	Association of a haplotype for tumor necrosis factor in siblings with late-onset Alzheimer disease: the NIMH Alzheimer Disease Genetics Initiative. 2000 , 96, 823-30	117
1140	Very low density lipoprotein receptor in Alzheimer disease. 2000 , 50, 273-7	16
1139	Apolipoprotein E isoforms in Alzheimer's disease pathology and etiology. 2000 , 50, 278-81	28
1138	Cerebrospinal fluid lipoproteins in Alzheimer's disease. 2000 , 50, 282-6	22
1137	Apolipoprotein J (clusterin) and Alzheimer's disease. 2000 , 50, 305-15	198
1136	A unifying hypothesis of Alzheimer's disease. III. Risk factors. 2000 , 15, 1-70	32
1135	Defective ubiquitination of cerebral proteins in Alzheimer's disease. 2000 , 62, 302-10	192

1134	Effect of apolipoprotein All on the interaction of apolipoprotein E with beta-amyloid: some apo(E-All) complexes inhibit the internalization of beta-amyloid in cultures of neuroblastoma cells. 2000 , 62, 608-14	15
1133	Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model. 2000 , 47, 739-747	262
1132	No tissue damage by chronic deep brain stimulation in Parkinson's disease. 2000 , 48, 372-376	168
1131	Familial Alzheimer's disease: Site of mutation influences clinical phenotype. 2000 , 48, 376-379	32
1130	Severe congenital myasthenic syndrome due to homozygosity of the 1293insG ϵ acetylcholine receptor subunit mutation. 2000 , 48, 379-383	11
1129	Acquired hippocampal damage after temporal lobe seizures in 2 infants. 2000 , 48, 384-387	21
1128	Gene polymorphism affecting α -antichymotrypsin and interleukin-1 plasma levels increases Alzheimer's disease risk. 2000 , 48, 388-391	85
1127	Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex. 2000 , 48, 391-395	98
1126	An enzyme-linked immunosorbent assay to quantify 14-3-3 proteins in the cerebrospinal fluid of suspected Creutzfeldt-Jakob disease patients. 2000 , 48, 395-398	49
1125	Alteration of the serotonergic nervous system in fatal familial insomnia. 2000 , 48, 788-791	24
1124	Inhibition of cyclooxygenase-2 protects motor neurons in an organotypic model of amyotrophic lateral sclerosis. 2000 , 48, 792-795	107
1123	Down's syndrome is associated with increased 8,12-iso-iPF ₂ ?-VI levels: Evidence for enhanced lipid peroxidation in vivo. 2000 , 48, 795-798	59
1122	PABP2 polyalanine tract expansion causes intranuclear inclusions in oculopharyngeal muscular dystrophy. 2000 , 48, 798-802	38
1121	High mortality in Nipah encephalitis is associated with presence of virus in cerebrospinal fluid. 2000 , 48, 802-805	61
1120	Variant Alzheimer's disease with spastic paraparesis and cotton wool plaques is caused by PS-1 mutations that lead to exceptionally high amyloid- β concentrations. 2000 , 48, 806-808	113
1119	Increased 8,12-iso-iPF ₂ EV1 in Alzheimer's disease: Correlation of a noninvasive index of lipid peroxidation with disease severity. 2000 , 48, 809-812	295
1118	Intranuclear inclusions in oculopharyngeal muscular dystrophy contain poly(A) binding protein 2. 2000 , 48, 812-815	37
1117	Sandwich ELISA for the measurement of Apo-E4 levels in serum and the estimation of the allelic status of Apo-E4 isoforms. 2000 , 14, 260-4	7

1116	Oestrogens and Alzheimer's disease. 2000 , 15, 600-9	11
1115	Neuropathological heterogeneity in Alzheimer's disease: a study of 80 cases using principal components analysis. 2000 , 20, 31-7	36
1114	Untangling Alzheimer's disease from fibrous lesions of neurofibrillary tangles and senile plaques. 2000 , 20 Suppl, S55-60	8
1113	Predictors of severity of behavioral disturbance among community-dwelling elderly individuals with Alzheimer's disease: a 6-year follow-up study. 2000 , 54, 673-7	10
1112	No effect of apolipoprotein E on neuronal cell death due to excitotoxic and apoptotic agents in vitro and neonatal hypoxic ischaemia in vivo. 2000 , 12, 2235-42	18
1111	Apolipoprotein E exhibits isoform-specific promotion of lipid efflux from astrocytes and neurons in culture. 2000 , 74, 1008-16	156
1110	Single nucleotide polymorphisms and the future of genetic epidemiology. 2000 , 58, 250-64	250
1109	High suicidal ideation in persons testing for Huntington's disease. 2000 , 102, 150-61	54
1108	Physiopathologie des amyloses. 2000 , 67, 189-196	1
1107	Psychiatric genetics: back to the future. 2000 , 5, 22-31	60
1106	Do susceptibility loci contribute to the expression of more than one mental disorder? A view from the genetics of Alzheimer's disease. 2000 , 5, 131-6	20
1105	Apolipoprotein E is a genetic risk factor for fetal iodine deficiency disorder in China. 2000 , 5, 363-8	16
1104	Apolipoprotein E receptors: linking brain development and Alzheimer's disease. 2000 , 1, 51-8	172
1103	Dental management of patients with Alzheimer's disease and other dementias. 2000 , 17, 8-16	34
1102	Amyloid-beta-induced degeneration of human brain pericytes is dependent on the apolipoprotein E genotype. 2000 , 903, 187-99	34
1101	Marked hippocampal neuronal damage without motor deficits after mild concussive-like brain injury in apolipoprotein E-deficient mice. 2000 , 903, 357-65	25
1100	Making drug discovery a SN(i)P. 2000 , 5, 388-396	10
1099	Identification of novel genes in late-onset Alzheimer's disease. 2000 , 35, 1343-52	165

1098	The efficiency of genetic analysis of DNA from aged siblings to detect chromosomal regions implicated in longevity. 2000 , 119, 25-39	7
1097	Quantitative evaluation of the rRNA in Alzheimer's disease. 2000 , 120, 57-64	39
1096	Animal models of Alzheimer's disease and evaluation of anti-dementia drugs. 2000 , 88, 93-113	133
1095	Apolipoprotein E epsilon4 and tardive dyskinesia in a Japanese population. 2000 , 34, 329-32	11
1094	Alzheimer disease constricts the dynamic range of spatial attention in visual search. 2000 , 38, 1126-35	53
1093	The value of genotyping for apolipoprotein E alleles in relation to vitamin E supplementation. 2000 , 410, 161-163	10
1092	Apolipoprotein E polymorphism and breast carcinoma: correlation with cell proliferation indices and clinical outcome. 2000 , 63, 193-8	17
1091	Intake of flavonoids and risk of dementia. 2000 , 16, 357-63	429
1090	The endosomal-lysosomal system of neurons in Alzheimer's disease pathogenesis: a review. 2000 , 25, 1161-72	251
1089	Conformational flexibility in the apolipoprotein E amino-terminal domain structure determined from three new crystal forms: implications for lipid binding. 2000 , 9, 886-97	43
1088	The cerebral proteopathies: neurodegenerative disorders of protein conformation and assembly. 2000 , 21, 83-95	71
1087	Apolipoprotein E4: an allele associated with many diseases. 2000 , 32, 118-27	102
1086	Apolipoprotein E: far more than a lipid transport protein. 2000 , 1, 507-37	1199
1085	Apolipoprotein E polymorphism: automated determination of apolipoprotein E2, E3, and E4 isoforms. 2000 , 35, 99-104	3
1084	The genetics of Alzheimer's disease. 2000 , 2, 158-64	46
1083	Hypercholesterolemia and Dyslipidemia. 2000 , 2, 173-187	7
1082	No evidence of association between apolipoprotein E gene regulatory region polymorphism and Alzheimer's disease in Japanese. 2000 , 107, 1449-56	6
1081	No association between the alpha2-macroglobulin (A2M) deletion and Alzheimer's disease, and no change in A2M mRNA, protein, or protein expression. 2000 , 107, 1065-79	88

1080	Growth-associated protein GAP-43 in the frontal cortex and in the hippocampus in Alzheimer's disease: an immunohistochemical and quantitative study. 2000 , 107, 463-78	46
1079	Apolipoprotein E4 promotes the early deposition of Abeta42 and then Abeta40 in the elderly. 2000 , 100, 36-42	66
1078	Lewy body and Alzheimer pathology in a family with the amyloid-beta precursor protein APP717 gene mutation. 2000 , 100, 145-52	48
1077	Blood levels of alpha-1-antichymotrypsin and risk factors for Alzheimer's disease: effects of gender and apolipoprotein E genotype. 2000 , 11, 25-8	71
1076	APOE epsilon 4 influences the manifestation of Alzheimer's disease in adults with Down's syndrome. 2000 , 176, 468-72	54
1075	Role of tissue plasminogen activator receptor LRP in hippocampal long-term potentiation. 2000 , 20, 542-9	254
1074	Amyloid-beta and treatment opportunities for Alzheimer's disease. 2000 , 2, 231-59	5
1073	Apolipoprotein E genotyping for pharmacogenetic purposes in Alzheimer's disease: emerging ethical issues. 2000 , 45, 917-22	22
1072	Revisiting Alzheimer's Disease from a New Perspective: Can "Risk Factors" Play a Key Role?. 2000 , 2, 97-108	5
1071	Evaluation of the Apo E Genotyping Kit on the LightCycler. 2000 , 46, 722-724	32
1070	Elevated Aβ and Apolipoprotein E in APP Transgenic Mice and Its Relationship to Amyloid Accumulation in Alzheimer's Disease. 2000 , 6, 430-439	62
1069	The serotonin transporter in Alzheimer's and Parkinson's disease. 2000 , 345-350	10
1068	Cerebral white matter lesions are not associated with apoE genotype but with age and female sex in Alzheimer's disease. 2000 , 68, 653-6	41
1067	Genetics and visual attention: selective deficits in healthy adult carriers of the epsilon 4 allele of the apolipoprotein E gene. 2000 , 97, 11661-6	113
1066	Usefulness of MRI measures of entorhinal cortex versus hippocampus in AD. 2000 , 54, 1760-7	328
1065	The molecular and genetic basis of AD: the end of the beginning: the 2000 Wartenberg lecture. 2000 , 54, 2045-54	126
1064	Longitudinal change in hippocampal volume as a function of apolipoprotein E genotype. 2000 , 55, 134-6	150
1063	Transcranial Doppler recording in a patient with transient positional cerebral ischemia. 2000 , 55, 731-2	5

1062	Cholinergic dysfunction in diseases with Lewy bodies. 2000 , 54, 407-11	277
1061	Apolipoprotein E polymorphism and serum concentration in Alzheimer's disease in nine European centres: the ApoEurope study. ApoEurope group. 2000 , 38, 721-30	60
1060	Apolipoprotein E polymorphisms and concentration in chronic diseases and drug responses. 2000 , 38, 841-52	51
1059	Lack of association of the alpha2-macroglobulin locus on chromosome 12 in AD. 2000 , 54, 433-8	42
1058	The serotonergic agent m-chlorophenylpiperazine induces migraine attacks: A controlled study. 2000 , 55, 136-9	33
1057	Fear recognition deficits after focal brain damage: a cautionary note. 2000 , 54, 575-81	133
1056	Alpha2-macroglobulin polymorphism is not associated with AD or AD-type neuropathology in the Japanese. 2000 , 54, 443-6	21
1055	A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. 2000 , 54, 588-93	425
1054	Lu 25-109, a muscarinic agonist, fails to improve cognition in Alzheimer's disease. Lu25-109 Study Group. 2000 , 54, 421-6	48
1053	Prevalence and outcomes of vascular cognitive impairment. Vascular Cognitive Impairment Investigators of the Canadian Study of Health and Aging. 2000 , 54, 447-51	304
1052	APOE epsilon4 does not predict mortality, cognitive decline, or dementia in the oldest old. 2000 , 54, 412-5	90
1051	Access www.neurology.org now for full-text articles. 2000 , 54, 587-587	
1050	Early-life risk factors and the development of Alzheimer's disease. 2000 , 54, 415-20	150
1049	A novel presenilin 1 mutation (Leu166Arg) associated with early-onset Alzheimer disease. 2000 , 57, 485-8	15
1048	Educational attainment and socioeconomic status of patients with autopsy-confirmed Alzheimer disease. 2000 , 57, 85-9	30
1047	Apolipoprotein E and neuromuscular disease: a critical review of the literature. 2000 , 57, 1561-5	56
1046	MPO and APOEepsilon4 polymorphisms interact to increase risk for AD in Finnish males. 2000 , 55, 1284-90	76
1045	Ongoing trials in Alzheimer's disease. 2000 , 9, 899-915	9

1044	Effect of APOE genotype and promoter polymorphism on risk of Alzheimer's disease. 2000 , 55, 1644-9	48
1043	Age-related cognitive decline, mild cognitive impairment or preclinical Alzheimer's disease?. 2000 , 32, 6-14	119
1042	Patterns of brain activation in people at risk for Alzheimer's disease. 2000 , 343, 450-6	1029
1041	Talkativeness in Cognitively Normal Women at Genetic Risk for Alzheimer's Disease. 2000 , 7, 217-226	2
1040	Sequence diversity and large-scale typing of SNPs in the human apolipoprotein E gene. 2000 , 10, 1532-45	131
1039	Apolipoprotein E polymorphism and Alzheimer disease: The Indo-US Cross-National Dementia Study. 2000 , 57, 824-30	272
1038	Transcriptional regulation of Alzheimer's disease genes: implications for susceptibility. 2000 , 9, 2383-94	55
1037	Advances in Research on Neurodegeneration. 2000 ,	0
1036	APOE and AD concordance in twin pairs as predictors of AD in first-degree relatives. 2000 , 54, 593-8	12
1035	Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. 2000 , 57, 100-5	478
1034	Alpha2 macroglobulin and the risk of Alzheimer's disease. 2000 , 54, 438-42	67
1033	Neuropsychological Profile of a Large Kindred with Familial Alzheimer's Disease Caused by the E280A Single Presenilin-1 Mutation. 2000 , 15, 515-528	81
1032	Apolipoprotein E epsilon3 allele is not a risk factor of schizophrenia: a study of 314 Japanese patients. 2000 , 42, 66-8	2
1031	Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. 2000 , 57, 1439-43	1234
1030	Mechanisms of neurodegenerative disorders: Part 1: protein aggregates. 2000 , 57, 793-6	63
1029	Self-association of human apolipoprotein E3 and E4 in the presence and absence of phospholipid. 2000 , 275, 36758-65	101
1028	Apolipoprotein E and multiple sclerosis: impact of the epsilon-4 allele on susceptibility, clinical type and progression rate. 2000 , 6, 226-30	58
1027	Internal carotid artery dissection. 2000 , 54, 442	7

1026	Memory and MRI-based hippocampal volumes in aging and AD. 2000 , 54, 581-7	334
1025	Isoaspartate formation and neurodegeneration in Alzheimer's disease. 2000 , 381, 225-34	154
1024	Apolipoprotein E and apolipoprotein D expression in a murine model of singlet oxygen-induced cerebral stroke. 2000 , 268, 835-41	8
1023	Effect of estradiol on neuronal Swedish-mutated beta-amyloid precursor protein metabolism: reversal by astrocytic cells. 2000 , 271, 82-5	30
1022	Deficiency in mitochondrial aldehyde dehydrogenase increases the risk for late-onset Alzheimer's disease in the Japanese population. 2000 , 273, 192-6	144
1021	Age-dependent cytokine responses: trimethyltin hippocampal injury in wild-type, APOE knockout, and APOE4 mice. 2000 , 14, 288-304	23
1020	Decreased hippocampal metabolic activity in Alzheimer patients is not reflected in the immunoreactivity of cytochrome oxidase subunits. 2000 , 163, 440-51	21
1019	Apolipoprotein E epsilon4 allele has no effect on age at onset or duration of disease in cases of frontotemporal dementia with pick- or microvacuolar-type histology. 2000 , 163, 452-6	33
1018	Effects of age on gene expression during estrogen-induced synaptic sprouting in the female rat. 2000 , 165, 46-57	36
1017	Analysis of association at single nucleotide polymorphisms in the APOE region. 2000 , 63, 7-12	53
1016	Review: Alzheimer's amyloid beta-peptide-associated free radical oxidative stress and neurotoxicity. 2000 , 130, 184-208	611
1015	Oxidative insults are associated with apolipoprotein E genotype in Alzheimer's disease brain. 2000 , 7, 23-37	153
1014	The future of genetic analysis of neurological disorders. 2000 , 7, 65-9	10
1013	Genetic mapping of complex traits: promises, problems, and prospects. 2000 , 57, 1-11	28
1012	Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. 2000 , 157, 277-86	603
1011	Prominent axonopathy and disruption of axonal transport in transgenic mice expressing human apolipoprotein E4 in neurons of brain and spinal cord. 2000 , 157, 1495-510	123
1010	Effect of apolipoprotein E allele epsilon4 on the initial phase of amyloid beta-protein accumulation in the human brain. 2000 , 157, 2093-9	101
1009	Expression of human apolipoprotein E4 in neurons causes hyperphosphorylation of protein tau in the brains of transgenic mice. 2000 , 156, 951-64	197

1008	Susceptibility loci for bipolar disorder: overlap with inherited vulnerability to schizophrenia. 2000 , 47, 245-51	137
1007	A search for susceptibility loci for anorexia nervosa: methods and sample description. 2000 , 47, 794-803	100
1006	Molecular genetics of Alzheimer's disease. 2000 , 47, 183-99	249
1005	Sodium dodecyl sulfate-resistant complexes of Alzheimer's amyloid beta-peptide with the N-terminal, receptor binding domain of apolipoprotein E. 2000 , 79, 1008-15	20
1004	Does apolipoprotein E genotype relate to BMD and bone markers in postmenopausal women?. 2000 , 34, 33-41	29
1003	No evidence for cholinergic problems in apolipoprotein E knockout and apolipoprotein E4 transgenic mice. 2000 , 97, 411-8	23
1002	Synaptic loss is accompanied by an increase in synaptic area in the dentate gyrus of aged human apolipoprotein E4 transgenic mice. 2000 , 97, 685-92	55
1001	Dominant negative effects of apolipoprotein E4 revealed in transgenic models of neurodegenerative disease. 2000 , 97, 207-10	90
1000	Reversal of presynaptic deficits of apolipoprotein E-deficient mice in human apolipoprotein E transgenic mice. 2000 , 97, 419-24	30
999	Comparison of astrocytic and myocytic metabolic dysregulation in apolipoprotein E deficient and human apolipoprotein E transgenic mice. 2000 , 98, 353-9	12
998	Expression of the apolipoprotein E gene does not affect motor recovery after sensorimotor cortex injury in the mouse. 2000 , 99, 705-10	3
997	Neuropeptides in hippocampus and cortex in transgenic mice overexpressing V717F beta-amyloid precursor protein--initial observations. 2000 , 100, 259-86	68
996	Characterization of transgenic mice expressing apolipoprotein E4(C112R) and apolipoprotein E4(L28P; C112R). 2000 , 101, 211-8	18
995	Susceptibility of transgenic mice expressing human apolipoprotein E to closed head injury: the allele E3 is neuroprotective whereas E4 increases fatalities. 2000 , 101, 879-84	96
994	Implications of genetic epidemiology for the prevention of substance use disorders. 2000 , 25, 807-20	80
993	Molecular mechanism of neurodegeneration induced by Alzheimer's beta-amyloid protein: channel formation and disruption of calcium homeostasis. 2000 , 53, 389-97	185
992	Molecular insights into neurodevelopmental and neurodegenerative diseases. 2000 , 53, 455-69	21
991	Current and future clinical trials for Alzheimer's disease: evolving ethical concerns. 2000 , 24, 1229-49	0

990	The cause of neuronal degeneration in Alzheimer's disease. 2000 , 60, 139-65	201
989	Presenilins and Alzheimer's disease: biological functions and pathogenic mechanisms. 2000 , 60, 363-84	125
988	Serotonin transporter (5-HTT) gene polymorphism in psychogeriatric patients. 2000 , 284, 113-5	33
987	Brain oestradiol and testosterone levels in Alzheimer's disease. 2000 , 286, 1-4	37
986	Phospholipase A2 activity is decreased selectively in the hippocampus of aged apolipoprotein E deficient mice. 2000 , 288, 211-4	3
985	Apolipoprotein E in Southern Italy: protective effect of epsilon 2 allele in early- and late-onset sporadic Alzheimer's disease. 2000 , 292, 79-82	34
984	Polymorphisms in the alpha-2 macroglobulin gene in psychogeriatric patients. 2000 , 294, 69-72	10
983	Intelligence and event-related potentials for young female human volunteer apolipoprotein E epsilon4 and non-epsilon4 carriers. 2000 , 294, 179-81	76
982	Association of apolipoprotein E polymorphism to clinical heterogeneity of multiple sclerosis. 2000 , 296, 174-6	30
981	The role of apolipoprotein E in Alzheimer's disease, acute brain injury and cerebrovascular disease: evidence of common mechanisms and utility of animal models. 2000 , 21, 245-55	122
980	Causes or consequences of inflammation and pathological signs of Alzheimer disease. 2000 , 21, 423-5	6
979	Apolipoprotein E polymorphism in Pick's disease and in Huntington's disease. 2000 , 21, 555-8	36
978	[Alzheimer's disease: from pathology to preventive methods?]. 2000 , 21, 524-32	
977	Genetic analysis for common complex disease. 2000 , 140, S36-44	20
976	The number of trait loci in late-onset Alzheimer disease. 2000 , 66, 196-204	257
975	QTL fine mapping by measuring and testing for Hardy-Weinberg and linkage disequilibrium at a series of linked marker loci in extreme samples of populations. 2000 , 66, 1027-45	53
974	Fine mapping of the chromosome 12 late-onset Alzheimer disease locus: potential genetic and phenotypic heterogeneity. 2000 , 66, 922-32	101
973	SNPping away at complex diseases: analysis of single-nucleotide polymorphisms around APOE in Alzheimer disease. 2000 , 67, 383-94	300

972	Apolipoprotein E variation at the sequence haplotype level: implications for the origin and maintenance of a major human polymorphism. 2000 , 67, 881-900	314
971	Neuropsychological Profile of a Large Kindred with Familial Alzheimer's Disease Caused by the E280A Single Presenilin-1 Mutation. 2000 , 15, 515-528	1
970	New insights into genetic and molecular mechanisms of brain degeneration in tauopathies. 2000 , 20, 225-44	44
969	Performance characteristics of a two-stage dementia screen in a population sample. 2000 , 53, 531-40	64
968	Transgenic mouse models of Alzheimer's disease. 2000 , 1502, 63-75	83
967	The role of apolipoprotein E in Alzheimer's disease: pharmacogenomic target selection. 2000 , 1502, 85-94	69
966	Diagnostic approaches to Alzheimer's disease. 2000 , 1502, 188-200	26
965	Presenilin-1 protein specifically expressed in Leydig cells with its expression level increased during rat testis development. 2000 , 32, 81-7	5
964	The synthesis and transport of lipids for axonal growth and nerve regeneration. 2000 , 1486, 84-96	103
963	Strategies in complex disease mapping. 2000 , 10, 330-4	60
962	Part V. Genetic advances and biological markers for Alzheimer's disease. 2000 , 46, 731-43	0
961	Differential effects of apolipoprotein E isoforms on phosphorylation at specific sites on tau by glycogen synthase kinase-3 beta identified by nano-electrospray mass spectrometry. 2000 , 485, 99-103	20
960	Aging, mild cognitive impairment, and Alzheimer's disease. 2000 , 18, 789-806	98
959	Alzheimer's disease: transgenic mouse models and drug assessment. 2000 , 42, 107-14	6
958	Susceptibility locus for Alzheimer's disease on chromosome 10. <i>Science</i> , 2000 , 290, 2304-5	33-3 345
957	SDS-stable complex formation between native apolipoprotein E3 and beta-amyloid peptides. 2000 , 39, 16119-24	30
956	Behavioural genetics in the 21st century. 2000 , 24, 30-34	26
955	Genetics of psychiatric disease. 2000 , 51, 465-79	74

954	APOE polymorphisms and the development of diabetic nephropathy in type 1 diabetes: results of case-control and family-based studies. 2000 , 49, 2190-5	86
953	Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. 2000 , 97, 6037-42	610
952	Tilted peptides: a motif for membrane destabilization (hypothesis). 2000 , 17, 31-40	68
951	Differences in stability among the human apolipoprotein E isoforms determined by the amino-terminal domain. 2000 , 39, 11657-66	255
950	The genetics of childhood psychiatric disorders: a decade of progress. 2000 , 39, 946-62	23
949	Relation between aluminum concentrations in drinking water and Alzheimer's disease: an 8-year follow-up study. 2000 , 152, 59-66	242
948	Epidemiology of dementia: concepts and overview. 2000 , 18, 923-50	57
947	Investigations Into Geriatric Psychiatry Challenges: AAGP Senior Investigator Award 2000. 2000 , 8, 276-283	1
946	A Longitudinal Study of Apolipoprotein-E Genotype and Depressive Symptoms in Community-Dwelling Older Adults. 2000 , 8, 196-200	26
945	Galantamine: a review of its use in Alzheimer's disease. 2000 , 60, 1095-122	241
944	Are schizophrenic and bipolar disorders related? A review of family and molecular studies. 2000 , 48, 531-8	246
943	Genetic risk factors of sporadic Alzheimer's disease among Chinese in Taiwan. 2000 , 181, 127-31	26
942	Analysis of genetic linkage data for Mendelian traits. 2001 , Chapter 1, Unit 1.4	2
941	Association of APOE epsilon4 allele with survival in amyotrophic lateral sclerosis. 2001 , 190, 17-20	78
940	Preclinical cognitive decline in late middle-aged asymptomatic apolipoprotein E-e4/4 homozygotes: a replication study. 2001 , 189, 93-8	52
939	Neurodegenerative tauopathies. 2001 , 24, 1121-59	2089
938	Proteoglycan Protocols. 2001 ,	10
937	Single photon emission CT and positron emission tomography in the evaluation of neurologic disease. 2001 , 39, 1007-33	10

936	Up-regulation of calcineurin Abeta mRNA in the Alzheimer's disease brain: assessment by cDNA microarray. 2001 , 284, 310-6	102
935	Non-replication of association between cathepsin D genotype and late onset Alzheimer disease. 2001 , 105, 179-82	24
934	Downregulation of microglial activation by apolipoprotein E and apoE-mimetic peptides. 2001 , 167, 74-85	160
933	Behavioral phenotyping of GFAP-apoE3 and -apoE4 transgenic mice: apoE4 mice show profound working memory impairments in the absence of Alzheimer's-like neuropathology. 2001 , 170, 326-44	128
932	Apolipoprotein E is upregulated in olfactory bulb glia following peripheral receptor lesion in mice. 2001 , 172, 128-36	32
931	The endosomal trafficking of apolipoprotein E3 and E4 in cultured human brain neurons and astrocytes. 2001 , 8, 78-89	30
930	Local cellular sources of apolipoprotein E in the human retina and retinal pigmented epithelium: implications for the process of drusen formation. 2001 , 131, 767-81	197
929	Alzheimer's disease in man and transgenic mice: females at higher risk. 2001 , 158, 797-801	26
928	Apolipoprotein E modulates glial activation and the endogenous central nervous system inflammatory response. 2001 , 114, 107-13	150
927	Medical utility of apoe allele determination in assessing the need for antioxidant therapy. 2001 , 56, 357-9	11
926	High-resolution multipoint linkage-disequilibrium mapping in the context of a human genome sequence. 2001 , 69, 159-78	104
925	Apolipoprotein E epsilon4 positive individuals demonstrate delayed olfactory event-related potentials. 2001 , 22, 439-47	27
924	The role of TNF and its receptors in Alzheimer's disease. 2001 , 22, 873-83	212
923	Glial activation in Alzheimer's disease: the role of Abeta and its associated proteins. 2001 , 22, 885-93	192
922	The inflammation-induced pathological chaperones ACT and apo-E are necessary catalysts of Alzheimer amyloid formation. 2001 , 22, 923-30	69
921	Alzheimer's disease as a disorder of mechanisms underlying structural brain self-organization. 2001 , 102, 723-65	148
920	Neuronal injury-induced expression and release of apolipoprotein E in mixed neuron/glia co-cultures: nuclear factor kappaB inhibitors reduce basal and lesion-induced secretion of apolipoprotein E. 2001 , 104, 223-34	35
919	Altered expression of apolipoprotein E, amyloid precursor protein and presenilin-1 is associated with chronic reactive gliosis in rat cortical tissue. 2001 , 106, 557-69	33

918	Genetics of menopause-associated diseases. 2001 , 40, 103-16	37
917	Clinical features and alterations in the inferior horn sizes in lateral ventricle in Alzheimer's patients with different ApoE genotype in Japanese population. 2001 , 25, 1377-84	3
916	Alpha2-macroglobulin polymorphisms in Italian sporadic and familial Alzheimer's disease. 2001 , 299, 9-12	15
915	The -491 TT apolipoprotein E promoter polymorphism is associated with reduced risk for sporadic Alzheimer's disease. 2001 , 304, 204-8	16
914	Allele varepsilon4 of apolipoprotein E gene is less frequent in Down syndrome patient of the Sicilian population and has no influence on the grade of mental retardation. 2001 , 306, 129-31	15
913	Modulation by age and gender of risk for Alzheimer's disease and vascular dementia associated with the apolipoprotein E-epsilon4 allele in Latin Americans: findings from the Maracaibo Aging Study. 2001 , 307, 5-8	47
912	Effect of ApoE and tau on age of onset of progressive supranuclear palsy and multiple system atrophy. 2001 , 312, 118-20	21
911	Susceptibility gene(s) for Alzheimer's disease on chromosome 10. 2001 , 24, 557-9	13
910	Cholesterol, A beta and Alzheimer's disease. 2001 , 24, S45-8	82
909	Cholesterol, Aβ and Alzheimer's disease. 2001 , 24, 45-48	61
908	Impact of apoE deficiency on oxidative insults and antioxidant levels in the brain. 2001 , 86, 76-83	70
907	Estrogen use and brain metabolic change in older adults. A preliminary report. 2001 , 107, 11-8	37
906	Structural models of human apolipoprotein A-I: a critical analysis and review. 2001 , 1531, 4-46	187
905	Alzheimer's disease and estrogen. 2001 , 76, 227-30	16
904	Apolipoprotein E1 Baden (Arg(180)-->Cys). A new apolipoprotein E variant associated with hypertriglyceridemia. 2001 , 303, 41-8	14
903	Alzheimer's disease: a review for the ophthalmologist. 2001 , 45, 516-24	37
902	Apolipoprotein E4 and coronary heart disease in middle-aged men who smoke: a prospective study. 2001 , 358, 115-9	204
901	New approaches to diagnose and treat Alzheimer's disease: a glimpse of the future. 2001 , 17, 393-410	17

900	Gene identification in Alzheimer's disease. 2001 , 2, 239-49	21
899	Finding genes influencing susceptibility to complex diseases in the post-genome era. 2001 , 1, 203-21	59
898	Genetic screening for Alzheimer's disease: what factors predict intentions to take a test?. 2001 , 27, 101-9	50
897	Apolipoprotein A-I directly interacts with amyloid precursor protein and inhibits A beta aggregation and toxicity. 2001 , 40, 3553-60	100
896	Secretase targets for Alzheimer's disease: identification and therapeutic potential. 2001 , 44, 2039-60	122
895	Genetic association studies: genes in search of diseases. 2001 , 57, 1153-4	93
894	Current Understanding of the Genetic Basis of Reading and Spelling Disability. 2001 , 24, 141-157	31
893	A Genomic Search for Alzheimer's Disease Genes. 31-43	
892	Intelligence, Genetics of: Cognitive Abilities. 2001 , 7645-7651	2
891	Etiology, Genetics, and Pathogenesis of Alzheimer's Disease. 2001 , 333-348	
890	Early-onset Alzheimer's disease in Scotland: environmental and familial factors. 2001 , 40, s53-9	14
889	Apolipoprotein E a cholesterol transport protein with lipid transport-independent cell signaling properties. 2001 , 6, d526-535	
888	The Natural History of Alzheimer's Disease: Minding the Gaps in Understanding the Mechanisms of Neurodegeneration. 2001 , 1-21	
887	Association of the apolipoprotein E epsilon4 allele with late-onset depression. 2001 , 20, 268-72	48
886	Amyloid beta40/42 clearance across the blood-brain barrier following intra-ventricular injections in wild-type, apoE knock-out and human apoE3 or E4 expressing transgenic mice. 2001 , 3, 23-30	74
885	Glutamate Receptors in Aging and Alzheimer's Disease. 2001 , 283-314	4
884	Alzheimer's disease: genes, proteins, and therapy. 2001 , 81, 741-66	4885
883	The AD7c-NTP neuronal thread protein biomarker for detecting Alzheimer's disease. 2001 , 3, 345-353	25

882	Molecular biology of Alzheimer's dementia and its clinical relevance to early diagnosis and new therapeutic strategies. 2001 , 47, 65-71	16
881	Hippocampal atrophy correlates with clinical features of Alzheimer disease in African Americans. 2001 , 58, 1593-7	20
880	Genetic Factors Contributing to Learning and Language Delays and Disabilities. 2001 , 10, 259-277	7
879	Apolipoprotein E genotype in Korean schizophrenic patients. 2001 , 16, 781-3	9
878	APOE polymorphism in a rural older population-based sample in India. 2001 , 73, 135-44	15
877	APOE epsilon4 and Alzheimer's disease: positive association in a Colombian clinical series and review of the Latin-American studies. 2001 , 59, 11-7	22
876	The genomic approach to candidate genes. 2001 , 9, 197-207	1
875	Interactions between apolipoprotein E gene and dietary alpha-tocopherol influence cerebral oxidative damage in aged mice. 2001 , 21, 5993-9	29
874	Alpha-1-antichymotrypsin promotes beta-sheet amyloid plaque deposition in a transgenic mouse model of Alzheimer's disease. 2001 , 21, 1444-51	119
873	A novel action of alzheimer's amyloid beta-protein (Abeta): oligomeric Abeta promotes lipid release. 2001 , 21, 7226-35	142
872	Genotyping Single-Nucleotide Polymorphisms by the Invader Assay with Dual-Color Fluorescence Polarization Detection. 2001 , 47, 1373-1377	76
871	Assessment of suspected dementia. 2001 , 28 Suppl 1, S28-41	39
870	Genetic counselling and genetic screening for Alzheimer's disease and other dementias. 2001 , 28 Suppl 1, S52-5	2
869	Down syndrome: advances in molecular biology and the neurosciences. 2001 , 22, 40-59	81
868	Diagnosis, classification and natural history of degenerative dementias. 2001 , 28 Suppl 1, S17-27	7
867	Preventing dementia. 2001 , 28 Suppl 1, S56-66	18
866	Evidence-based review of sport-related concussion: basic science. 2001 , 11, 160-5	79
865	The genetics of late-onset Alzheimer's disease. 2001 , 14, 433-40	60

864	The effects of APOE genotype on age at onset and progression of neurodegenerative diseases. 2001 , 57, 1482-5	58
863	The neuronal endosomal-lysosomal system in Alzheimer's disease. 2001 , 3, 97-107	107
862	Elevated serum total and LDL cholesterol in very old patients with Alzheimer's disease. 2001 , 12, 138-45	59
861	3-hydroxy-3-methylglutaryl-coenzyme A reductase mRNA in Alzheimer and control brain. 2001 , 12, 2935-8	20
860	Codeposition of cystatin C with amyloid-beta protein in the brain of Alzheimer disease patients. 2001 , 60, 94-104	128
859	The relationship between apolipoprotein E4 and lipid metabolism is impaired in Alzheimer's disease. 2001 , 47, 213-8	36
858	Influence of apoE Genotype and PET Brain Imaging on Preclinical Prediction of Alzheimer's Disease. 193-203	1
857	Brain Functional Imaging in Early and Preclinical Alzheimer's Disease. 153-164	4
856	Androgen Treatment Reduces Cognitive Deficits in Female apoE4 Transgenic Mice. 747-757	
855	Two distal downstream enhancers direct expression of the human apolipoprotein E gene to astrocytes in the brain. 2001 , 21, 812-22	100
854	Effect of apolipoprotein E genotype on cerebral autoregulation during cardiopulmonary bypass. 2001 , 32, 1514-9	14
853	Alzheimer's disease: molecular concepts and therapeutic targets. 2001 , 88, 261-7	42
852	New developments in animal models of Alzheimer's disease. 2001 , 1, 451-7	33
851	Expression and regulation of apolipoprotein E receptors in the cells of the central nervous system in culture: A review. 2001 , 24, 1-10	14
850	Molecular and cell biological aspects of Alzheimer disease. 2001 , 46, 609-18	8
849	A novel apolipoprotein E5 variant with a 24-bp insertion causing hyperlipidemia. 2001 , 46, 633-9	5
848	Linkage and association analysis of chromosome 19q13 in multiple sclerosis. 2001 , 3, 195-201	28
847	APOE and APOC1 genetic polymorphisms in age-associated memory impairment. 2001 , 3, 215-9	10

846	Does apolipoprotein E (Apo-E) genotype influence nicotinic receptor binding in Alzheimer's disease. 2001 , 108, 1043-50	14
845	Tacrine and rate of progression in Alzheimer's disease--relation to ApoE allele genotype. 2001 , 108, 451-8	41
844	Dementia with Lewy bodies and Alzheimer's disease. 2001 , 102, 621-6	33
843	Polymorphisms in the apolipoprotein E (APOE) gene in gerontopsychiatric patients. 2001 , 251, 24-8	9
842	Intracellular apolipoprotein E affects Amyloid Precursor Protein processing and amyloid Abeta production in COS-1 cells. 2001 , 265, 791-800	7
841	Polymorphism in the alpha(1)-antichymotrypsin (ACT) gene promoter: effect on expression in transfected glial and liver cell lines and plasma ACT concentrations. 2001 , 109, 303-10	26
840	Cerebral blood flow and metabolic abnormalities in Alzheimer's disease. 2001 , 15, 85-92	164
839	Apolipoprotein E polymorphism and lithogenic factors in gallbladder bile. 2001 , 31, 789-95	21
838	ApoE protects cortical neurones against neurotoxicity induced by the non-fibrillar C-terminal domain of the amyloid-beta peptide. 2001 , 76, 117-27	47
837	The relationship of APOE genotype to cognitive functioning in older African-American and Caucasian community residents. 2001 , 49, 1148-55	54
836	Prevalence of Alzheimer's type dementia in an elderly Arab population. 2001 , 8, 119-23	56
835	Tau-associated neuropathology in ganglion cell tumours increases with patient age but appears unrelated to ApoE genotype. 2001 , 27, 197-205	27
834	Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. 2001 , 250, 186-200	182
833	Apolipoprotein E polymorphism and lipid levels differ by gender and family history of diabetes: the Rancho Bernardo Study. 2001 , 60, 132-7	27
832	Molecular linkage studies of bipolar disorders. 2001 , 3, 276-83	55
831	The load and distribution of beta-amyloid in brain tissue of patients with Alzheimer's disease. 2001 , 103, 88-92	17
830	Genetic polymorphisms in older subjects with vascular or Alzheimer's dementia. 2001 , 103, 304-8	58
829	Associations between apolipoprotein E phenotype, glucose metabolism and cognitive function in men. An explorative study in a population sample. 2001 , 18, 991-7	7

828	Astrocytes down-regulate neuronal beta-amyloid precursor protein expression and modify its processing in an apolipoprotein E isoform-specific manner. 2001 , 14, 256-66	25
827	Neuroinflammation-induced acceleration of amyloid deposition in the APPV717F transgenic mouse. 2001 , 14, 474-82	87
826	Apolipoprotein E immunoreactivity in neurons and neurofibrillary degeneration of aged non-demented and Alzheimer's disease patients. 2001 , 55, 48-58	4
825	Alzheimer beta-amyloid peptides: structures of amyloid fibrils and alternate aggregation products. 2001 , 60, 381-94	44
824	Apolipoprotein E epsilon4 allele is a risk factor for late-onset Alzheimer's disease and vascular dementia in Han Chinese. 2001 , 16, 438-9	14
823	Is apolipoprotein e4 associated with cognitive decline in depression?. 2001 , 16, 436-7	5
822	Long-term memory correlates negatively with plasma transcobalamin in healthy elderly with normal plasma cobalamin levels. 2001 , 16, 439-41	3
821	Memory self-appraisal and depressive symptoms in people at genetic risk for Alzheimer's disease. 2001 , 16, 1071-7	28
820	Investigation of association of 13 polymorphisms in eight genes in southeastern African American Alzheimer disease patients as compared to age-matched controls. 2001 , 105, 332-42	67
819	Familial influence on age of onset among siblings with Huntington disease*. 2001 , 105, 399-403	75
818	Mortality and apolipoprotein E in Hispanic, African-American, and Caucasian elders. 2001 , 103, 121-7	41
817	Multiple-threshold models for genetic influences on age of onset for Alzheimer disease: findings in Swedish twins. 2001 , 105, 724-8	39
816	Apolipoprotein E phenotype and the efficacy of intravenous tissue plasminogen activator in acute ischemic stroke. 2001 , 49, 736-44	49
815	Endocytic disturbances distinguish among subtypes of alzheimer's disease and related disorders. 2001 , 50, 661-665	67
814	Synthesis and processing of apolipoprotein E in human brain cultures. 2001 , 33, 298-305	40
813	Clinical features of dementia associated with apolipoprotein epsilon4: discrimination with a neural network genetic algorithm. 2001 , 16, 77-81	5
812	Identification of the apolipoprotein E4 isoform in cerebrospinal fluid with preparative two-dimensional electrophoresis and matrix assisted laser desorption/ionization-time of flight-mass spectrometry. 2001 , 22, 1834-7	30
811	Genetic Association between the Apolipoprotein E (APOE) Gene and Different Forms of Alzheimer's Disease. 2001 , 37, 422-427	7

810	Intracellular calcium changes in neuronal cells induced by Alzheimer's beta-amyloid protein are blocked by estradiol and cholesterol. 2001 , 21, 1-13	59
809	Role of apoe/Abeta interactions in the pathogenesis of Alzheimer's disease and cerebral amyloid angiopathy. 2001 , 17, 147-55	107
808	Low-density lipoprotein receptor family: endocytosis and signal transduction. 2001 , 23, 53-67	101
807	Apolipoprotein E protects against neuropathology induced by a high-fat diet and maintains the integrity of the blood-brain barrier during aging. 2001 , 81, 953-60	64
806	Delayed, but marked, expression of apolipoprotein E is involved in tissue clearance after cerebral infarction. 2001 , 21, 1199-207	30
805	Schizophrenic women with the APOE epsilon 4 allele have a worse prognosis than those without it. 2001 , 6, 307-10	25
804	No Association between Presenilin 1 Intron Gene or Butyrylcholinesterase K Variant and Alzheimer's Disease in Japanese Populations. 2001 , 1, 108-118	1
803	Geriatric Neuropsychopharmacology: Unmet Needs. 2001 , 1, 14-26	
802	The genetics of age-related macular degeneration. 2001 , 84, 182-189	5
801	Genetic risk factors in familial Alzheimer's disease. 2001 , 122, 1951-60	22
800	On the allelic spectrum of human disease. 2001 , 17, 502-10	914
799	The molecular bases of Alzheimer's disease and other neurodegenerative disorders. 2001 , 32, 367-81	331
798	Platelet secretion of beta-amyloid is increased in hypercholesterolaemia. 2001 , 896, 161-4	20
797	Compartmentalization of beta-secretase (Asp2) into low-buoyant density, noncaveolar lipid rafts. 2001 , 11, 1288-93	282
796	Variations of cardiovascular disease associated genes exhibit sex-dependent influence on human longevity. 2001 , 36, 1303-15	19
795	Cholesterol modulation as an emerging strategy for the treatment of Alzheimer's disease. 2001 , 6, 1049-1055	56
794	Genetic dissection of neurodegenerative disease. 2001 , 1, 134-141	7
793	Tracking the decline in cerebral glucose metabolism in persons and laboratory animals at genetic risk for Alzheimer's disease. 2001 , 1, 194-206	18

792	Apolipoprotein E: a major piece in the Alzheimer's disease puzzle. 2001 , 5, 254-66	89
791	A study of apolipoproteins E and A-I in cutaneous amyloids. 2001 , 145, 422-7	9
790	Activated cAMP-response element-binding protein regulates neuronal expression of presenilin-1. 2001 , 276, 9688-98	36
789	Apolipoprotein E genotypes and the incidence of Alzheimer's disease among persons aged 75 years and older: variation by use of antihypertensive medication?. 2001 , 153, 225-31	42
788	The functions of the amyloid precursor protein gene. 2001 , 12, 1-39	28
787	Alzheimer's Disease: Physiological and Pathogenetic Role of the Amyloid Precursor Protein (APP), its A β Amyloid Domain and Free A β Amyloid Peptide. 2001 , 97-117	3
786	Peaks and valleys. 2001 , 38, 38-40	
785	Neurogenetics in the postgenomic era. 2001 , 58, 1758-9	
784	Apolipoprotein-E gene polymorphism and lipid profiles in Alzheimer's disease. 2001 , 16, 77-81	27
783	Transcription factors Zic1 and Zic2 bind and transactivate the apolipoprotein E gene promoter. 2001 , 276, 1881-8	49
782	Discrepancies between apolipoprotein E phenotyping and genotyping in the elderly. 2001 , 39, 405-13	4
781	Quantitation of apoE domains in Alzheimer disease brain suggests a role for apoE in A β aggregation. 2001 , 60, 342-9	85
780	Alzheimer beta amyloid deposition enhanced by apoE epsilon4 gene precedes neurofibrillary pathology in the frontal association cortex of nondemented senior subjects. 2001 , 60, 731-9	46
779	Apolipoprotein E4 stimulates cAMP response element-binding protein transcriptional activity through the extracellular signal-regulated kinase pathway. 2001 , 276, 3046-53	75
778	Is ApoE gene a risk factor for vascular dementia in Han Chinese?. 2001 , 7, 217-9	9
777	Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. 2001 , 276, 21562-70	691
776	When to retire after concussion?. 2001 , 35, 380-2	29
775	Site-specific phosphorylation of tau accompanied by activation of mitogen-activated protein kinase (MAPK) in brains of Niemann-Pick type C mice. 2001 , 276, 10314-9	81

774	Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. 2001 , 98, 3334-9	392
773	Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. 2001 , 98, 5856-61	949
772	The relative power of SNPs and haplotype as genetic markers for association tests. 2001 , 2, 11-24	119
771	Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons. 2001 , 98, 8838-43	307
770	Introduction of human apolipoprotein E4 "domain interaction" into mouse apolipoprotein E. 2001 , 98, 11587-91	143
769	Alzheimer's disease: its diagnosis and pathogenesis. 2001 , 48, 167-217	15
768	Gender and age modify the association between APOE and AD-related neuropathology. 2001 , 56, 1696-701	85
767	Dementia and Alzheimer's Disease. 1995 , 230-249	
766	Perspective of neurochemistry in neurological disorders. 1995 , 363, 1-13	
765	Apolipoprotein E: Structure, Function, and Possible Roles in Modulating Neurite Extension and Cytoskeletal Activity. 1996 , 49-58	1
764	The Search for Additional Alzheimer's Disease Genes. 1996 , 180-186	
763	Non-Anticoagulant Actions of Glycosaminoglycans (GAGs). 1996 , 249-279	4
762	Untersuchungen zum Apolipoprotein E-Genotyp an histologisch gesicherten Fällen von Morbus Alzheimer. 1996 , 541-547	
761	Interactions of Apolipoprotein E with Microtubule-Associated Proteins. 1996 , 145-150	
760	Differential Regulation of APP Secretion by Apolipoprotein E3 and E4. 1996 , 97-102	1
759	Die organisch bedingten Psychosen. 1996 , 156-201	2
758	Apolipoprotein E Uptake is Increased by Beta-Amyloid Peptides and Reduced by Blockade of the LDL Receptor. 1996 , 103-108	
757	Reduktion des Ca ²⁺ -amplifizierenden Effektes von β Amyloid an Lymphozyten von Alzheimer-Patienten [Möglicher Bezug zum Apolipoprotein E Polymorphismus. 1996 , 787-792	

- 756 Tau Protein and Alzheimer Paired Helical Filament Assembly: Interacting Domains and Control Residues. **1996**, 126-135
- 755 Ethnic Variation in the Association Between APOE- ϵ and Alzheimer β Disease: A Follow-up Study. **1996**, 170-179
- 754 Clinical Drug Trials in Alzheimer's Disease. **1996**, 1
- 753 Pathology, Neurobiology, and Animal Models of Alzheimer's Disease. **1996**,
- 752 Clinical Assessment of Patients with Dementia. **1996**,
- 751 The Metabolism of Apolipoprotein E and the Alzheimer's Diseases. **1996**,
- 750 Potential Biological Mechanisms of ApoE in Alzheimer β Disease. **1997**, 21-37
- 749 Pathological Changes in the Elderly Human Brain. **1997**, 5-114
- 748 Is Alzheimer β Disease Accelerated Aging? Different Patterns of Age and Alzheimer β Disease-Related Neuronal Losses in the Hippocampus. **1997**, 141-147
- 747 Pet Imaging of Nicotinic Receptors in Alzheimer β Disease [Implication with Diagnosis and Drug Treatment. **1997**, 439-444
- 746 Etiological Considerations. **1997**, 153-185
- 745 Peptides Inhibitor of Amyloidogenesis in Alzheimer β Disease. **1997**, 91-97
- 744 The Neuropsychology of Alzheimer β Disease. **1997**, 141-158 1
- 743 Apolipoprotein E4 and Cholinergic Activity in Alzheimer β Disease. **1997**, 55-60
- 742 Apolipoprotein E Genotype in Vascular Dementia. **1998**, 153-157
- 741 Muscarinic Modulation of β Amyloid Precursor Protein (β App) Processing in Vitro and in Vivo. **1998**, 509-513
- 740 The Apolipoprotein E ϵ Allele. **1998**, 39-43
- 739 Regulation of APP Metabolism by Protein Phosphorylation. **1998**, 133-140

738 Nicotinic Receptors as a new Target for Treatment of Alzheimer's Disease. **1998**, 463-468

737 ϵ -Antichymotrypsin and Apolipoprotein E Polymorphism in Alzheimer's Disease. **1998**, 757-764

736 Role of Apolipoprotein E in Alzheimer's Disease. **1998**, 179-209

3

735 Alzheimer-Krankheit. **1998**, 82-95

734 How Can we Improve the Drug Development Process in Alzheimer's Disease?. **1998**, 833-839

733 Divergent Metabolism of Apolipoproteins E3 and E4 by Cells. **1998**, 17-23

732 Model of Genetic Susceptibility to Late-Onset Alzheimer's Disease: Mice Transgenic for Human Apolipoprotein E Alleles. **1999**, 215-243

731 Dementia with Lewy Bodies. **1999**, 137-149

730 Alzheimer's Disease. **1999**, 77-101

729 Genes that Modulate Longevity and Senescence. **1999**, 11-21

1

728 Molekulargenetik und Molekularbiologie der Alzheimer-Krankheit. **1999**, 117-165

727 Alzheimer's Disease and Genetically Engineered Animal Models. **1999**, 187-214

726 Genetik der Alzheimer Demenz. **1999**, 33-54

0

725 Predicting Who Will Develop Alzheimer's Disease. **1999**, 19-31

1

724 Implementation of Exome Sequencing Assay. **2015**, 225-240

723 Gene Expression Studies and Complex Diseases. **2015**, 67-83

722 Genetic Risk Factors for Neurodegenerative Diseases. **2015**, 117-134

721 Obesity, Metabolic Dysfunction and Dementia. **2015**, 1-16

- 720 Genetics of Brain Aging [Twin Aging?]. **2015**, 2
- 719 Alzheimer's Disease. **2015**, 223-261
- 718 Biomarkers in Alzheimer's Disease: From Pathogenic Initiation to Downstream Outcomes. **2015**, 341-354
- 717 Cardiometabolic Risk, Inflammation, and Neurodegenerative Disorders. **2015**, 133-159
- 716 Revisão dos principais genes e proteínas associadas à demência frontotemporal tau-positiva. **2015**, 18, 201-211 0
- 715 References. **2015**, 310-326
- 714 Obesity, Metabolic Dysfunction, and Dementia. **2016**, 709-722
- 713 Compendium of Inflammatory Diseases. **2016**, 34-43
- 712 Genetic Models of Alzheimer's Disease: The Influence of Apolipoprotein E allele Isoforms on Behaviour in Laboratory Animals. **2016**, 199-228
- 711 Pathological Consequences of Aβ From Extracellular to Intraneuronal. **2016**, 69-113
- 710 Genetik und Gen-Umwelt-Interaktionen bei psychischen Erkrankungen. **2016**, 1-45
- 709 Encyclopedia of Clinical Neuropsychology. **2016**, 1-8
- 708 16. The relationship between cholesterol metabolism and inflammation in chronic disease. **2016**, 297-316
- 707 Case-control association mapping without cases. 2
- 706 Neuropsychological Screening and Advanced Neuropsychological Tests. **2016**, 51-90
- 705 Genetic risk factor APOEε4 associates with plasma amyloid beta in amnesic mild cognitive impairment and alzheimer's disease. **2016**, 25, 44-50
- 704 Late Onset Alzheimer's disease risk variants in cognitive decline: The PATH Through Life Study. 0
- 703 Multivariate association between single-nucleotide polymorphisms in Alzgene linkage regions and structural changes in the brain: discovery, refinement and validation.

- 702 Effect of APOE Genotype Polymorphism on Stress in Alzheimer's Disease. **2017**, 06, 56-64
- 701 Biological Markers in Nursing Research. **2017**, 25, 275-291 0
- 700 Genetik und Gen-Umwelt-Interaktionen bei psychischen Erkrankungen. **2017**, 1-45
- 699 High Frequency Actionable Pathogenic Exome Mutations in an Average-Risk Cohort. 1
- 698 Chapter 10. The effect of language skills on dementia in a Swedish longitudinal cohort. 205-218
- 697 A histone acetylome-wide association study of Alzheimer's disease: neuropathology-associated regulatory variation in the human entorhinal cortex. 1
- 696 The Growing Evidence for Photobiomodulation as a Promising Treatment for Alzheimer's Disease. **2018**, 06, 100-110 0
- 695 Encyclopedia of Clinical Neuropsychology. **2018**, 147-154
- 694 Clinical Meaningfulness of Biomarker Endpoints in Alzheimer's Disease Research. **2018**, 235-248
- 693 Neurodegeneration and the Ordered Assembly of Tau. **2018**, 81-98
- 692 Mitochondrial Function and Neurodegenerative Diseases. **2018**, 369-414 1
- 691 Genetic variants associated with Alzheimer's disease confer different cerebral cortex cell-type population structure. 1
- 690 Bi-threshold frequent subgraph mining for Alzheimer disease risk assessment. **2018**,
- 689 Complement receptor 1 gene (CR1) intragenic duplication and risk of Alzheimer's disease. 1
- 688 Paired Immunoglobulin-like Type 2 Receptor Alpha G78R variant alters ligand binding and confers protection to Alzheimer's disease.
- 687 Genome-wide analysis of genetic predisposition to Alzheimer's disease and related sex-disparities. 1
- 686 The spatial correspondence and genetic influence of inter-hemispheric connectivity with white matter microstructure.
- 685 5-HAYED peptide can protect AD brain by scavenging the redundant iron ions and the catalyzed radicals.

- 684 APP-induced patterned neurodegeneration exacerbated by APOE4 in *C. elegans*.
- 683 Inferring the molecular mechanisms of noncoding Alzheimer's disease-associated genetic variants. 1
- 682 A human embryonic stem cell model of A β -dependent chronic progressive neurodegeneration. 0
- 681 Integrated DNA methylation and gene expression profiling across multiple brain regions implicate novel genes in Alzheimer's disease.
- 680 Identification of a simple and novel cut-point based CSF and MRI signature for predicting Alzheimer's disease progression that reinforces the 2018 NIA-AA research framework. 0
- 679 In Silico Identification of Novel Apolipoprotein E4 Inhibitor for Alzheimer's Disease Therapy. **2019**, 15, 97-103 2
- 678 Genetic Markers of Extreme Human Longevity. **2019**, 137-153
- 677 Nanolipidic Carriers as Potential Drug Delivery Vehicles in Alzheimer's Disease. **2019**, 307-341
- 676 VGF in cerebrospinal fluid, when combined with conventional biomarkers, enhances prediction of conversion from mild cognitive impairment to Alzheimer's Disease.
- 675 Brain proteomics links oxidative stress with metabolic and cellular stress response proteins in behavioural alteration of Alzheimer's disease model rats. **2019**, 6, 299-315 2
- 674 Diet and Nutrition in Alzheimer's Disease and Healthy Aging. **2019**, 183-208 1
- 673 Encyclopedia of Behavioral Medicine. **2019**, 1-1
- 672 The TMEM106B rs1990621 protective variant is also associated with increased neuronal proportion. 1
- 671 Polygenic risk score for Alzheimer's disease and trajectories of cardiometabolic risk factors in children.
- 670 Sex differences in gene expression patterns associated with the APOE4 allele. **2019**, 8, 387 9
- 669 Early Hippocampal Sharp-Wave Ripple Deficits Predict Later Learning and Memory Impairments in an Alzheimer's Disease Mouse Model.
- 668 Pupillary dilation responses as a midlife indicator of risk for Alzheimer's Disease: Association with Alzheimer's disease polygenic risk. 0
- 667 Comparative profiling of the synaptic proteome from Alzheimer's disease patients with focus on the APOE genotype.

- 666 Basal forebrain volume reliably predicts the cortical spread of Alzheimer's degeneration. 2
- 665 Genetic risk for Alzheimer's disease predicts hippocampal volume through the lifespan. 1
- 664 Relating Global and Local Connectome Changes to Dementia and Targeted Gene Expression in Alzheimer's Disease. 1
- 663 Genome sequencing for early-onset dementia: high diagnostic yield and frequent observation of multiple contributory alleles. 1
- 662 Case-control vs. case-only estimates of gene-environment interactions with common and misclassified clinical diagnosis.
- 661 Sex differences in interrelationships between arterial stiffness, carotid intima-media thickness, white matter hyperintensities, depression and cognition: A UK Biobank study.
- 660 Isolation housing exacerbates Alzheimer's Disease phenotype in aged APP KI mice.
- 659 Unmasking selective path integration deficits in Alzheimer's disease risk carriers. 0
- 658 Exploring Survival Models Associated with MCI to AD Conversion: A Machine Learning Approach. 0
- 657 Genetics of Alzheimer's Disease in Clinical Practice. **2019**, 20, 352-355
- 656 Exceptionally low likelihood of Alzheimer's dementia in APOE2 homozygotes. 0
- 655 Insulin Resistance and Oligodendrocyte/Microvascular Endothelial Cell Dysfunction as Mediators of White Matter Degeneration in Alzheimer's Disease. 123-145
- 654 Dementia. **2020**, 105-123 1
- 653 Mild Cognitive Impairment and Early Dementia. **2020**, 215-236
- 652 Self-Reported Sleep Relates to Microstructural Hippocampal Decline in Amyloid Positive Adults Beyond Genetic Risk.
- 651 Regulation of beta-amyloid production in neurons by astrocyte-derived cholesterol. 6
- 650 Monocyte-specific changes in gene expression implicate LACTB2 and PLIN2 in Alzheimer's disease.
- 649 Impact of Apo Lipoprotein E Gene Polymorphism on Hepatitis C Virus Disease Progression and Response to Direct Acting Antivirals in the Egyptian Population. **2020**, 20,

648	How understudied populations have contributed to our understanding of Alzheimer's disease genetics.	1
647	Conformational Reorganisation of Apolipoprotein E Triggered by Phospholipid Assembly.	
646	Dicer1 promotes A β clearance via blocking B2 RNA-mediated repression of apolipoprotein E.	
645	Dementia Risk and Dynamic Response to Exercise: Methodology for an Acute Exercise Clinical Trial.	
644	A Review of Brain-Targeted Nonviral Gene-Based Therapies for the Treatment of Alzheimer's Disease. 2021 , 18, 4237-4255	0
643	Why Have the Benefits of DHA Not Been Borne Out in the Treatment and Prevention of Alzheimer's Disease? A Narrative Review Focused on DHA Metabolism and Adipose Tissue. 2021 , 22,	0
642	Dissecting the Crosstalk between Endothelial Mitochondrial Damage, Vascular Inflammation, and Neurodegeneration in Cerebral Amyloid Angiopathy and Alzheimer's Disease. 2021 , 10,	3
641	Effects of Sex, Age, and Apolipoprotein E Genotype on Brain Ceramides and Sphingosine-1-Phosphate in Alzheimer's Disease and Control Mice. 2021 , 13, 765252	1
640	Isoform-Specific Effects of Apolipoprotein E on Hydrogen Peroxide-Induced Apoptosis in Human Induced Pluripotent Stem Cell (iPSC)-Derived Cortical Neurons. 2021 , 22,	1
639	Real-Time Analysis of Specific Binding between Apolipoprotein E Isoforms and Amyloid β Peptide by Dual Polarization Interferometry. 2021 , 93, 1472-1479	1
638	The Combined Effect of APOE and BDNF Val66Met Polymorphisms on Spatial Navigation in Older Adults. 2020 , 78, 1473-1492	2
637	Role of Forkhead Transcription Factors of the O Class (FoxO) in Development and Progression of Alzheimer's Disease. 2020 , 19, 709-721	2
636	Memory precision of object-location binding is unimpaired in APOE ϵ -carriers with spatial navigation deficits.	
635	Alzheimer's Disease: Etiology, Neuropathology and Pathogenesis. 1-22	5
634	Identification of hippocampal volume as a mediator of the association between APOE4 and dementia.	
633	Investigating the role of APOE: limitations of human pluripotent stem cell-derived cerebral organoids.	
632	A Urinary Metabolomics Analysis Based on UPLC-MS and Effects of Moxibustion in APP/PS1 Mice. 2020 , 17, 753-765	0
631	APOE Genotypes and Brain Imaging Classes in Normal Cognition, Mild Cognitive Impairment, and Alzheimer's Disease: A Longitudinal Study. 2020 , 17, 766-780	1

- 630 Physical Fitness and Apolipoprotein E Genotype Influence Cortical Networking and Intelligence in Adolescents. **2021**, 8, 92-99
- 629 LRP6 in WNT Signalling. **2021**, 269, 45-73 4
- 628 Identification of epigenome-wide DNA methylation differences between carriers of APOE ϵ 4 and APOE ϵ 2.
- 627 Attacks on genetic privacy via uploads to genealogical databases. 2
- 626 Der Mensch beeinflusst seine Biologie | Wie Weltbilder die Zukunft formen. **2020**, 97-120
- 625 Genetic and dietary influences on life span. **2020**, 671-685
- 624 Polygenic Risk Scoring is an Effective Approach to Predict Those Individuals Most Likely to Decline Cognitively Due to Alzheimer's Disease. **2021**, 8, 78-83 3
- 623 Genetic risk for Alzheimer's disease influences neuropathology via multiple biological pathways. **2020**, 2, fcaa167 1
- 622 Pharmacogenomic approaches to the treatment of sporadic Alzheimer's disease. **2020**, 81-94
- 621 Encyclopedia of Behavioral Medicine. **2020**, 142-143
- 620 Dissecting the role of Amerindian genetic ancestry and ApoE ϵ 4 allele on Alzheimer disease in an admixed Peruvian population.
- 619 Joint Effect of ABCA7 rs4147929 and Body Mass Index on Progression from Mild Cognitive Impairment to Alzheimer's Disease: The Shanghai Aging Study. **2020**, 17, 185-195
- 618 Amyloid and Tau in Alzheimer's Disease: Biomarkers or Molecular Targets for Therapy? Are We Shooting the Messenger?. **2021**, 178, 1014-1025 1
- 617 Neurodegenerative Diseases and Cholesterol: Seeing the Field Through the Players. **2021**, 13, 766587 2
- 616 A joint model for multivariate longitudinal and survival data to discover the conversion to Alzheimer's disease. **2021**, 41, 356 1
- 615 Alzheimer's Disease and Diabetes Mellitus in Comparison: The Therapeutic Efficacy of the Vanadium Compound. **2021**, 22, 3
- 614 Genetic risk for Alzheimer's disease influences neuropathology and cognition via multiple biological pathways.
- 613 APOE4 Copy Number-Dependent Proteomic changes in the Cerebrospinal Fluid.

- 612 Imaging studies and APOE genotype in persons at risk for Alzheimer's disease. **1996**, 8, 11-17 1
- 611 Chlamydia pneumoniae in the Pathogenesis of Alzheimer's Disease. **2005**, 211-226
- 610 Does Apolipoprotein E Polymorphism Determine the Survivability of Vascular Accidents at Advanced Ages? Implications for Mortality Differentials. **2006**, 141-150
- 609 Two Hits and You're Out? A Novel Mechanistic Hypothesis of Alzheimer Disease. **2008**, 191-204
- 608 Cholesterol and A β Production: Methods for Analysis of Altered Cholesterol De Novo Synthesis. **2008**, 221-230
- 607 Intraneuronal A β and Alzheimer's Disease. **2008**, 297-304
- 606 Genetics and Neurobiology of Alzheimer's Disease and Frontotemporal Dementias. **2006**, 1130-1141
- 605 Mouse Model for Alzheimer's Disease. **2008**, 191-199
- 604 ApoE Polymorphisms and Severity of Open-Angle Glaucoma. **2008**, 289-307
- 603 Genetic Epidemiology. **2005**, 1139-1167 0
- 602 Grundlagen. **2007**, 9-65
- 601 Single cell gene expression profiling in Alzheimer's disease. **2006**, 3, 302-318
- 600 Polyphenols as Potential Therapeutic Drugs in Neurodegeneration. 0
- 599 Sexual differences regarding Alzheimer's disease: a narrative review. **2020**, 68, 168-173
- 598 Integrative Brain Transcriptome Analysis Links Complement Component 4 and HSPA2 to the APOE ϵ Protective Effect in Alzheimer Disease. 1
- 597 Using Direct-to-Consumer Genetic Testing Results to Accelerate Alzheimer Disease Clinical Trial Recruitment. **2021**, 35, 141-147 0
- 596 Matters of the heart transcriptome: a brief history of cardiovascular genomics. **2002**, 29, 81-91 1
- 595 Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer's disease. **2003**, 28, 13-26 30

594	Apolipoprotein E in the brain and its role in Alzheimer's disease. 1996 , 21, 128-34	31
593	Apolipoprotein E4, cholinergic integrity and the pharmacogenetics of Alzheimer's disease. 1999 , 24, 147-53	39
592	The prediction and prevention of Alzheimer's disease--towards a research agenda. 1999 , 24, 413-30	9
591	Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer's amyloid beta peptides. 2000 , 348 Pt 2, 359-65	104
590	Alzheimer's disease: current knowledge, management and research. 1997 , 157, 1047-52	5
589	Dementia--an update. 1995 , 163, 473-4	1
588	Aluminum and Alzheimer's disease. 1995 , 152, 468-9	
587	Gene-environment interactions in mental disorders. 2004 , 3, 73-83	83
586	Apolipoprotein E and Alzheimer disease: genotype-specific risks by age and sex. 1997 , 60, 439-46	86
585	A prospective study of cognitive health in the elderly (Oregon Brain Aging Study): effects of family history and apolipoprotein E genotype. 1997 , 60, 948-56	37
584	Age of onset in Huntington disease: sex specific influence of apolipoprotein E genotype and normal CAG repeat length. 1999 , 36, 108-11	71
583	Genetic counseling in a Swedish Alzheimer family with amyloid precursor protein mutation. 1995 , 56, 332-5	15
582	Cerebral lipid deposition in aged apolipoprotein-E-deficient mice. 1997 , 151, 1371-7	25
581	Free fatty acids stimulate the polymerization of tau and amyloid beta peptides. In vitro evidence for a common effector of pathogenesis in Alzheimer's disease. 1997 , 150, 2181-95	252
580	Reduction in amyloid A amyloid formation in apolipoprotein-E-deficient mice. 1998 , 152, 1387-95	38
579	The pathogenesis of amyloidosis: understanding general principles. 1998 , 152, 1125-7	28
578	Expression of the macrophage scavenger receptor, a multifunctional lipoprotein receptor, in microglia associated with senile plaques in Alzheimer's disease. 1996 , 148, 399-403	109
577	The Golgi apparatus and the pathogenesis of Alzheimer's disease. 1996 , 148, 355-60	15

576	Heme oxygenase-1 is associated with the neurofibrillary pathology of Alzheimer's disease. 1994 , 145, 42-7	304
575	Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. 1994 , 145, 1030-5	329
574	Influence of apolipoprotein E genotype on senile dementia of the Alzheimer and Lewy body types. Significance for etiological theories of Alzheimer's disease. 1994 , 145, 1472-84	83
573	Relative risk of Alzheimer disease and age-at-onset distributions, based on APOE genotypes among elderly African Americans, Caucasians, and Hispanics in New York City. 1996 , 58, 574-84	92
572	Gender difference in apolipoprotein E-associated risk for familial Alzheimer disease: a possible clue to the higher incidence of Alzheimer disease in women. 1996 , 58, 803-11	149
571	Evidence for major gene inheritance of Alzheimer disease in families of patients with and without apolipoprotein E epsilon 4. 1996 , 59, 664-75	24
570	Influence of apolipoprotein E genotype on the transmission of Alzheimer disease in a community-based sample. 1996 , 58, 191-200	52
569	Apolipoprotein E: risk factor for Alzheimer disease. 1994 , 54, 643-9	181
568	The apolipoprotein E/CI/CII gene cluster and late-onset Alzheimer disease. 1994 , 54, 631-42	66
567	Evidence for familial factors that protect against dementia and outweigh the effect of increasing age. 1994 , 54, 650-7	14
566	A population-based study of familial Alzheimer disease: linkage to chromosomes 14, 19, and 21. 1994 , 55, 714-27	28
565	Multiple etiologies for Alzheimer disease are revealed by segregation analysis. 1994 , 55, 991-1000	27
564	Localization of disinhibition-dementia-parkinsonism-amyotrophy complex to 17q21-22. 1994 , 55, 1159-65	229
563	Complete penetrance of Creutzfeldt-Jakob disease in Libyan Jews carrying the E200K mutation in the prion protein gene. 1995 , 1, 607-13	31
562	Alzheimer amyloid-beta peptide forms denaturant-resistant complex with type epsilon 3 but not type epsilon 4 isoform of native apolipoprotein E. 1996 , 2, 175-80	14
561	Apolipoprotein E polymorphisms and primary glaucoma in Saudis. 2009 , 15, 912-9	36
560	Pathogenesis of Alzheimer's disease. 2007 , 2, 347-59	148
559	Genetics and biology of Alzheimer's disease and frontotemporal lobar degeneration. 2010 , 3, 129-43	16

558	Frontiers in the pathogenesis of Alzheimer's disease. 2009 , 51 Suppl 1, S56-60	3
557	LRP-1 variation is not associated with risk of Alzheimer's disease. 2010 , 1, 104-13	8
556	APOE ϵ and δ influence the susceptibility for Alzheimer's disease but not other dementias. 2010 , 1, 193-200	11
555	Neuroinflammatory Cytokines-The Common Thread in Alzheimer's Pathogenesis. 2010 , 6, 19-27	19
554	Genome-wide association studies in myocardial infarction and coronary artery disease. 2010 , 5, 116-21	1
553	Association between Alzheimer's Disease and Apolipoprotein E Polymorphisms. 2010 , 39, 1-6	29
552	Can zebrafish be used as animal model to study Alzheimer's disease?. 2012 , 1, 32-48	22
551	C9ORF72 repeat expansions and other FTD gene mutations in a clinical AD patient series from Mayo Clinic. 2012 , 1, 107-18	31
550	Pathways to neurodegeneration: mechanistic insights from GWAS in Alzheimer's disease, Parkinson's disease, and related disorders. 2013 , 2, 145-75	106
549	Evidence of endothelial dysfunction in the development of Alzheimer's disease: Is Alzheimer's a vascular disorder?. 2013 , 3, 197-226	114
548	Development, appraisal, validation and implementation of a consensus protocol for the assessment of cerebral amyloid angiopathy in post-mortem brain tissue. 2014 , 3, 19-32	89
547	An updated meta-analysis: apolipoprotein E genotypes and risk of primary open-angle glaucoma. 2014 , 20, 1025-36	8
546	CHOLESTEROL AND NEURONAL SUSCEPTIBILITY TO BETA-AMYLOID TOXICITY. 2010 , 5, 35-56	5
545	Genetics of Vascular Dementia. 2010 , 51, 9-25	1
544	Role of endolysosomes and cholesterol in the pathogenesis of Alzheimer's disease: Insights into why statins might not provide clinical benefit. 2014 , 2,	1
543	Vitamin D Receptor (VDR) Polymorphisms and Late-Onset Alzheimer's Disease: An Association Study. 2013 , 42, 1253-8	8
542	Association of apolipoprotein E with the progression of hepatitis B virus-related liver disease. 2015 , 8, 14749-56	7
541	The presenilin 1 p.Gly206Ala mutation is a frequent cause of early-onset Alzheimer's disease in Hispanics in Florida. 2016 , 5, 94-101	4

540	Neural stem/progenitor cells in Alzheimer's disease. 2016 , 89, 23-35	39
539	Chronic Traumatic Encephalopathy in Athletes Involved with High-impact Sports. 2016 , 9, 34-48	13
538	Catastrophe, chaos and Alzheimer's disease. The F E Williams Lecture. 1995 , 29, 412-8	3
537	Taming Alzheimer's disease: New perspectives, newer horizons. 2017 , 16, 146-155	4
536	Analysis of apolipoprotein E genetic variation in patients with Alzheimer disease referred to Imam Reza Clinic, Rasht, Iran, in 2015. 2017 , 16, 173-177	3
535	Amyloid beta accumulation in HIV-1 infected brain: the role of altered cholesterol homeostasis. 2014 , 1,	
534	A Review on the Trajectory of Attentional Mechanisms in Aging and the Alzheimer's Disease Continuum through the Attention Network Test. 2019 , 92, 37-51	13
533	Molecular Biology. 1995 , 19, 217-220	1
532	Alkyl-Acylglycerols and the Important Clinical Ramifications of Raising Plasmalogens in Dementia and Alzheimer's Disease. 2020 , 19, 12-16	1
531	Homogeneous Assays for Single-Nucleotide Polymorphism Typing Using AlphaScreen. 2001 , 11, 600-608	13
530	Neurodegenerative diseases. 2022 , 1-67	
529	Axonal plasma membrane-mediated toxicity of cholesterol in Alzheimer's disease: A microsecond molecular dynamics study. 2021 , 281, 106718	0
528	Genome-Wide Association Studies. 2021 , 205-227	1
527	Linkage Analysis. 2021 , 105-168	
526	Designing a Study for Identifying Genes in Complex Traits. 2021 , 1-12	
525	Complex Genetic Interactions/Data Mining/Dimensionality Reduction. 2021 , 265-277	
524	Using Genomic Techniques in Sports and Exercise Science: Current Status and Future Opportunities. 2021 , 20, 617-623	1
523	The landscape of metabolic brain alterations in Alzheimer's disease.	1

522	Building on a Solid Foundation: Adding Relevance and Reproducibility to Neurological Modeling Using Human Pluripotent Stem Cells. 2021 , 15, 767457	
521	Engagement of vascular early response genes typifies mild cognitive impairment. 2021 ,	1
520	Cholesterol Dysmetabolism in Alzheimer's Disease: A Starring Role for Astrocytes?. 2021 , 10,	1
519	Bench Research Informed by GWAS Results. 2021 , 10,	0
518	Iron Homeostasis Disorder and Alzheimer's Disease. 2021 , 22,	8
517	Bioinformatic Annotation of Genes for Alzheimer's Disease and Coronary Heart Disease. 2021 , 57, 1285-1293	
516	Structural biology of cell surface receptors implicated in Alzheimer's disease.. 2022 , 14, 233-255	0
515	A Scoping Review of Dietary Factors Conferring Risk or Protection for Cognitive Decline in APOE ϵ Carriers. 2021 , 25, 1167-1178	
514	A brain proteomic signature of incipient Alzheimer's disease in young ϵ carriers identifies novel drug targets. 2021 , 7, eabi8178	2
513	The probabilistic model of Alzheimer disease: the amyloid hypothesis revised. 2021 ,	17
512	A missense variant in SHARPIN mediates Alzheimer's disease-specific brain damages. 2021 , 11, 590	2
511	Brain transcriptomes of zebrafish and mouse Alzheimer's disease knock-in models imply early disrupted energy metabolism. 2021 ,	0
510	Pursuit of precision medicine: Systems biology approaches in Alzheimer's disease mouse models. 2021 , 161, 105558	3
509	Mitochondrial DNA and Alzheimer's disease: a first case-control study of the Tunisian population. 2021 , 1	
508	Evidence against altered excitatory/inhibitory balance in the posteromedial cortex of young adult APOE E4 carriers: A resting state 1H-MRS study. 2021 , 1, 100059	
507	Cleavage-Free Human Genome Editing. 2021 ,	0
506	THE EVOLVING CONCEPT OF CAVEOLINS AND INTERMEDIARY ROLE IN VARIOUS MECHANISMS VIA BIOMOLECULAR PATHWAYS. 2018 , 55, 7-17	
505	APOE Missense Variant R145C is Associated with Increased Alzheimer's Disease Risk in African Ancestry Individuals with the APOE ϵ / ϵ Genotype.	

504	Large-scale sequencing studies expand the known genetic architecture of Alzheimer's disease.. 2021 , 13, e12255	
503	The Role of Apolipoprotein E ϵ in Early and Late Mild Cognitive Impairment. 2021 , 84, 472-480	0
502	Association between serum urate and CSF markers of Alzheimer's disease pathology in a population-based sample of 70-year-olds.. 2021 , 13, e12241	0
501	Challenge accepted: uncovering the role of rare genetic variants in Alzheimer's disease.. 2022 , 17, 3	1
500	APOE4 confers transcriptomic and functional alterations to primary mouse microglia.. 2022 , 164, 105615	4
499	Apolipoprotein E derived from CD11c cells ameliorates atherosclerosis.. 2022 , 25, 103677	1
498	The effect of Alzheimer's disease risk factors on brain aging in normal Chinese: Cognitive aging and cognitive reserve.. 2021 , 771, 136398	2
497	Associations of circulating C-reactive proteins, APOE ϵ , and brain markers for Alzheimer's disease in healthy samples across the lifespan.. 2021 , 100, 243-253	1
496	Olfactory Impairment and Neurodegenerative Disorders. 2021 , 145-158	
495	Determining the Genetic Component of a Disease. 2021 , 36-57	
494	Synapses, Microglia, and Lipids in Alzheimer's Disease.. 2021 , 15, 778822	2
493	Remembering your A, B, C's: Alzheimer's disease and ABCA1.. 2022 , 12, 995-1018	0
492	Anxiety and Depressive Symptoms and Cortical Amyloid- β Burden in Cognitively Unimpaired Older Adults.. 2022 , 9, 286-296	
491	Short structural variants as informative genetic markers for ALS disease risk and progression.. 2022 , 20, 11	0
490	Shared genetic influences on resting-state functional networks of the brain.. 2022 ,	1
489	Protein degradation-associated mechanisms that are affected in Alzheimer's disease.. 2022 , 477, 915	2
488	Man Influences His Biology: How World Views Shape the Future. 2022 , 85-105	
487	Identifying differential regulatory control of APOE ϵ P on African versus European haplotypes as potential therapeutic targets.. 2022 ,	1

486	Functional insight into LOAD-associated microglial response genes.. 2022 , 12, 210280	2
485	Association Between Body Mass Index and Cognitive Function in Mild Cognitive Impairment Regardless of APOE ϵ Status.. 2022 , 21, 30-41	1
484	Sex-specific transcriptome of spinal microglia in neuropathic pain due to peripheral nerve injury.. 2022 ,	2
483	Mechanistic Link between Vitamin B12 and Alzheimer's Disease.. 2022 , 12,	2
482	Alzheimer's Disease Variant Portal: A Catalog of Genetic Findings for Alzheimer's Disease.. 2022 ,	0
481	APOE ϵ effects on hippocampal atrophy in the healthy elderly reflect future cognitive decline.	
480	Primary Age-Related Tauopathy (PART) in a Finnish Population-Based Study of the Oldest Old (Vantaa 85+).. 2021 ,	1
479	Don't forget about tau: the effects of ApoE4 genotype on Alzheimer's disease cerebrospinal fluid biomarkers in subjects with mild cognitive impairment-data from the Dementia Competence Network.. 2022 , 1	1
478	APOE ϵ resilience for Alzheimer's disease is mediated by plasma lipid species: Analysis of three independent cohort studies.. 2022 ,	2
477	APOE ϵ 4 Allele Moderates the Association Between Basal Forebrain Nuclei Volumes and Allocentric Navigation in Older Adults Without Dementia.. 2022 ,	
476	Reassessing Diabetes and APOE Genotype as Potential Interacting Risk Factors for Alzheimer's Disease.. 2022 , 37, 15333175211070912	
475	Apolipoprotein E ϵ /4 genotype limits response to dietary induction of hyperhomocysteinemia and resulting inflammatory signaling.. 2022 , 271678X211069006	0
474	Apolipoprotein E Genotype Moderation of the Association Between Physical Activity and Brain Health. A Systematic Review and Meta-Analysis.. 2021 , 13, 815439	0
473	Genome-wide analysis identified abundant genetic modulators of contributions of the apolipoprotein E alleles to Alzheimer's disease risk.. 2022 ,	1
472	KIBRA, MTNR1B, and FKBP5 genotypes are associated with decreased odds of incident delirium in elderly post-surgical patients.. 2022 , 12, 556	0
471	Self-reported sleep characteristics associated with dementia among rural-dwelling Chinese older adults: a population-based study.. 2022 , 22, 5	1
470	The National Institute on Aging Late-Onset Alzheimer's Disease Family Based Study: A resource for genetic discovery.. 2022 ,	0
469	Impact of APOE β and ϵ genotypes on plasma proteome signatures in Alzheimer's disease.	0

468	Long-term associations between amyloid positron emission tomography, sex, apolipoprotein E and incident dementia and mortality among individuals without dementia: hazard ratios and absolute risk.. 2022 , 4, fcac017	2
467	Use of fish oil supplements is differently related to incidence of all-cause and vascular dementia among people with the distinct APOE ϵ dosage.. 2022 , 41, 731-736	1
466	Association of APOE e4 and Plasma p-tau181 with Preclinical Alzheimer's Disease and Longitudinal Change in Hippocampus Function.. 2021 ,	0
465	Studying APOE e4 Allele Dose Effects with a Univariate Morphometry Biomarker.. 2021 ,	0
464	Selective reduction of astrocyte apoE3 and apoE4 strongly reduces A β accumulation and plaque-related pathology in a mouse model of amyloidosis.. 2022 , 17, 13	2
463	Association of fish oil supplementation with risk of incident dementia: A prospective study of 215,083 older adults.. 2022 , 41, 589-598	0
462	Deep learning-based identification of genetic variants: application to Alzheimer's disease classification.. 2022 ,	1
461	Understanding Anhedonia from a Genomic Perspective.. 2022 , 1	
460	The tocopherol transfer protein TTP mediates Vitamin E trafficking between cerebellar astrocytes and neurons.. 2022 , 101712	1
459	Diabetes: Risk Factor and Translational Therapeutic Implications for Alzheimer's Disease.. 2022 ,	0
458	ASIC-E4: Interplay of Beta-Amyloid, Synaptic Density and Neuroinflammation in Cognitively Normal Volunteers With Three Levels of Genetic Risk for Late-Onset Alzheimer's Disease - Study Protocol and Baseline Characteristics.. 2022 , 13, 826423	0
457	Correlation Between Urine Formaldehyde and Cognitive Abilities in the Clinical Spectrum of Alzheimer's Disease.. 2022 , 14, 820385	1
456	Mutation analysis of disease causing genes in patients with early onset or familial forms of Alzheimer's disease and frontotemporal dementia.. 2022 , 23, 99	0
455	Exposure to air pollution and risk of incident dementia in the UK Biobank.. 2022 , 112895	3
454	Apolipoprotein E4 has extensive conformational heterogeneity in lipid free and bound forms.	
453	Blood and brain transcriptome analysis reveals APOE genotype-mediated and immune-related pathways involved in Alzheimer disease.. 2022 , 14, 30	0
452	Single-cell RNA sequencing reveals time- and sex-specific responses of mouse spinal cord microglia to peripheral nerve injury and links ApoE to chronic pain.. 2022 , 13, 843	5
451	Predictive link between systemic metabolism and immune signaling in the brain of APOE4 mice.	0

450	Pathophysiology of Lipid Droplets in Neuroglia.. 2021 , 11,	2
449	Recent advances in molecular genetics of cardiovascular disorders. Implications for atherosclerosis and diseases of cellular lipid metabolism. 1998 , 4, 152-60	2
448	Platelet-derived growth factor-BB and white matter hyperintensity burden in APOE4 carriers. 2022 , 3, 100131	
447	The Current Progress of Psychiatric Genomics. 2022 , 68, 2-11	
446	OUP accepted manuscript.	0
445	Improving mouse models for the study of Alzheimer's disease.. 2022 , 148, 79-113	
444	Machine learning methods applied to genotyping data capture interactions between single nucleotide variants in late onset Alzheimer's disease.. 2022 , 14, e12300	
443	Are apolipoprotein E fragments a promising new therapeutic target for Alzheimer's disease?. 2022 , 13, 20406223221081605	1
442	Triazolinedione protein modification: from an overlooked off-target effect to a tryptophan-based bioconjugation strategy.	0
441	Early considerations of genetics in aphasia rehabilitation: a narrative review. 1-19	
440	APOE mediated neuroinflammation and neurodegeneration in Alzheimer's disease.. 2022 , 101594	5
439	A Systematic Review of Neuroimaging Studies Comparing Individuals with Subjective Cognitive Decline to Healthy Controls.. 2022 ,	0
438	Isoform-Dependent Effects of Apolipoprotein E on Sphingolipid Metabolism in Neural Cells.. 2021 ,	
437	TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A.. 2022 , 603, 131-137	14
436	-Acetyl-Cysteine: Modulating the Cysteine Redox Proteome in Neurodegenerative Diseases.. 2022 , 11,	3
435	Human APOE e3 and APOE e4 Alleles Have Differential Effects on Mouse Olfactory Epithelium.. 2021 ,	0
434	The Relationship Between Low-Density Lipoprotein Cholesterol and Progression of Mild Cognitive Impairment: The Influence of rs6859 in .. 2022 , 13, 823406	1
433	Effect of Cholesterol Molecules on A β -42 Wild-Type and Mutants Trimers.. 2022 , 27,	4

432	Slc9a6 mutation causes Purkinje cell loss and ataxia in the shaker rat.	0
431	Computational and Experimental Analysis of Genetic Variants.. 2022 , 12, 3303-3336	2
430	Early-life educational attainment, APOE ϵ alleles, and incident dementia risk in late life.. 2022 , 1	1
429	CYCLOBUTANES IN SMALL MOLECULE DRUG CANDIDATES.. 2022 ,	7
428	Rapid and gentle immunopurification of brain synaptic vesicles.. 2022 ,	1
427	Single molecule, long-read Apoer2 sequencing identifies conserved and species-specific splicing patterns.. 2022 , 110318	0
426	Microglial activation in Alzheimer's disease: The role of flavonoids and microRNAs.. 2022 ,	2
425	ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease.. 2022 , 115, 20-28	1
424	APOE gene region methylation is associated with cognitive performance in middle-aged urban adults.. 2022 , 116, 41-48	
423	Isoform- and cell-state-specific lipidation of ApoE in astrocytes.. 2022 , 38, 110435	1
422	Endogenous Human Proteins Interfering with Amyloid Formation.. 2022 , 12,	1
421	The Association Between Alzheimer's Disease-Related Markers and Physical Activity in Cognitively Normal Older Adults.. 2022 , 14, 771214	1
420	Potential Mechanisms Underlying Resistance to Dementia in Non-Demented Individuals with Alzheimer's Disease Neuropathology.. 2022 ,	1
419	APOE ϵ , Alzheimer's disease neuropathology and sleep disturbance, in individuals with and without dementia.. 2022 , 14, 47	2
418	From synapses to circuits and back: bridging levels of understanding in animal models of Alzheimer disease.. 2022 ,	0
417	Amyloid and Tau Protein Concentrations in Children with Meningitis and Encephalitis.. 2022 , 14,	
416	Whole-genome analysis of human embryonic stem cells enables rational line selection based on genetic variation.. 2022 ,	1
415	Alzheimer's disease - the journey of a healthy brain into organ failure.. 2022 , 17, 18	3

414	Lung function impairment in relation to cognition and vascular brain lesions: the Rotterdam Study.. 2022 , 1	1
413	ApoE Cascade Hypothesis in the pathogenesis of Alzheimer's disease and related dementias.. 2022 ,	5
412	Cerebrospinal fluid biomarkers and genetic factors associated with normal pressure hydrocephalus and Alzheimer's disease: a narrative review. 2022 , 23,	
411	Incidence and Cognitive Decline of Alzheimer's Disease and Other Dementia by Apolipoprotein E Allele Presence: A Community-Based Cohort Study in Korean Elderly.. 2022 ,	
410	Apolipoprotein E proteinopathy is a major dementia-associated pathologic biomarker in individuals with or without the APOE epsilon 4 allele.. 2021 ,	0
409	Inhibition of colony stimulating factor-1 receptor (CSF-1R) as a potential therapeutic strategy for neurodegenerative diseases: opportunities and challenges.. 2022 , 79, 219	2
408	Prediction Models for Conversion From Mild Cognitive Impairment to Alzheimer's Disease: A Systematic Review and Meta-Analysis.. 2022 , 14, 840386	1
407	Dissecting the clinical heterogeneity of early-onset Alzheimer's disease.. 2022 ,	3
406	A robust and interpretable machine learning approach using multimodal biological data to predict future pathological tau accumulation.. 2022 , 13, 1887	2
405	Association of Apolipoprotein E e4 allele with Enlarged Perivascular Spaces.. 2022 ,	0
404	Genetic Architecture of RNA Editing Regulation in Alzheimer Disease across Diverse Ancestral Populations.. 2022 ,	0
403	Neuropsychiatric Inventory-Questionnaire Assessed Nighttime Behaviors in Cognitively Asymptomatic Patients with Pathologically Confirmed Alzheimer's Disease Predict More Rapid Cognitive Deterioration.. 2022 ,	1
402	Antiamyloid Toxicity effect of genistein via activation of DAF-16 and HSP-16.2 signal pathways in Caenorhabditis elegans.. 2022 , e23055	0
401	Advancements in the development of multi-target directed ligands for the treatment of Alzheimer's disease.. 2022 , 61, 116742	3
400	Therapeutic potential of ApoE-mimetic peptides in CNS disorders: Current perspective.. 2022 , 114051	1
399	Genome-wide DNA methylation profiling in nonagenarians suggests an effect of in late onset Alzheimer's disease.. 2021 , 1-27	0
398	The E4 Allele Affects Cognitive Functions Differently in Carriers of Mutations Compared to Carriers of Mutations in Autosomal-Dominant Alzheimer's Disease.. 2021 , 12,	
397	Genomic Characterization of Host Factors Related to SARS-CoV-2 Infection in People with Dementia and Control Populations: The GR@ACE/DEGESCO Study.. 2021 , 11,	2

- 396 Apolipoprotein E Polymorphism and Alzheimer's Risk in Kashmiri Population. **2021**, 18, 673-680
- 395 Liver Health and Dementia in an Italian Older Population: Findings From the Salus in Apulia Study.. **2021**, 13, 748888 1
- 394 Integrated Bioinformatics and Machine Learning Algorithms Analyses Highlight Related Pathways and Genes Associated with Alzheimer's Disease. **2021**, 17,
- 393 Structural Covariance Network as an Endophenotype in Alzheimer's Disease-Susceptible Single-Nucleotide Polymorphisms and the Correlations With Cognitive Outcomes.. **2021**, 13, 721217 0
- 392 Pharmacological modulation of autophagy for Alzheimer's disease therapy: Opportunities and obstacles. **2021**, 1
- 391 Using imputation to provide harmonized longitudinal measures of cognition across AIBL and ADNI. **2021**, 11, 23788 3
- 390 Explaining World-Wide Variation in Navigation Ability from Millions of People: Citizen Science Project Sea Hero Quest. **2021**, 6
- 389 Relating Global and Local Connectome Changes to Dementia and Targeted Gene Expression in Alzheimer's Disease.. **2021**, 15, 761424 0
- 388 Multi-method investigation of factors influencing amyloid onset and impairment in three cohorts. 0
- 387 Causal inference for semi-competing risks data.. **2021**, 1
- 386 Genetic Factors, Brain Atrophy, and Response to Rehabilitation Therapy After Stroke.. **2021**, 15459683211062899
- 385 Brain myelin water fraction is associated with APOE4 allele status in patients with cognitive impairment.. **2021**, 1
- 384 Genetic basis of cardiovascular aging is at the core of human longevity.. **2022**, 2,
- 383 Midlife lipid and glucose levels are associated with Alzheimer's disease.. **2022**, 0
- 382 Peripheral Pathways to Neurovascular Unit Dysfunction, Cognitive Impairment, and Alzheimer's Disease.. **2022**, 14, 858429 0
- 381 Young Adults with a Parent with Dementia Show Early Abnormalities in Brain Activity and Brain Volume in the Hippocampus: A Matched Case-Control Study.. **2022**, 12, 1
- 380 The Effect of APOE e4 on the Functional Connectivity in Frontoparietal Network in Hypertensive Patients. **2022**, 12, 515
- 379 The Relationship Between Sleep Disturbance and Apolipoprotein E ϵ 4 in Adults With Mild Cognitive Impairment and Alzheimer's Disease Dementia: An Integrative Review.. **2022**, 10998004221081044

378 Tau polygenic risk scoring: a cost-effective aid for prognostic counseling in Alzheimer's disease.. **2022**, 143, 571 ○

377 Lipid Peroxidation Induced ApoE Receptor-Ligand Disruption as a Unifying Hypothesis Underlying Sporadic Alzheimer's Disease in Humans.. **2022**, ○

376 Brain integrity is altered by hepatic APOE ϵ in humanized-liver mice.. **2022**, ○

375 Actigraphy-estimated physical activity is associated with functional and structural brain connectivity among older adults.. **2022**, 116, 32-40 ○

374 Genetic Epidemiology. **2005**, 1139-1167

373 Image_1.JPEG. **2019**,

372 Image_10.JPEG. **2019**,

371 Image_11.JPEG. **2019**,

370 Image_12.JPEG. **2019**,

369 Image_2.JPEG. **2019**,

368 Image_3.JPEG. **2019**,

367 Image_4.JPEG. **2019**,

366 Image_5.JPEG. **2019**,

365 Image_6.JPEG. **2019**,

364 Image_7.JPEG. **2019**,

363 Image_8.JPEG. **2019**,

362 Image_9.JPEG. **2019**,

361 Table_1.XLSX. **2019**,

360 Table_2.XLSX. 2019,

359 Table_3.XLSX. 2019,

358 Table_1.DOCX. 2019,

357 Table_2.DOCX. 2019,

356 Table_3.DOCX. 2019,

355 Table_4.docx. 2019,

354 Table1.DOCX. 2018,

353 Table2.DOCX. 2018,

352 Image_1.pdf. 2018,

351 Presentation_1.PDF. 2018,

350 Image_1.JPEG. 2019,

349 Image_2.JPEG. 2019,

348 Data_Sheet_1.docx. 2019,

347 Table_1.XLSX. 2019,

346 Table_2.xlsx. 2019,

345 Table_3.xlsx. 2019,

344 Table_4.XLSX. 2019,

343 Table_5.XLSX. 2019,

342 Table_1.DOCX. 2020,

341 Image_1.tiff. 2020,

340 Image_2.tiff. 2020,

339 Image_3.tiff. 2020,

338 Image_4.tiff. 2020,

337 Image_5.tiff. 2020,

336 Image_6.tiff. 2020,

335 Table_1.DOCX. 2020,

334 Image_1.TIF. 2019,

333 Image_2.TIF. 2019,

332 Image_3.TIF. 2019,

331 Table_1.DOCX. 2019,

330 ¹H, ¹³C and ¹⁵N chemical shift assignments of the N-terminal domain of the two isoforms of the human apolipoprotein E.. 2022, 1

329 Memory self-appraisal in middle-aged and older adults with the apolipoprotein E-4 allele. 1999, 156, 1035-8 48

328 Different Age Related Neurological and Cardiac Effects of Verapamil on a Transgenic Mouse Model of Alzheimer's Disease. 2021, 47, 263-269

327 Strategies to gain novel Alzheimer's disease diagnostics and therapeutics using modulators of ABCA transporters.. 2021, 2, 1

326 Alzheimer's Disease: A Washing Machine on the Fritz. 2022, 12, 131-163 0

325 Modification of vascular receptor pharmacology by cholesterol: From molecular determinants to impact on arterial function. 2022, 825-851

324	Association of the top 20 Alzheimer's disease risk genes with [F]lortaucipir PET.. 2022 , 14, e12308	
323	Molecular recognition of the interaction between ApoE and the TREM2 protein.. 2022 , 13, 93-103	1
322	Dementia in People with Intellectual Disabilities. 2022 , 719-756	0
321	Whole genome analysis in APOE4 homozygotes identifies the DAB1-RELN pathway in Alzheimer's disease pathogenesis.	
320	Apolipoprotein E4 Effects a Distinct Transcriptomic Profile and Dendritic Arbor Characteristics in Hippocampal Neurons Cultured .. 2022 , 14, 845291	0
319	AD Resemblance Atrophy Index of Brain Magnetic Resonance Imaging in Predicting the Progression of Mild Cognitive Impairment Carrying Apolipoprotein E- ϵ Allele.. 2022 , 14, 859492	0
318	Differential Effects of APOE Genotype on MicroRNA Cargo of Cerebrospinal Fluid Extracellular Vesicles in Females With Alzheimer's Disease Compared to Males.. 2022 , 10, 864022	0
317	Integration of Protein Structure and Population-Scale DNA Sequence Data for Disease Gene Discovery and Variant Interpretation.. 2022 ,	
316	Disentangling Alzheimer's disease neurodegeneration from typical brain ageing using machine learning.	0
315	A multi-hit hypothesis for an APOE4-dependent pathophysiological state.. 2022 ,	0
314	A transcriptional mechanism involving R-loop, m6A modification and RNA abasic sites regulates an enhancer RNA of APOE.	0
313	Olfactory Evaluation in Alzheimer's Disease Model Mice. 2022 , 12, 607	
312	Population Genomics of Stone Age Eurasia.	1
311	Neurogenesis in Aging and Age-related Neurodegenerative Diseases.. 2022 , 101636	4
310	The genetic architecture of Alzheimer disease risk in the Ohio and Indiana Amish. 2022 , 3, 100114	
309	Microglia in the Neuroinflammatory Pathogenesis of Alzheimer's Disease and Related Therapeutic Targets.. 2022 , 13, 856376	2
308	The Current Landscape of Prevention Trials in Dementia.. 2022 ,	0
307	Periodontitis as a Risk Factor for Alzheimer's Disease: The Experimental Journey So Far, with Hope of Therapy. 2022 , 241-260	0

- 306 Inflammation—Cause or consequence of late onset Alzheimer’s disease or both? A review of the evidence. **2022**, 20, 1721727X2210953
- 305 Polygenic resilience scores capture protective genetic effects for Alzheimer’s disease.
- 304 Leveraging large multi-center cohorts of Alzheimer disease endophenotypes to understand the role of Klotho heterozygosity on disease risk. **2022**, 17, e0267298 1
- 303 A comparative study of structural variant calling strategies using the Alzheimer’s Disease Sequencing Project’s whole genome family data.
- 302 Shared pathophysiology: Understanding stroke and Alzheimer’s disease. **2022**, 218, 107306 2
- 301 A PDK-1 Allosteric Agonist Improves Spatial Learning and Memory in a Δ APP/PS-1 Transgenic Mouse-High Fat Diet Intervention Model of Alzheimer’s Disease.
- 300 A Diet Rich in Docosahexaenoic Acid Enhances Reactive Astrogliosis and Ramified Microglia Morphology in Apolipoprotein E Epsilon 4-Targeted Replacement Mice.
- 299 Genome-Wide Association Study Statistical Models: A Review. **2022**, 43-62 0
- 298 Systemic hormone therapy and dementia: A nested case-control and co-twin control study. **2022**, 1 1
- 297 Assessment of a polygenic hazard score for the onset of pre-clinical Alzheimer’s disease. **2022**, 23, 0
- 296 Impact of APOE ϵ Carrier Status on Associations Between Subthreshold, Positive Amyloid- β Deposition, Brain Function, and Cognitive Performance in Cognitively Normal Older Adults: A Prospective Study. 14, 0
- 295 The Role of Mitochondrial genome abundance in Alzheimer’s Disease.
- 294 Increasing brain gamma activity improves episodic memory and restores cholinergic dysfunction in Alzheimer’s disease. 1
- 293 Association of Rare APOE Missense Variants V236E and R251G With Risk of Alzheimer Disease. 2
- 292 Glycosylation of HDL-Associated Proteins and Its Implications in Cardiovascular Disease Diagnosis, Metabolism and Function. **2022**, 9, 1
- 291 Effects of Sex on the Relationship Between Apolipoprotein E Gene and Serum Lipid Profiles in Alzheimer’s Disease. 14, 0
- 290 Rare APOE Missense Variants—Can We Overcome APOE ϵ and Alzheimer Disease Risk?. 0
- 289 Genetics of Alzheimer’s disease: an East Asian perspective. 0

288	Shortening of Saccades as a Possible Easy-to-Use Biomarker to Detect Risk of Alzheimer's Disease. 2022 , 1-10	
287	Mapping the genetic landscape of early-onset Alzheimer's disease in a cohort of 36 families. 2022 , 14,	0
286	A new generation of AD biomarkers: 2019 to 2021. 2022 , 79, 101654	1
285	Age-Dependent Association Between Cognitive Reserve Proxy and Longitudinal White Matter Microstructure in Older Adults. 13,	0
284	Whole Exome Sequencing Reveals a Novel APOE Mutation in a Patient With Sporadic Early-Onset Alzheimer's Disease. 13,	1
283	Neuroimmune contributions to Alzheimer's disease: a focus on human data.	0
282	Inter- and intra-chromosomal modulators of the APOE ϵ and δ effects on the Alzheimer's disease risk.	
281	Chimeric cerebral organoids reveal the essentials of neuronal and astrocytic APOE4 for Alzheimer's tau pathology. 2022 , 7,	2
280	Retinal Vascular Study Using OCTA in Subjects at High Genetic Risk of Developing Alzheimer's Disease and Cardiovascular Risk Factors. 2022 , 11, 3248	2
279	PhenGenVar: A User-Friendly Genetic Variant Detection and Visualization Tool for Precision Medicine. 2022 , 12, 959	1
278	Neuronal hyperexcitability in Alzheimer's disease: what are the drivers behind this aberrant phenotype?. 2022 , 12,	2
277	Quantitative proteomic analysis reveals apoE4-dependent phosphorylation of the actin-regulating protein VASP.	
276	Coenzyme A-Dependent Tricarboxylic Acid Cycle Enzymes Are Decreased in Alzheimer's Disease Consistent With Cerebral Pantothenate Deficiency. 14,	0
275	Aberrant Synaptic Pruning in CNS Diseases: A Critical Player in HIV-Associated Neurological Dysfunction?. 2022 , 11, 1943	0
274	The Role of Astrocytes in Synapse Loss in Alzheimer's Disease: A Systematic Review. 16,	0
273	Genetics of Alzheimer Disease. 2022 , 28, 852-871	1
272	Cholesterol and Dementia: A Possible Therapeutic Approach. 2022 , 357-385	
271	ApoE: A Risk Factor for Dementia. 2022 , 3-29	0

- 270 Brain Amyloid- β Accumulation in AD Mouse Models Modified by Their Altered Gene Expression in the Presence of Human apoE Isoforms Through Aging Process.
- 269 Imipramine and olanzapine block apoE4-catalyzed polymerization of A β and show evidence of improving Alzheimer's disease cognition. **2022**, 14, 1
- 268 Association of perturbation of oral bacterial with incident of Alzheimer's disease: A pilot study. **2022**, 36, 1
- 267 Genotypic effects of APOE- ϵ on resting-state connectivity in cognitively intact individuals support functional brain compensation. 0
- 266 Genome Guided Personalized Drug Therapy in Attention Deficit Hyperactivity Disorder. 13,
- 265 Vascular Dysfunction Is Central to Alzheimer's Disease Pathogenesis in APOE e4 Carriers. **2022**, 23, 7106 0
- 264 Inter- and intra-chromosomal modulators of the APOE e2 and e4 effects on the Alzheimer's disease risk. 0
- 263 Neuroprotective Effects of Resveratrol by Modifying Cholesterol Metabolism and A β Processing in SAMP8 Mice. **2022**, 23, 7580 1
- 262 CCR5 deficiency normalizes TIMP levels, working memory, and gamma oscillation power in APOE4 targeted replacement mice.
- 261 Silencing of ApoE with Divalent siRNAs Drives Activation of Immune Clearance Pathways and Improves Amyloid Pathology in Mouse Models of Alzheimer's Disease. 0
- 260 Apolipoprotein E Genotype e2: Neuroprotection and Its Limits. 14, 0
- 259 RNASE6 is a novel modifier of APOE- ϵ effects on cognition. **2022**, 0
- 258 Using Polygenic Hazard Scores to Predict Age at Onset of Alzheimer's Disease in Nordic Populations. **2022**, 1-12
- 257 A locus at 19q13.31 significantly reduces the ApoE ϵ risk for Alzheimer's Disease in African Ancestry. **2022**, 18, e1009977 0
- 256 Differential Neuropathology, Genetics, and Transcriptomics in Two Kindred Cases with Alzheimer's Disease and Lewy Body Dementia. **2022**, 10, 1687
- 255 Altered Balance of Reelin Proteolytic Fragments in the Cerebrospinal Fluid of Alzheimer's Disease Patients. **2022**, 23, 7522 0
- 254 Polygenic score for Alzheimer's disease identifies differential atrophy in hippocampal subfield volumes. **2022**, 17, e0270795
- 253 Central nervous system cholesterol metabolism in health and disease. 0

- 252 APOE ϵ 4 carriership associates with microglial activation independently of A β plaques and tau tangles.
- 251 Osteoarthritis and APOE4 Interact to Influence Memory Decline in Non-Demented Older People. **2022**, 1-8
- 250 Study of Alzheimer's disease- and Frontotemporal dementia- associated genes in the Cretan Aging Cohort. **2022**,
- 249 Apolipoprotein E Polymorphism: A New Genetic Marker of Hip Fracture Risk in the Study of Osteoporotic Fractures. **1999**, 14, 1175-1181 1
- 248 Predictive Genetic Testing for Alzheimer's Disease. **2014**, 43, 437-438
- 247 Death gene as it is understood by theology and genetics. **2014**, 1, 83-88
- 246 Polygenic resilience scores capture protective genetic effects for Alzheimer's disease. **2022**, 12, 0
- 245 Effects of Sex, APOE4, and Lifestyle Activities on Cognitive Reserve in Older Adults. 10.1212/WNL.0000000000000675
- 244 If amyloid drives Alzheimer disease, why have anti-amyloid therapies not yet slowed cognitive decline?. **2022**, 20, e3001694 3
- 243 Multi-method investigation of factors influencing amyloid onset and impairment in three cohorts. 4
- 242 Current understanding of the interactions between metal ions and Apolipoprotein E in Alzheimer's disease. **2022**, 172, 105824 0
- 241 Preface to the Second Edition. **2007**, v-vi
- 240 Copyright Page. **2007**, iv-iv
- 239 Contributors. **2007**, xix-xxii
- 238 Genetic Variants at the APOE Locus Predict Cardiometabolic Traits and Metabolic Syndrome: A Taiwan Biobank Study. **2022**, 13, 1366 1
- 237 Mutations in SORL1 and MTHFDL1 possibly contribute to the development of Alzheimer's disease in a multigenerational Colombian Family. **2022**, 17, e0269955
- 236 Adenosine receptor signalling in Alzheimer's disease. **2022**, 18, 359-381 0
- 235 Apolipoprotein E genotype modulates longitudinal atrophy at the temporal lobe after mild traumatic brain injury.

- 234 Plasma high-density lipoprotein cargo is altered in Alzheimer's disease and is associated with regional brain volume. 0
- 233 Correlations between sleep disturbance and brain structures associated with neurodegeneration in the National Alzheimer's Coordinating Center Uniform Data Set. **2022,** 0
- 232 Sirtuins promote brain homeostasis, preventing Alzheimer's disease through targeting neuroinflammation. 13, 0
- 231 Low-Density Lipoprotein Receptor-Related Protein 8 at the Crossroad between Cancer and Neurodegeneration. **2022,** 23, 8921 1
- 230 Correlations between APOE4 allele and regional amyloid and tau burdens in cognitively normal older individuals. **2022,** 12, 0
- 229 Mercury Ion Binding to Apolipoprotein E Variants ApoE2, ApoE3, and ApoE4: Similar Binding Affinities but Different Structure Induction Effects. **2022,** 7, 28924-28931 0
- 228 Research advances in the study of sleep disorders, circadian rhythm disturbances and Alzheimer's disease. 14, 0
- 227 In Alzheimer-prone brain regions, metabolism and risk-gene expression are strongly correlated. 0
- 226 Associations Between Sub-Threshold Amyloid- β Deposition, Cortical Volume, and Cognitive Function Modulated by APOE e4 Carrier Status in Cognitively Normal Older Adults. **2022,** 1-14 0
- 225 Modeling the early stages of Alzheimer's disease by administering intracerebroventricular injections of human native A β oligomers to rats. **2022,** 10, 0
- 224 Functional diversity of apolipoprotein E: from subcellular localization to mitochondrial function. **2022,** 79, 2
- 223 Astrocyte-secreted glypican-4 drives APOE4-dependent tau hyperphosphorylation. **2022,** 119, 0
- 222 Ligustilide Improves Cognitive Impairment via Regulating the SIRT1/IRE1 α /XBP1s/CHOP Pathway in Vascular Dementia Rats. **2022,** 2022, 1-15 0
- 221 Temporal and sex-linked protein expression dynamics in a familial model of Alzheimer's Disease. **2022,** 100280 1
- 220 The CORCOBIA study: Cut-off points of Alzheimer's disease CSF biomarkers in a clinical cohort. **2022,** 1
- 219 APOE4 drives inflammation in human astrocytes via TAGLN3 repression and NF- κ B activation. **2022,** 40, 111200 2
- 218 HDL-like-Mediated Cell Cholesterol Trafficking in the Central Nervous System and Alzheimer's Disease Pathogenesis. **2022,** 23, 9356 1
- 217 Pre-symptomatic reduction of individuality in the AppNL-F knock-in model of Alzheimer's disease. 0

216	Multifaceted role of polyphenols in the treatment and management of neurodegenerative diseases. 2022 , 307, 136020	2
215	Whole genome analysis in APOE4 homozygotes identifies the DAB1-RELN pathway in Alzheimer's disease pathogenesis. 2022 , 119, 67-76	
214	Expression of ATP-binding cassette transporter A1 is induced by nerve injury and its deficiency affects neurite tip morphology and elongation in cultured neurons. 2022 , 125, 102164	0
213	Influence of genetic and cardiometabolic risk factors in Alzheimer's disease. 2022 , 81, 101723	1
212	Apolipoprotein E and mimetic peptide initiate a calcium-dependent signaling response in macrophages. 2001 , 70, 677-683	13
211	Sex and gender differences in dementia. 2022 , 179-233	0
210	A healthy mind in a healthy body: Effects of arteriosclerosis and other risk factors on cognitive aging and dementia. 2022 ,	0
209	A diet rich in docosahexaenoic acid enhances reactive astrogliosis and ramified microglia morphology in apolipoprotein E epsilon 4-targeted replacement mice. 2022 , 2, 100046	0
208	Longitudinal Changes in 18F-Flutemetamol Amyloid Load in Cognitively Intact APOE4 Carriers Versus Noncarriers: Methodological Considerations.	0
207	Shared Risk Factors between Dementia and Atherosclerotic Cardiovascular Disease. 2022 , 23, 9777	2
206	An Optimized Comparative Proteomic Approach as a Tool in Neurodegenerative Disease Research. 2022 , 11, 2653	0
205	Sex and APOE Genotype Alter the Basal and Induced Inflammatory States of Primary Microglia from APOE Targeted Replacement Mice. 2022 , 23, 9829	1
204	A multi-omics analysis of blood-brain barrier and synaptic dysfunction in APOE4 mice. 2022 , 219,	0
203	A Diabetes Genetic Risk Score Is Associated With All-Cause Dementia and Clinically Diagnosed Vascular Dementia in the Million Veteran Program.	1
202	Enlarged perivascular spaces are associated with decreased brain tau deposition.	0
201	Expression Changes in Mitochondrial Genes Affecting Mitochondrial Morphology, Transmembrane Potential, Fragmentation, Amyloidosis, and Neuronal Cell Death Found in Brains of Alzheimer's Disease Patients. 2022 , 1-19	0
200	Elevating microglia TREM2 reduces amyloid seeding and suppresses disease-associated microglia. 2022 , 219,	0
199	Estudio CORCOBIA: determinación de puntos de corte de biomarcadores de enfermedad de Alzheimer en LCR en una cohorte clínica. 2022 ,	0

198	Human tau mutations in cerebral organoids induce a progressive dyshomeostasis of cholesterol. 2022 , 17, 2127-2140	0
197	APOE ϵ influences cognitive decline positively in APP and negatively in PSEN1 mutation carriers with autosomal-dominant Alzheimer's disease.	0
196	APOE ϵ gene dose effect on imaging and blood biomarkers of glial reactivity and β amyloid pathology.	0
195	A review of brain imaging biomarker genomics in Alzheimer's disease: implementation and perspectives. 2022 , 11,	0
194	Monobutyrin and monovalerin improve gut blood brain biomarkers and alter gut microbiota composition in high-fat fed apolipoprotein-E-knockout rats. 2022 , 12,	0
193	SNPs in apolipoproteins contribute to sex-dependent differences in blood lipids before and after a high-fat dietary challenge in healthy U.S. adults. 2022 , 8,	1
192	Apolipoprotein E4 modulates astrocyte neuronal support functions in the presence of amyloid- β	0
191	Building in vitro models of the brain to understand the role of APOE in Alzheimer's disease. 2022 , 5, e202201542	0
190	The role of upstream lipid and metabolic systems in Alzheimer's disease, Parkinson's disease and dementias.	1
189	Gene-environment interactions in Alzheimer disease: the emerging role of epigenetics.	3
188	Genetic correlations between gut microbiota genera and Alzheimer's Disease.	0
187	Oxidative Stress Kinase Activation and Impaired Insulin Receptor Signaling Precede Overt Alzheimer's Disease Neuropathology. 2022 , 1-17	0
186	A Haptoglobin (HP) Structural Variant Alters the Effect of APOE Alleles on Alzheimer's Disease.	0
185	The Immune System as a Therapeutic Target for Alzheimer's Disease. 2022 , 12, 1440	1
184	The COVID-19 pandemic and Alzheimer's disease: mutual risks and mechanisms. 2022 , 11,	2
183	The Selection Landscape and Genetic Legacy of Ancient Eurasians.	0
182	Clinical relevance of biomarkers, new therapeutic approaches, and role of post-translational modifications in the pathogenesis of Alzheimer's disease. 14,	0
181	HSPA1A, HSPA2, and HSPA8 Are Potential Molecular Biomarkers for Prognosis among HSP70 Family in Alzheimer's Disease. 2022 , 2022, 1-16	1

180	APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimer's disease pathology and brain diseases. 2022 , 17,	5
179	Biomarkers Related to Synaptic Dysfunction to Discriminate Alzheimer's Disease from Other Neurological Disorders. 2022 , 23, 10831	1
178	Association of rs2072446 in the NGFR gene with the risk of Alzheimer's disease and amyloid- β deposition in the brain.	1
177	Alzheimer's disease related single nucleotide polymorphisms and correlation with intracerebral hemorrhage incidence. 2022 , 101, e30782	0
176	Machine Learning Workflow to Explain Black-Box Models for Early Alzheimer's Disease Classification Evaluated for Multiple Datasets. 2022 , 3,	0
175	Cancer and Vascular Comorbidity Effects on Dementia Risk and Neuropathology in the Oldest-Old. 2022 , 1-13	0
174	Novel molecular mechanisms in Alzheimer's disease: The potential role of DEK in disease pathogenesis. 14,	0
173	Apolipoprotein E loss of function: Influence on murine brain markers of physiology and pathology. 2022 , 2, 100055	0
172	Sex Modifies the Associations of APOE e4 with Neuropsychiatric Symptom Burden in Both At-Risk and Clinical Cohorts of Alzheimer's Disease. 2022 , 1-18	0
171	The role of mitochondrial genome abundance in Alzheimer's disease.	1
170	Hypothesis review: Alzheimer's overture guidelines.	1
169	Perivascular spaces as a potential biomarker of Alzheimer's disease. 16,	0
168	Observational studies in Alzheimer disease: bridging preclinical studies and clinical trials.	0
167	Alzheimer's Disease: Challenges and a Therapeutic Opportunity to Treat It with a Neurotrophic Compound. 2022 , 12, 1409	0
166	A PDK-1 allosteric agonist improves spatial learning and memory in a APP/PS-1 transgenic mouse-high fat diet intervention model of Alzheimer's Disease. 2022 , 114183	0
165	The Role of the Thioredoxin System in Brain Diseases. 2022 , 11, 2161	0
164	Computer-based Eye-tracking Analysis of King-Devick Test Differentiates Persons With Idiopathic Normal Pressure Hydrocephalus From Cognitively Unimpaired. Publish Ahead of Print,	0
163	Suppression of Wnt/ β Catenin Signaling Is Associated with Downregulation of Wnt1, PORCN, and Rspo2 in Alzheimer's Disease.	1

162	The influence of 17q21.31 and APOE genetic ancestry on neurodegenerative disease risk. 14,	0
161	Domino-like Effect of C112R Mutation on APOE4 Aggregation and Its Suppression by Alzheimer β Disease Drug Candidate.	0
160	The use of subjective cognitive complaints for detecting mild cognitive impairment in older adults across cultural and linguistic groups: A comparison of the Cognitive Function Instrument to the Montreal Cognitive Assessment.	0
159	Ovariectomy-induced hormone deprivation aggravates A β -42 deposition in the basolateral amygdala and cholinergic fiber loss in the cortex but not cognitive behavioral symptoms in a triple transgenic mouse model of Alzheimer β disease. 13,	0
158	Optimizing and benchmarking polygenic risk scores with GWAS summary statistics.	1
157	Structural Determinant of β Amyloid Formation: From Transmembrane Protein Dimerization to β Amyloid Aggregates. 2022 , 10, 2753	1
156	A multi-network comparative analysis of whole-transcriptome and translome reveals the effect of high-fat diet on APP/PS1 mice and the intervention with Chinese medicine. 9,	0
155	Potential value of cerebrospinal fluid β synuclein in the identification of postoperative delirium undergoing knee/hip arthroplasty: The perioperative neurocognitive disorder and biomarker lifestyle study. 16,	0
154	Amyloidogenesis and Neurotrophic Dysfunction in Alzheimer β Disease: Do They have a Common Regulating Pathway?. 2022 , 11, 3201	1
153	ApoE3 vs. ApoE4 Astrocytes: A Detailed Analysis Provides New Insights into Differences in Cholesterol Homeostasis. 2022 , 11, 2168	0
152	Neurodegeneration Markers Galectin-3 and Apolipoprotein E Are Elevated in the Aqueous Humor of Eyes With Glaucoma. 2022 , 11, 1	0
151	ApoE/NOS3 Knockout Mice as a Novel Cardiovascular Disease Model of Hypertension and Atherosclerosis. 2022 , 13, 1998	0
150	Unravelling the relationship between amyloid accumulation and brain network function in normal aging and very mild cognitive decline: a longitudinal analysis.	0
149	Microglial efferocytosis: Diving into the Alzheimer β disease gene pool. 2022 , 110, 3513-3533	1
148	Immunosenescence and Aging: Neuroinflammation Is a Prominent Feature of Alzheimer β Disease and Is a Likely Contributor to Neurodegenerative Disease Pathogenesis. 2022 , 12, 1817	1
147	Protein footprinting by mass spectrometry: H/D exchange, specific amino acid labeling, and fast photochemical oxidation of proteins. 2023 , 227-270	0
146	Alzheimer's Disease. 2003 , 228-259	0
145	Effects of Interactions Between Environmental and Genetic Factors on Healthy Aging: A Review on the Relevant Prior Research. 2022 , 315-328	0

144	Linking the Amyloid, Tau, and Mitochondrial Hypotheses of Alzheimer's Disease and Identifying Promising Drug Targets. 2022 , 12, 1676	3
143	Pulse pressure trajectories predict brain microstructure in community-dwelling older adults: Associations with executive function and modification by APOE.	0
142	Emerging roles of innate and adaptive immunity in Alzheimer's disease. 2022 ,	1
141	APOE ϵ genotype, amyloid- β and sex interact to predict tau in regions of high APOE mRNA expression. 2022 , 14,	0
140	APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes.	6
139	Lipid Dys-Homeostasis Contributes to APOE4-Associated AD Pathology. 2022 , 11, 3616	0
138	Somatic Loss of the Y Chromosome and Alzheimer's Disease Risk.	0
137	Co-aggregation with Apolipoprotein E modulates the function of Amyloid- β in Alzheimer's disease.	0
136	Associations of Alzheimer Disease Protective APOE Variants With Age-Related Macular Degeneration.	0
135	Note the Nuance Examining the Association of Alzheimer-Protective APOE Variation With Risk for Age-Related Macular Degeneration.	0
134	Alzheimer's Disease and Other Dementias. 2023 , 1-20	0
133	Infectious origin of Alzheimer's disease: Amyloid beta as a component of brain antimicrobial immunity. 2022 , 18, e1010929	2
132	Tau immunotherapy in Alzheimer's disease and progressive supranuclear palsy. 2022 , 113, 109445	0
131	Rough Set Rules (RSR) Predominantly Based on Cognitive Tests Can Predict Alzheimer's Related Dementia. 2022 , 129-141	0
130	Lack of ApoE inhibits AD and amyloidosis in a mouse model of familial Danish dementia. 2023 , 299, 102751	0
129	Determinants of approved acetylcholinesterase inhibitor response outcomes in Alzheimer's disease: relevance for precision medicine in neurodegenerative diseases. 2023 , 84, 101819	0
128	An AS-qPCR-based method for the detection of Alzheimer's disease-related SNPs.	0
127	Evidence of emerging BBB changes in mid-age apolipoprotein E epsilon-4 carriers. 2022 , 12,	0

126	Suicide-Related Single Nucleotide Polymorphisms, rs4918918 and rs10903034: Association with Dementia in Older Adults. 2022 , 13, 2174	0
125	How Alpha Linolenic Acid May Sustain BloodBrain Barrier Integrity and Boost Brain Resilience against Alzheimer's Disease. 2022 , 14, 5091	0
124	Enhanced activity of Alzheimer disease-associated variant of protein kinase C Drives cognitive decline in a mouse model. 2022 , 13,	1
123	SNP-by-CpG Site Interactions in ABCA7 Are Associated with Cognition in Older African Americans. 2022 , 13, 2150	0
122	A common transcriptional mechanism involving R-loop and RNA abasic site regulates an enhancer RNA of APOE. 2022 , 50, 12497-12514	1
121	Insights into the Pathophysiology of Alzheimer's Disease and Potential Therapeutic Targets: A Current Perspective. 2022 , 1-24	0
120	Amyloid- β in Alzheimer's Disease Front and centre after all?.	0
119	Enlarged perivascular spaces are associated with decreased brain tau deposition.	0
118	Effects of APOE ϵ allele on basal forebrain functional connectivity in mild cognitive impairment.	0
117	APOE Allele Frequency in Southern Greece: Exploring the Role of Geographical Gradient in the Greek Population. 2023 , 8, 1	0
116	Apolipoprotein E intersects with amyloid- β within neurons.	0
115	Overview of Risk Factors for Dementia. 2022 , 6, 27-33	0
114	Disclosure of Genetic Risk Factors for Alzheimer's Disease to Cognitively Healthy Individuals From Current Practice towards a Personalised Medicine Scenario. 2022 , 10, 3177	0
113	Amyloid- β and APOE genotype predict memory decline in cognitively unimpaired older individuals independently of Alzheimer's disease polygenic risk score. 2022 , 22,	0
112	Genetic correlations between gut microbiome genera, Alzheimer's disease diagnosis, and APOE genotypes: a polygenic risk score study.	0
111	Accumulation of amyloid- β in the brain of mouse models of Alzheimer's disease is modified by altered gene expression in the presence of human apoE isoforms during aging. 2022 ,	0
110	iPSC-Derived PSEN2 (N141I) Astrocytes and Microglia Exhibit a Primed Inflammatory Phenotype.	0
109	BloodBrain Barrier Disruption and Its Involvement in Neurodevelopmental and Neurodegenerative Disorders. 2022 , 23, 15271	1

- 108 Diabetic Retinopathy and Dementia Association, Beyond Diabetes Severity. **2022**, 0
- 107 Modulations of bioactive lipids and their receptors in postmortem Alzheimer's disease brains. **14**, 1
- 106 Predictive link between systemic metabolism and cytokine signatures in the brain of apolipoprotein E4 mice. **2022**, 0
- 105 APOE Genotype-specific Methylation Patterns are Linked to Alzheimer Disease Pathology and Estrogen Response. 0
- 104 An increase in mitochondrial TOM activates apoptosis to drive retinal neurodegeneration. **2022**, 12, 0
- 103 Association of CSF GAP-43 and APOE4 with Cognition in Mild Cognitive Impairment and Alzheimer's Disease. **2023**, 12, 13 0
- 102 Extracellular Chaperone Networks and the Export of J-Domain Proteins. **2022**, 102840 0
- 101 Whole patient knowledge modeling of COVID-19 symptomatology reveals common molecular mechanisms. **2**, 0
- 100 Experimental Approach to Alzheimer's Disease with Emphasis on Insulin Resistance in the Brain. **2022**, 1657-1708 0
- 99 Apolipoprotein E4 inhibits B-secretase activity via binding to the B-secretase complex. 0
- 98 Explainable machine learning aggregates polygenic risk scores and electronic health records for Alzheimer's disease prediction. **2023**, 13, 0
- 97 APOE effects on regional tau in preclinical Alzheimer's disease. **2023**, 18, 0
- 96 Longitudinal changes in 18F-Flutemetamol amyloid load in cognitively intact APOE4 carriers versus noncarriers: Methodological considerations. **2023**, 37, 103321 0
- 95 Cell type-specific histone acetylation profiling of Alzheimer's disease subjects and integration with genetics. **15**, 0
- 94 Identification and characterization of peptides from marine crustacean crabs and their bioactive properties; An approach to develop novel drugs for Alzheimer's disease. 0
- 93 Human ApoE2 Endows Stronger Contractility in Rat Cardiomyocytes Enhancing Heart Function. **2023**, 12, 347 0
- 92 Exploring the combined effects of sleep apnea and APOE-e4 on biomarkers of Alzheimer's disease. **14**, 0
- 91 LILRB3 is a putative cell surface receptor of APOE4. 0

- 90 APOE ϵ status and plasma p-tau181 interact to influence cognitive performance among non-demented older adults. **2023**, 796, 137052 ○
- 89 Omega-3 fatty acids and cognitive function. **2023**, 34, 12-21 ○
- 88 Fecal Microbiota Transplantation Reduces Pathology and Improves Cognition in a Mouse Model of Alzheimer's Disease. **2023**, 12, 119 ○
- 87 Effects of non-modifiable risk factors of Alzheimer's disease on intracortical myelin content. **2022**, 14, ○
- 86 APOE genotype or presence of brain amyloid alters the plasma proteome in cognitively normal, elderly subjects. ○
- 85 TREATMENT DEVELOPMENT STRATEGIES FOR ALZHEIMER'S DISEASE. **1995**, 30, 147s-162s ○
- 84 Alzheimer Disease. **2016**, 1-10 ○
- 83 Alzheimer's Disease. **2016**, 1-10 ○
- 82 APOE ϵ potentiates A β effects on longitudinal tangle accumulation via tau phosphorylation. ○
- 81 Particle Nanoarchitectonics for Nanomedicine and Nanotherapeutic Drugs with Special Emphasis on Nasal Drugs and Aging. **2023**, 11, 354 ○
- 80 The neuroimmune axis of Alzheimer's disease. **2023**, 15, ○
- 79 Myeloid masquerade: Microglial transcriptional signatures in retinal development and disease. 17, ○
- 78 In vitro characterization on the role of APOE polymorphism in human hippocampal neurogenesis. 1 ○
- 77 How does apolipoprotein E genotype influence the relationship between physical activity and Alzheimer's disease risk? A novel integrative model. **2023**, 15, ○
- 76 Celebrating a Century of Research in Behavioral Genetics. **2023**, 53, 75-84 ○
- 75 Regional White Matter Hyperintensities and Alzheimer's Disease Biomarkers Among Older Adults with Normal Cognition and Mild Cognitive Impairment. **2023**, 1-17 ○
- 74 The role of ApoE-mediated microglial lipid metabolism in brain aging and disease. **2023**, 5, e00018 ○
- 73 Heart Disease and Stroke Statistics 2023 Update: A Report From the American Heart Association. 9 ○

- 72 Aging, genomic mitochondrial, and regulatory changes. **2023**, 243-272 ○
- 71 Human Leukocyte Antigen (HLA) Modulates the Dependence on Age of the Variability of Synchronous Neural Interactions. **2023**, 18, 263310552311596 ○
- 70 The association between white matter hyperintensities and amyloid and tau deposition. **2023**, 38, 103383 ○
- 69 Honey and Alzheimer's Disease: Current Understanding and Future Prospects. **2023**, 12, 427 ○
- 68 Haptools: a toolkit for admixture and haplotype analysis. **2023**, 39, ○
- 67 CCR5 deficiency normalizes TIMP levels, working memory, and gamma oscillation power in APOE4 targeted replacement mice. **2023**, 179, 106057 ○
- 66 CRISPR/Cas9 system and its applications in nervous system diseases. **2023**, ○
- 65 Proposal of novel ApoE4 inhibitors from the natural spice Cinnamon for the treatment of Alzheimer's disease: Ab initio molecular simulations. **2023**, 296, 106990 ○
- 64 Evaluating depressive symptoms, BDNF Val66Met, and APOE- ϵ as moderators of response to computerized cognitive training in heart failure. **2023**, 59, 146-156 ○
- 63 Long-term effects of amyloid-beta deposits in human iPSC-derived astrocytes. **2023**, 125, 103839 ○
- 62 The unique neuropathological vulnerability of the human brain to aging. **2023**, 87, 101916 ○
- 61 Apolipoprotein E4 targets mitochondria and the mitochondria-associated membrane complex in neuropathology, including Alzheimer's disease. **2023**, 79, 102684 1
- 60 T-cell deficiency induces deficits in social behavior and dyslipidemia in mice. **2023**, 648, 81-86 ○
- 59 Chronic stress is associated with specific path integration deficits. **2023**, 442, 114305 ○
- 58 Sequential sampling in prospective observational studies. **2023**, 17, ○
- 57 Cognitive trajectories diverge by genetic risk in a preclinical longitudinal cohort. ○
- 56 Discovery of a Missense Mutation (Q222K) of the APOE Gene from the Australian Imaging, Biomarker and Lifestyle Study. **2023**, 7, 165-172 ○
- 55 Lipoprotein Metabolism, Protein Aggregation, and Alzheimer's Disease: A Literature Review. **2023**, 24, 2944 ○

- 54 Toxic Tau Aggregation in AD. **2023**, 1-30
- 53 Identification of novel genes for age-at-onset of Alzheimer's disease by combining quantitative and survival trait analyses.
- 52 The mitochondrial BCKD complex interacts with hepatic apolipoprotein E in cultured cells in vitro and mouse livers in vivo. **2023**, 80,
- 51 MS4A4A modifies the risk of Alzheimer disease by regulating lipid metabolism and immune response in a unique microglia state.
- 50 Apolipoprotein E ϵ modulates astrocyte neuronal support functions in the presence of amyloid- β
- 49 White matter hyperintensities in cholinergic pathways are associated with dementia severity in e4 carriers but not in non-carriers. 14,
- 48 Plasma IAPP-Autoantibody Levels in Alzheimer's Disease Patients Are Affected by APOE4 Status. **2023**, 24, 3776
- 47 The Alzheimer's Disease Mitochondrial Cascade Hypothesis: A Current Overview. **2023**, 92, 751-768
- 46 Human brain organoids to explore SARS-CoV-2-induced effects on the central nervous system. **2023**, 33,
- 45 The Fault in Our Astrocytes - cause or casualties of proteinopathies of ALS/FTD and other neurodegenerative diseases?. 3,
- 44 Neuronal APOE4 removal protects against tau-mediated gliosis, neurodegeneration and myelin deficits. **2023**, 3, 275-296
- 43 Ethical issues when using digital biomarkers and artificial intelligence for the early detection of dementia.
- 42 Predictors of cognitive and physical decline: Results from the Health Aging and Body Composition Study. 15,
- 41 Association of African Ancestry-specific APOE Missense Variant R145C With Risk of Alzheimer Disease. **2023**, 329, 551
- 40 Peripheral metabolism of lipoprotein-amyloid beta as a risk factor for Alzheimer's disease: potential interactive effects of APOE genotype with dietary fats. **2023**, 18,
- 39 The role of opioid receptors in modulating Alzheimer's Disease. 14,
- 38 Pathway-specific polygenic risk scores correlate with clinical status and Alzheimer's-related biomarkers.
- 37 Understanding the relationships between physiological and psychosocial stress, cortisol and cognition. 14,

- 36 Healthy Brain Ageing and Longevity; the Harmony of 'Natural Products,' APOE Polymorphism, and 'Melatonin. **2023**, 143-164 ○
- 35 Heparan sulfate proteoglycan in Alzheimer's disease: aberrant expression and functions in molecular pathways related to amyloid- β metabolism. **2023**, 324, C893-C909 ○
- 34 Alzheimer's disease as a synaptopathy: Evidence for dysfunction of synapses during disease progression. 15, ○
- 33 Mass Spectrometry for Lipidomics: Methods and Applications [Aging and Alzheimer's Disease. **2023**, 657-668 ○
- 32 Hippocampal connectivity and memory decline in cognitively intact APOE ϵ carriers. ○
- 31 Sphingolipids in Cerebrospinal Fluid and Plasma Lipoproteins of APOE4 Homozygotes and Non-APOE4 Carriers with Mild Cognitive Impairment versus Subjective Cognitive Decline. 1-16 ○
- 30 Statistical Methods for Disease Risk Prediction with Genotype Data. **2023**, 331-347 ○
- 29 Leveraging Electronic Medical Records and Knowledge Networks to Predict Disease Onset and Gain Biological Insight Into Alzheimer's Disease. ○
- 28 Apolipoproteins in fish: From lipid transport to innate immunity. **2017**, 87, ○
- 27 Plasma ApoE4 Levels Are Lower than ApoE2 and ApoE3 Levels, and Not Associated with Plasma A β 40/42 Ratio as a Biomarker of Amyloid- β Amyloidosis in Alzheimer's Disease. **2023**, 1-16 ○
- 26 Identification and characterization of bioactive peptides from marine crustacean crabs: a possible drug candidate for Alzheimer's disease. ○
- 25 MMP2 rs243866 and rs2285053 Polymorphisms and Alzheimer's Disease Risk in Slovak Caucasian Population. **2023**, 13, 882 ○
- 24 Clinical Management in Alzheimer's Disease in the Era of Disease-Modifying Therapies. **2023**, 25, 121-133 ○
- 23 APOE and immunity: Research highlights. ○
- 22 Alzheimer's disease genetic risk and cognitive reserve in relationship to long-term cognitive trajectories among cognitively normal individuals. **2023**, 15, ○
- 21 Genetic correlations between Alzheimer's disease and gut microbiome genera. **2023**, 13, ○
- 20 Association of APOE ϵ / ϵ with fluid biomarkers in patients from the PUMCH dementia cohort. 15, ○
- 19 Characterization of uranyl (UO₂²⁺) ion binding to amyloid beta (A β) peptides: effects on A β structure and aggregation. ○

- 18 Genetic Phenotypes of Alzheimer's Disease: Mechanisms and Potential Therapy. ○
- 17 APOE ε gene dose effect on imaging and blood biomarkers of neuroinflammation and beta-amyloid in cognitively unimpaired elderly. **2023**, 15, ○
- 16 Quantitative proteomic analysis reveals apoE4-dependent phosphorylation of the actin-regulating protein VASP. **2023**, 100541 ○
- 15 Mediation of Reduced Hippocampal Volume by Cerebral Amyloid Angiopathy in Pathologically Confirmed Patients with Alzheimer's Disease. **2023**, 1-13 ○
- 14 APOE ε associates with microglial activation independently of Aβ plaques and tau tangles. **2023**, 9, ○
- 13 A global view of the genetic basis of Alzheimer disease. ○
- 12 Biyoinformatik analizi aracılığıyla insan APOE (Apolipoprotein E) genindeki yanlış anlamalı SNV'lerin değerlendirilmesi. ○
- 11 Differential and substrate-specific inhibition of β-secretase by the C-terminal region of ApoE2, ApoE3, and ApoE4. **2023**, ○
- 10 Ancestry-related differences in chromatin accessibility and gene expression of APOE ε are associated with Alzheimer's disease risk. ○
- 9 Visit-to-Visit Blood Pressure Variability and Cognitive Decline in Apolipoprotein e4 Carriers versus Apolipoprotein e3 Homozygotes. **2023**, 1-11 ○
- 8 A haptoglobin (HP) structural variant alters the effect of APOE alleles on Alzheimer's disease. ○
- 7 Interaction between KLOTHO-VS Heterozygosity and APOE ε Allele Predicts Rate of Cognitive Decline in Late-Onset Alzheimer's Disease. **2023**, 14, 917 ○
- 6 Pre-symptomatic reduction of individuality in the App NL-F knock-in model of Alzheimer's disease. **2023**, ○
- 5 Programmed ageing: decline of stem cell renewal, immunosenescence, and Alzheimer's disease. ○
- 4 Redox Imbalance in Neurological Disorders in Adults and Children. **2023**, 12, 965 ○
- 3 The Functions and Phenotypes of Microglia in Alzheimer's Disease. **2023**, 12, 1207 ○
- 2 microRNA-132 regulates gene expression programs involved in microglial homeostasis. **2023**, 26, 106829 ○
- 1 Allelic variation within the major APOE CpG island affects its methylation in the brain of targeted replacement mice expressing human APOE. **2023**, 194942 ○

